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Abstract 
Introduction: Although Antiretroviral therapy (ART) has dramatically reduced HIV-
associated morbidity and mortality, non-HIV-related conditions and comorbidities continue 
to rise in this population. Cardiovascular disease (CVD) has been reported to be the 
leading cause of death in the HIV-positive population receiving ART. ART is thought to 
impair vascular endothelial function through increased reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) production. In this study, we aim to assess the effects of 
melatonin - a potent antioxidant -supplementation during ART on specific intracellular 
products of rat Aortic Endothelial Cells (AECs) as well as on the vascular reactivity of rat 
aortas. 
Methods: Cells were serum starved and treated with three different melatonin (1nM; 1uM; 
10uM) or ART (Low: EFV: 5µM; FTC: 5µM; TDF: 80nM; Mid: EFV: 8µM; FTC: 7.5µM; 
TDF: 400nM; High: EFV: 12µM; FTC: 10µM; TDF: 1µM) concntrations for up to 24 hours. 
Nitric oxide (NO), RNS and necrosis were measured with a platereader (control expressed 
as 100%). The concentration that resulted in the greatest differences, compared to 
untreated cells, was selected for co-treatment studies and protein investigations, where 
the same parameters were measured. The effects of acute melatonin and ART 
administration on vascular reactivity was measured by aortic ring isometric tension studies 
in aortas extracted from control male Wistar rats. The endothelium-dependent and 
independent vascular reactivity was measured by isometric tension studies on aortas 
harvested from male Wistar rats that were treated for 8 weeks with melatonin 
(10mg/kg/day) and/or ART (EFV: 51.6 mg/kg; FTC: 17.4 mg/kg; TDF: 25.8 mg/kg). 
Signalling proteins involved in these changes were measured by western blot analyses.  
Results (Mean±SEM): Dose Response Studies: 1nM melatonin decreased necrosis 
[92.56±3.11%;p=0.0004] compared to untreated controls [100.00±1.04%; p=0.0004]. High-
concentration ART lead to increased NO production [112.70±2.17%; 
Control:100.00±2.22%;p=0.0015], RNS production [108.80±2.20%; 
Control:100±0.79%;p=0.0152] and necrosis [107.30±1.34%; Control: 
100.00±0.86%;p=0.0251], compared to untreated controls. 
Main Studies: 1nM melatonin decreased necrosis [92.43±3.75%;p=0.0002], while High-
concentration ART increased necrosis [121.30±9.11%;p=0.0002] compared to untreated 
cells [100.00±1.07%;p=0.0002]. When combined, 1nM melatonin + High-concentration 
ART decreased necrosis [94.17±5.08%;p=0.0002] compared to ART alone.  
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Western blot analyses (arbitarty units) showed that ART increased nitrotyrosine levels 
[2.31±0.34; Control:1.00±0.18;p=0.0486], but decreased p22 PHOX [0.20±0.043; 
Control:1.00±0.15;p<0.0001], and cleaved caspase-3 [0.25±0.038; 
Control:1.00±0.18;p=0.0005], expression. 
In actute aortic ring experiments, ART exposure elicited a burst of contraction during the 
treatment period, followed by a significant  attenuation in accumulative contraction 
compared to all other groups. In  endothelium-dependent and independent contraction 
studies on aortas from treated rats, all groups showed a pro-contractile response 
compared to the control. Western blot analyses showed that ART decreased cleaved 
caspase-3 [0.27±0.08;p=0.0055] expression.  
Conclusion: Decreased necrosis in AECs treated with combined melatonin and ART, 
compared to AECs treated with ART alone shows the protective effect of melatonin. 
Further specific protein investigations are needed to elucidate this mechanism. Western 
blots showed that ART induced  anti-apoptotic effects and increased RNS production, but 
not NADPH-oxidase activity. The initial contractile burst following acute ART exposure 
may precondiition the aortas, resulting in the decreased accumulatve contractile capacity. 
Chronic ART treatment studies showed that ART treatment does not seem to affect 
vasorelxation. Blot data reconfirmed that ART is also anti-apoptoic in vivo. 
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Abstrak 
Inleiding: Alhoewel antiretrovirale terapie HIV verwante morbiditeit en mortaliteit 
dramaties verminder het, styg nie-HIV-verwante toestande in hierdie populasie. 
Kardiovaskulêre siektes word beskou as die hoof oorsaak van sterftes in die HIV positiewe 
populasie wat antiretrovirale terapie (ART) ontvang. ART kan die vaskulêre 
endoteelfunksie benadeel deur verhoogde reaktiewe suurstof species (ROS) en reaktiewe 
stikstof species (RNS) produksie. In hierdie studie was die effekte van melatonien 
(kragtige antioksidant) aanvulling   gedurende ART ondersoek, met spesifieke verwysing 
na intrasellulêre afskeidingsprodukte van rot aorta endoteelselle, asook in die konteks van  
rot aorta vaskulêre reaktiwiteit. 
Metodes: Selle was onderwerp aan serum weerhouding en behandel met drie 
verskillende melatonien (1nM; 1uM; 10uM) of ART (Laag: EFV: 5µM; FTC: 5µM; TDF: 
80nM; Medium: EFV: 8µM; FTC: 7.5µM; TDF: 400nM; Hoog: EFV: 12µM; FTC: 10µM; 
TDF: 1µM) konsentrasies vir tot 24uur. Stikstofoksied (NO), RNS and nekrose is gemeet 
met ‘n plaatleser (kontrole uitgedruk as 100%). Die konsentrasie wat gelei het tot die 
grootste verskille, in vergelyking met die onbehandelde selle, was gekies vir ko-
behandeling studies en proteïen ontledings, waar dieselfde veranderlikes gemeet was. Die 
effekte van akute melatonien en ART toediening op vaskulêre reaktiviteit is gemeet d.m.v. 
aortiese ring isometriese  spanningstudies in aortas afkomstig  van  gesonde manlike 
Wistar rotte. Die endoteel-afhanklike en onafhanklike vaskulêre reaktiwiteit is gemeet 
d.m.v. isometriese  spanningstudies  in aortas afkomstig van manlike Wistar rotte wat vir 8 
weke behandel was met melatonien (10mg/kg/day) en/of ART (EFV: 51.6 mg/kg; FTC: 
17.4 mg/kg; TDF: 25.8 mg/kg). Seinproteïne in hierdie weefsel is gemeet deur Western 
blot analises.  
Resultate (Mean±SEM): Dosis-reaksie Ondersoeke: 1nM melatonien het nekrose 
[92.56±3.11%;p=0.0004] laat verminder in vergelyking met onbehandelde kontrole 
[100.00±1.04%;p=0.0004]. Hoë-konsentrasie ART het tot verhoogde NO produksie 
[112.70±2.17%; kontrole:100.00±2.22%;p=0.0015], RNS produksie [108.80±2.20%; 
kontrole:100.00±0.79%;p=0.0152] en nekrose [107.30±1.34%; kontrole: 100.00±0.86%; 
p=0.0251] gelei, in vergelyking met onbehandelde kontrole.  
Hoof Ondersoeke: 1nM melatonien nekrose [92.43±3.75%;p=0.0002] laat toeneem, terwyl 
hoë-konsentrasie  ART  nekrose [121.30±9.11%;p=0.0002] in vergelyking met 
onbehandelde selle [100.00±1.07%;p=0.0002] verhoog.  Tydens gekombineerde 
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behandeling, het 1nM melatonien + Hoë-konsentrasie ART nekrose [94.17±5.08%; 
p=0.0002] verlaag teenoor ART alleen. Western blot analises (arbitrêre eenhede) het 
getoon dat ART nitrotirosien vlakke vermeerder het [2.31±0.34; 
kontrole:1.000±0.18;p=0.0486], maar  p22 PHOX [0.20±0.04; 
kontrole:1.00±0.15;p<0.0001], en  gekliefde kaspase-3 [0.25±0.038; 
kontrole:1.00±0.18;p=0.0005] uitdrukking verlaag het. In akute aorta ring eksperimente, 
het ART blootstelling  ‘n skielike en kortstondige  kontraksie gedurende die behandelings 
periode veroorsaak, gevolg deur ‘n beduidende  verswakking in akkumulatiewe kontraksie 
teenoor  al die ander groepe. In endoteel-afhanklike en onafhanklike kontraksie studies op 
aortas van behandelde rotte, het alle groepe ‘n pro-kontraktiele reaksie getoon in 
vergelyking met die kontrole. Western blot analises het getoon dat ART v gekliefde 
kaspase-3 uitdrukking verlaag het [0.27±0.08;p=0.0055].  
Gevolgtrekking: Die verlaagde nekrose wat in aorta endoteelselle (AECs),  behandel  
met gekombineerde melatonien en ART, waargeneem is teenoor  AECs wat slegs ART 
ontvang het, is ‘n bewys van  die beskermde effekte van melatonien.  Toekomstige studies 
wat spesifieke proteïene ondersoek is nodig om die meganisme verder te verklaar. 
Western blots ondersoeke het gewys dat ART anti-apoptotiese effekte en vermeerde RNS 
produksie veroorsaak, maar geen effekte op NADPH-oksidase aktiwiteit toon nie. Die 
aanvanklike kontraktiele  respons tydens akute ART blootstelling kan die aortas vooraf 
kondisioneer wat ‘n verlaagde akkumulatiewe kontraktiele kapasiteit veroorsaak het. 
Chroniese ART behandeling studies het getoon dat die behandeling nie die 
bloedvatverslapping beïnvloed nie. Die Western blot resultate van die in vivo studies het 
die anti-apoptotiese effekte van ART herbevestig. 
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1 - Literature Review 
1.1  General Introduction 
The human immunodeficiency virus (HIV) is a global pandemic affecting 34 million people, 
with African countries accounting for 70% of all HIV-infected individuals worldwide  
(Thienemann, Sliwa, & Rockstroh, 2013). In South Africa (SA) alone, there are 
approximately 7 million people living with HIV (Statistics South Africa, 2015). There is still 
no cure for HIV infection, however, implementation of antiretroviral therapy (ART) has 
allowed for the effective management of the virus. Although ART has dramatically reduced 
HIV-associated morbidity and mortality, non-HIV-related conditions and comorbidities 
continue to rise (Thienemann et al., 2013). Cardiovascular disease (CVD) has been 
reported to be the leading comorbidity and cause of death in the HIV-positive population 
receiving ART  (Thienemann et al., 2013), creating a double burden of disease – both 
communicable and non-communicable – specific to low-and-middle-income countries like 
SA. 
Endothelial dysfunction (ED) is defined as an imbalance between vasodilating and 
vasoconstricting substances produced by, or acting on the endothelium  (Deanfield et al., 
2005), and is recognised as a critical initiating factor in CVD. Numerous studies on the 
effects of ART on the vasculature indicate that ART may impair the function of the vascular 
endothelium  (Jiang et al., 2010). Increased production of reactive oxygen species (ROS) 
and imbalances between the levels of oxidants and antioxidants in the vasculature are 
considered important factors in ART-induced ED. 
There is need for a therapy with the potential to alleviate the oxidative stress induced by 
ART. Melatonin is a free radical scavenger and strong antioxidant  (Reiter, Tan, Osuna, & 
Gitto, 2000), giving it the potential to ameliorate damage caused by ART-induced ROS 
production, which leads to ED. 
1.2  The Vascular Endothelium 
The vascular endothelium is made up of a monolayer of endothelial cells (ECs), which line 
the lumen of blood vessels, providing a barrier between the vascular walls and circulating 
blood  (Lerman & Zeiher, 2005; M. S. Park, Ravi, & Araujo, 2010). For many years, the 
endothelium was thought of as an inert membrane, with the sole purpose of maintaining 
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vessel wall permeability through the physical separation of the tissue and blood  (Cines et 
al., 1998). Now, it is well established that the endothelium is in fact a dynamic organ that is 
heterogeneous and involved in the synthesis and secretion of key factors, as well as 
fulfilling important metabolic and immunological functions  (Fishman, 1982). The 
endothelium plays a vital role in preserving vascular homeostasis by maintaining a delicate 
balance between vasodilatory and vasoconstrictory factors  (Bevilacqua, Nelson, Mannori, 
& Cecconi, 1994; Versari, Daghini, Virdis, Ghiadoni, & Taddei, 2009). For this reason, 
maintaining endothelial health is fundamental in sustaining an antithrombotic and 
antiatherogenic milieu. Table 1.1 summarises the various atheroprotective effects of the 
healthy endothelium. 
Table 1.1: A list of favourable effects enforced by a healthy endothelium (Bonetti, Lerman, & 
Lerman, 2003). 
 
 
 
 
 
 
 
 
 
 
1.2.1 Localisation and Structure 
The vascular endothelium lines the entire circulatory system, from the heart, to the 
smallest capillaries  (Rajendran et al., 2013). Positioned at the interface between the blood 
and the tissue, the endothelium is in the ideal location to detect and respond to any 
biological changes in the local environment caused by trauma or inflammation  (Cines et 
al., 1998). The vascular wall is comprised of three layers (Fig 1.1): an inner layer called the 
intima, a middle layer known as the tunica media, and an outer layer called the tunica 
adventitia (Sandoo, van Zanten, Metsios, Carroll, & Kitas, 2010). The endothelium 
Favourable and Atheroprotective Effects of the Healthy Endothelium: 
Promotion of vasodilation 
Antioxidant effects 
Anti-inflammatory effects 
Inhibition of leukocyte adhesion and migration 
Inhibition of smooth muscle cell proliferation and migration 
Inhibition of platelet aggregation and adhesion 
Anticoagulant effects 
Profibrinolytic effects 
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comprises approximately 1.6 x 1013 cells, all of which are in close association with the 
smooth muscle cells  (Limaye & Vadas, 2007), and located on the intima. These cells are 
highly specialised, with the ability to receive and transmit biochemical and physical 
information  (Cines et al., 1998). This information can be transmitted directly – through 
active transport or direct permeation through the intercellular spaces between the ECs – or 
indirectly, whereby the ECs modulate the behaviour of the smooth muscle cells and other 
components of the vessel wall  (Cines et al., 1998). 
 
 
 
 
 
 
 
 
 
 
These actions are facilitated via membrane-bound receptors; which convey the signals of 
numerous molecules, such as proteins, lipid transporting particles, metabolites and 
hormones  (Cines et al., 1998). The ECs also have specialised junctional proteins and 
receptors, which govern cell-cell and cell-matrix interactions. 
1.2.2 Function 
It has been established that the endothelium embodies a wide range of homeostatic 
functions  (Durand & Gutterman, 2013). These functions are carried out through the 
secretion of specific mediators (Table 1.2) that have the ability to influence vascular 
hemodynamics  (Cines et al., 1998). The various mediators controlled by ECs play an 
important role in the regulation of vascular tone and growth of blood vessels, thrombosis 
and thrombolysis, as well as platelet and leukocyte interactions with the vessel wall  
(Verhamme & Hoylaerts, 2006). ECs also contribute to the regulation of blood pressure 
and blood flow, by releasing vasodilators and vasoconstrictors  (Cines et al., 1998). 
Figure 1.1: Morphologically distinct layers in a healthy artery  (Lusis, 2000). 
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Table 1.2: Endothelium Derived Vaso-regulatory Mediators (Adapted from (Cines et al., 1998; 
Mudau, Genis, Lochner, & Strijdom, 2012). 
 
Mediator Effects Source and Mechanism of Action 
Nitric Oxide 
(NO) 
 
 Potent vasodilator 
 Inhibits inflammation, VSMC 
proliferation and migration, 
platelet activation, aggregation 
and adhesion, and leukocyte 
adhesion 
 Regulates myocardial contractility 
 Regulates cardiac metabolism 
 Maintains basal tone of vessles 
 
 Synthesises by enzymes: eNOS; 
nNOS and iNOS, with eNOS the 
major endothelial source of NO 
during physiological conditions 
 
 Diffuses from ECs to underlying 
VSMCs where it binds to sGC, 
leading to a cascase of events 
that ultimately result in vascular 
relaxation 
Prostacyclin 
(PGI2) 
 Vasodilator 
 Inhibits platelet aggregation and 
deposition 
 Derived from arachidonic acid by 
cyclooxygenase-2 (COX-2) 
Endothelium-
derived 
hyperpolarising 
factor (EDHF) 
 Vasodilator, particularly in small 
arteries (≤ 300 μm) 
 Its identity is still under suspicion 
with proposed candidates such 
as potassium ions and hydrogen 
peroxide 
Endothelin-1 
(ET-1) 
 Potent vasoconstrictor 
 Mitogen for VSMCs 
  
 Synthesised by endothelin-
converting enzyme 
 Exerts its effects via two 
receptors: ETA expressed on 
endothelial cells which 
promote vasoconstriction and 
ETB on VSMCs, which 
promote NO production and 
ultimately reduction in ET-1 
production 
 
Thromboxane 
A (TXA2) 
 Potent vasoconstrictor 
 Derived from arachidonic acid by 
COX-1 
 
Angiotensin II 
(Ang II) 
 Potent vasoconstrictor 
 
 Synthesised by angiotensin 
converting enzyme 
 Elicits its effects via two 
receptors: AT1 which 
promotes vasoconstriction 
and cell proliferation, and 
AT2 which antagonises the 
effects of AT1 
 
VSMC (vascular smooth muscle cell); eNOS (endothelial nitric oxide synthase); nNOS 
(neuronal nitric oxide synthase); iNOS (inducible nitric oxide synthase); sGC (soluble guanylyl 
cyclase). 
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1.2.2.1 Nitric Oxide and Nitric Oxide Synthase 
As previously mentioned on page 3, there are numerous vasoactive substances produced 
by the ECs. Nitric Oxide (NO) is the most potent endothelium-dependant vasodilator 
synthesised in the endothelial cell layer  (Durand & Gutterman, 2013; Mudau et al., 2012), 
and causes the relaxation of the underlying vascular smooth muscle cells (VSMCs) 
(Sandoo et al., 2010). NO is the heterodiatomic free radical product that is formed through 
the oxidation of the amino acid L-arginine, to L-citrulline (Fig.1.2)  (K. Park & Park, 2015; 
Stamler, Singel, & Loscalzo, 1992). This conversion is facilitated by the enzyme nitric 
oxide synthase (NOS) (Palmer, Ashton, & Moncada, 1988). 
 
 
 
 
 
 
 
 
 
NOS exists in three different isoforms: neuronal NOS (nNOS); inducible NOS (iNOS) and 
endothelial NOS (eNOS). nNOS produces NO, which plays the role of a neuronal 
messenger that has the ability to regulate synaptic neurotransmitter release  (Prast & 
Philippu, 2001), while iNOS is only expressed in injured cells that have been exposed to 
inflammatory mediators that can activate macrophages  (Michel & Feron, 1997). eNOS is 
the most abundant isoform of NOS and is responsible for the NO produced in the 
vasculature, and therefore vessel dilation  (Sandoo et al., 2010). The various isoforms of 
NOS were originally named and classified according to the cells they were initially 
observed in, however, it is now evident that the different isoforms also occur in numerous 
other cells, including cardiac myocytes  (Balligand et al., 1995); as well as blood platelets, 
the hippocampus and skeletal muscle  (Arnal, Dinh-Xuan, Pueyo, Darblade, & Rami, 
1999). 
Figure 1.2: The formation of NO from L-Arginine, with the NADPH and oxygen 
requirements for each reaction shown  (Stuehr, 2004). NADPH (Nicotinamide adenine 
dinucleotide phosphate). 
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In the vascular endothelium, NO production is influenced by the release of chemical 
agonists acting on specific endothelial chemo-receptors  (K. Park & Park, 2015). Such NO 
agonists include acetylcholine (ACh), bradykinin (BK), adenosine tri-phosphate (ATP), 
adenosine di-phosphate (ADP), substance P (SP) and thrombin  (Moncada & Higgs, 2006) 
Inactive eNOS is bound to the protein caveolin and kept within small invaginations in the 
cell membrane, known as caveolae  (Bucci et al., 2000). eNOS is activated by the 
receptor-dependent NO agonists, which stimulate the release of calcium from the 
endoplasmic reticulum (ER) (Fig 1.4)  (Bae et al., 2003), thereby increasing intracellular 
calcium levels and causing the detachment of eNOS from caveolin (Fig 1.3)  (Sandoo et 
al., 2010; Venema, Sayegh, Arnal, & Harrison, 1995). When intracellular calcium from the 
ER is depleted, endothelial membrane receptors receive a signal to open the calcium 
channels and allow the entry of extracellular calcium into the cell  (Schilling, Cabello, & 
Rajan, 1992), which is known as store operated calcium entry or capacitative calcium entry  
(Putney, 1986). In order to bind to and activate eNOS, calcium must undergo a structural 
change, which is achieved through the binding of calcium to calmodulin within the cell 
cytoplasm  (Fleming & Busse, 1999). Active eNOS is then able to catalyse the production 
Figure 1.3: eNOS signaling in caveolae. Depicted in the figure is the cycle of eNOS activation and 
inhibition in caveolae. In step 1, Cav-1 is bound to eNOS, inhibiting eNOS activity. In step 2, agonist 
activation by Ach initiates an influx of calcium that binds to and activates calmodulin. In step 3, 
calcium-activated calmodulin binds to eNOS thereby relieving its inhibition by Cav-1 and NO is 
produced. Finally, in step 4, Cav-1 binds to eNOS again, completing the cycle  (Razani, Woodman, 
& Lisanti, 2002). Cav-1 (caveolin); Ca2+ (calcium). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
7 
of NO through the conversion of L-arginine (Fig 1.2). This process of NO production in 
ECs is shown in Figure 1.4. 
In this particular pathway, it is important to note that NO production is dependent on the 
amount of intracellular calcium in the ER, as well as the quantity of extracellular calcium 
that diffuses into the cell  (Sandoo et al., 2010). When calcium levels decrease, the 
calcium-calmodulin complex dissociates from eNOS. The unbound eNOS is then free to 
bind with caveolin again, and therefore becomes inactivated  (Fleming & Busse, 1999). In 
this way, short-term increases in NO are dependent on calcium levels, but once 
intracellular calcium is depleted, alternative mechanisms need to be activated in order to 
further regulate NO production. In such cases, eNOS can be alternatively activated 
through phosphorylation  (Butt et al., 2000), which occurs through specific protein kinases, 
like protein kinase A (PKA)  (Bae et al., 2003) and cyclic guanosine-3’, 5-monophosphate 
(cGMP) protein kinase dependent II  (Butt et al., 2000). 
 
Once eNOS has been activated and NO has been consequently synthesised, NO diffuses 
across the EC into the adjacent VSMC (Fig 1.4), where it binds to the enzyme soluble 
guanylyl cyclase (sGC), thereby activating it  (Ignarro, Harbison, Wood, & Kadowitz, 1986). 
Active sGC increases the conversion rate of guanosine triphosphate (GTP) to cGMP, 
which decreases smooth muscle tension  (Jones, Wong, Jankowski, Akao, & Warner, 
1999), effectively decreasing the release of calcium from the sarcoplasmic reticulum (SR) 
in the VSMCs  (Collins, Griffith, Henderson, & Lewis, 1986), which overall reduces VSMC 
contraction. All the mechanisms described above are continuously active, and the 
resultant production of NO is used to maintain basal vasodilatory tone  (Sandoo et al., 
2010). 
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Under normal physiological conditions, endothelial NO production is mainly regulated by 
mechanical forces, particularly shear stress, which act on specific mechano-receptors  
(Gutiérrez et al., 2013). This mechanical activation of eNOS is the most important 
regulator of eNOS activity and contributes to the phenomenon of flow-mediated 
vasodilatation (Fig 1.4), which is a vital autoregulatory mechanism that increases blood 
flow in response to physical activity or exercise  (Loscalzo & Vita, 1994). 
 
NO production and regulation is vital to maintaining vascular homeostasis and healthy 
endothelial function, and therefore quantifying NO levels in a specific vascular area might 
be helpful in determining endothelial function. However, NO is a volatile substance with a 
Figure 1.4: Endothelial NO production and its actions in the VSMCs. Agonists such as ACh and 
BK or mechanical forces, such as shear stress, lead to VSMC relaxation by stimulation of NO 
production. When ER calcium stores are depleted, the SOCa2+ channel allows extracellular 
calcium into the EC  (Durand & Gutterman, 2013; Sandoo et al., 2010). ACh (acetylcholine); 
BK (bradykinin); ATP (adenosine triphosphate); ADP (adenosine diphosphate); SP (substance 
P); SOCa2+ (store-operated Ca2+ channel); ER (endoplasmic reticulum); NO (nitric oxide); sGC 
(soluble guanylyl cyclase); cGMP (cyclic guanosine-3’,5-monophosphate); MLCK (myosin light 
chain kinase). 
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short half-life, making its moment-by-moment quantification almost impossible  (Versari et 
al., 2009). For this reason, NO bioavailability is usually evaluated through the 
measurement of its downstream effects. For example, endothelium-dependent relaxation 
can be measured through vascular reactivity tests  (Deanfield et al., 2005), using either 
receptor-operated (ACh; BK; SP) stimuli in vitro and ex vivo or mechanical stimuli such as 
shear stress in vivo, using flow-mediated vasodilation (FMD) as the technique of 
assessment  (John & Schmieder, 2000). 
 
It is clear that NO and NOS play key roles in endothelial function, not only in a 
vasdodilatory capacity, but also through a plethora of other important regulatory functions 
(Table 1.2). It is essential for the healthy endothelium that these two regulators are present 
in desirable quantities, since and imbalance in NO and NOS levels can have dire 
consequences for endothelial health.  
1.3 Endothelial Dysfunction 
When the endothelium loses its regulatory ability to maintain a balance between 
endothelial-derived vasodilatory and vasoconstrictory factors, it results in ED  (Mudau et 
al., 2012). ED is characterised by a shift in the actions of the endothelium toward reduced 
vasodilation, a proinflammatory state, and prothrombic properties  (Rajendran et al., 2013), 
resulting in progressive pathophysiological changes (Fig 1.5). Mechanisms by which these 
pathophysiological changes occur appear to be complex and multifactoral. ED is 
associated with most major cardiovascular risk factors  (Versari et al., 2009), and is 
therefore a key role player in the progression to atherosclerosis and CVD. Perhaps most 
importantly, ED represents an initial reversible step in the development of various CVDs  
(Bonetti et al., 2003), making it a promising target for the prevention of such diseases 
when identified early  (Chhabra, 2009). 
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Figure 1.5: The pathophysiological changes seen in a dysfunctional endothelium. In the healthy endothelium, the eNOS is responsible for most of 
the vascular NO production. However, eNOS becomes a potential ROS generator when in the pathological uncoupled state, due to various 
oxidative stresses  (K. Park & Park, 2015). ACE (angiotensin-converting enzyme); Ach (acetylcholine); AT-I (angiotensin I); AT-II (angiotensin II); 
AT1 (angiotensin 1 receptor); BH4 (tetrahydrobiopterin); BK (bradykinin); cAMP (cyclic adenosine monophosphate); cGMP (cyclic guanosine 
monophosphate); ECE (endothelin converting enzyme); eNOS (endothelial nitric oxide synthase); EDHF (endothelium derived hyperpolarizing 
factor); ETA and ETB (endothelin A and B receptors); ET-1 (endothelin-1); L-Arg (L-arginine); L-Cit (L-citrulline); M (muscarinic receptor); O2- 
(superoxide anion); ONOO- (peroxynitrite); NADPH (nicotinamide adenine dinucleotide phosphate); NO (nitric oxide); NOX (nicotinamide adenine 
dinucleotide phosphate oxidase); PGH2 (prostaglandin H2); PGI2 (prostaglandin I2); ROS (reactive oxygen species); S1B (serotonin receptor); TP 
(thromboxane prostanoid receptor); TXA2 (thromboxane); 5-HT (serotonin); Θ (inhibition); ⊕ (stimulation). 
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1.3.1 Pathophysiology  
The fundamental feature of ED is the impaired or reduced NO bioavailability  (Endemann 
& Schiffrin, 2004; Versari et al., 2009), resulting in the inability of the endothelium to initiate 
vasodilation in response to vasodilatory stimuli such as acetylcholine or shear stress  
(Mudau et al., 2012). In the presence of impaired NO bioavailability, the endothelium has 
to implement alternative physiological pathways in an attempt to compensate for NO 
deficiency  (Versari et al., 2009).  
ED comprises of a state of chronic “endothelial activation” (Bonetti et al., 2003), 
sometimes referred to as the endothelial activation–dysfunction–injury triad  (Bijl, 2003).  
This state is characterised by a proinflammatory, proliferative, and procoagulatory milieu  
(Anderson, 1999), which is detrimental to the progression of CVDs, specifically all stages 
of atherogenesis.  
Along with NO deficiency, a dysfunctional endothelium can become imbalanced in its 
release of other substances and mediators that are detrimental to the arterial wall, leading 
to excessive release of factors including endothelin-1 (ET-1), thromboxane (THA2), 
prostaglandin H2 (PGH2), and reactive oxygen species (ROS) (Fig 1.5)  (Taddei, Ghiadoni, 
Virdis, Versari, & Salvetti, 2003). As the endothelial function further deteriorates, the ECs 
exhibit reduced anti-oxidant and anti-inflammatory effects, increased vascular permeability 
to lipoproteins, and the increased expression of inflammatory cytokines and adhesion 
molecules  (Libby, Ridker, & Maseri, 2002). C-reactive protein (CRP) is an example of a 
specific compound that moves into the tissue and causes inflammation  (Devaraj, Singh, & 
Jialal, 2009), leading to further aggravation of the faulty endothelium. 
1.3.2 Aetiology and Mechanisms of ED 
Chronic exposure to cardiovascular risk factors and the harmful circulating stimuli 
associated with these conditions overwhelms the defence mechanisms of the vascular 
endothelium, hence compromising its integrity and ultimately initiating ED  (Deanfield, 
Halcox, & Rabelink, 2007). ED has been observed to be associated with major 
cardiovascular risk factors, such as aging, hyperhomocysteinemia, post-menopause state, 
smoking, diabetes, hypercholesterolemia, hypertension, and more  (Rajendran et al., 
2013; Versari et al., 2009). 
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Most cardiovascular risk factors are associated with the up-regulation of intracellular 
oxidative stress and ROS  (Cai & Harrison, 2000; K. Park & Park, 2015). Among various 
complex mechanisms, oxidative stress appears to be the most common underlying 
mechanism for the development of ED  (Drexler, 1997; K. Park & Park, 2015). Oxidative 
stress is caused by an imbalance between the pro-oxidative and anti-oxidative molecules  
(Cahill & Redmond, 2016; Pennathur & Heinecke, 2007), often resulting in biomolecular 
damage caused by excess ROS  (Halliwell, 2007).  ROS is a term that includes oxygen 
radicals such as superoxide (O2−) and the hydroxyl radical (OH−), as well as non-radical 
derivatives of oxygen (O2) including hydrogen peroxide (H2O2)  (Cahill & Redmond, 2016). 
In most instances, the human body has an adequate supply of endogenous antioxidants, 
as well as antioxidants obtained from various foods to neutralise these free radicals. If the 
body is depleted of these antioxidants, or in the presence of multiple cardiovascular 
factors, injury to the endothelium and a loss in NO homeostasis can occur  (Rajendran et 
al., 2013).  
 
In the presence of cardiovascular risk factors, NADPH oxidases (NOX) and eNOS are 
often both dysregulated  (Forstermann & Munzel, 2006), as a compensatory mechanism to 
increase NO levels and therefore all of the athero- and vaso-protective effects associated 
with it. The upregulation of NOX results in an increased production of ROS – specifically 
O2− - in the vascular wall, with NOX being implicated as the main source for oxidative 
excess in the vasculature  (Hamilton, Brosnan, Al-Benna, Berg, & Dominiczak, 2002). The 
upregulation of functional eNOS results in increased levels of NO, which is the desired 
effect. However, in the presence of excess O2−, NO cannot be utilised for its pro-dilatory 
properties, and instead O2− combines with NO to form the highly reactive nitrogen species 
(RNS), peroxynitrite (ONOO−) (Fig 1.6)  (Forstermann & Munzel, 2006). Under 
physiological conditions, the enzyme sodium oxide dismutase (SOD) usually regulates O2− 
levels, but in diseased states, this defensive mechanism is overwhelmed  (Landmesser & 
Harrison, 2001). This is to be expected considering O2− combines with NO at a rate that is 
three times faster than the dismutation of O2− by SOD  (Heitzer, Schlinzig, Krohn, 
Meinertz, & Munzel, 2001). Together, this all results in the characteristic 
pathophysiological reduced NO bioavailability in ED  (Tomasian, Keaney Jr, & Vita, 2000). 
O2−, along with ONOO−, also has the ability to directly inhibit the main target of NO, sGC 
and further enhance oxidative stress by inhibiting SOD  (Munzel, Daiber, Ullrich, & Mulsch, 
2005). 
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The consequently high levels of ONOO− are injurious to the cells, since it has the ability to 
oxidatively damage DNA, lipids and proteins  (Mudau et al., 2012). ONOO− can undergo 
protonation to form peroxynitrous acid (ONOOH), or it can combine with carbon dioxide 
(CO2) to form nitroso-peroxocarboxylate (ONOOCO2–), both of which yield tyrosine-
nitrating compounds  (Hurst, 2002). Via formation of these compounds, ONOO− causes 
the nitration of tyrosine residues of proteins, leading to formation of nitrotyrosine  (Pacher, 
Beckman, & Liaudet, 2007), causing cell damage. In addition to being cytotoxic, ONOO− 
causes oxidative damage to the zinc-thiolate cluster of eNOS, resulting in the loss of the 
zinc ion and the formation of disulfide bonds between the enzyme monomers, and thus 
disruption of the binding site for BH4 and L-arginine  (Forstermann & Munzel, 2006). 
ONOO−  can also oxidise tetrahydrobiopterin (BH4) - which is an essential cofactor of 
eNOS- to the trihydrobiopterin (BH3.) radical. Both of the above eventually lead to eNOS 
uncoupling (Fig 1.8)  (Forstermann & Munzel, 2006; Kuzkaya, Weissmann, Harrison, & 
Dikalov, 2003). Figure 1.7 gives an overview of everything discussed above. 
 
Figure 1.6: Oxidative and nitro-oxidative stress. Superoxide released from sources such 
as NADPH oxidase, mitochondria and xanthine oxidase is dismutated to hydrogen 
peroxide by SOD, which is then converted to water and oxygen by catalase. However, 
superoxide has a higher affinity for NO than SOD, and when in excess, it preferentially 
combines with NO to produce peroxynitrite with various pathophysiological consequences  
(Mudau et al., 2012). SOD (superoxide dismutase); O2– (superoxide); H2O2 (hydrogen 
peroxide); NO (nitrogen oxide); ONOO− (peroxynitrite); NO2− (nitrite); OH− (hydroxly); H2O 
(water); O2 (oxygen). 
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Figure 1.7: Potential mechanisms by which cardiovascular risk factors lead to ED through 
increased oxidative stress  (Forstermann & Munzel, 2006). 
 
eNOS uncoupling involves the dissociation of the ferrous-oxygen complex of eNOS. The 
resultant faulty eNOS enzyme can now produce O2− from the oygenase domain (Fig 1.8), 
rather than its natural product, NO  (Forstermann & Munzel, 2006). This makes uncoupled 
eNOS a potential ROS genenrator  (Landmesser & Harrison, 2001; K. Park & Park, 2015). 
In addition to ONOO− -induced eNOS uncoupling, other oxidants such as H2O2 have also 
been shown to uncouple the enzyme  (Mudau et al., 2012).  
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Figure 1.8: Coupled and uncoupled eNOS. (A) In the presence of sufficient levels of substrates 
and co-factors, and the absence of harmful reactive species, eNOS monomers will form a 
dimerised, coupled enzyme and produce physiological amounts of NO. (B) Decreased levels of the 
substrate, L-arginine and/or harmful effects exerted by increased levels of ONOO–, cause failure 
of the enzyme to dimerise, leading to the uncoupling of eNOS and the production of O2– instead of 
NO  (Mudau et al., 2012). 
 
H2O2 is formed as a by-product of the dismutation of O2− by SOD (Fig 1.6). Excess 
production of H2O2, along with being implicated in eNOS uncoupling, can increase eNOS 
expression, through transcriptional and post-transcriptional mechanisms  (Forstermann & 
Munzel, 2006). In the presence of antioxidant enzymes such as catalase or glutathione 
peroxidase, H2O2 can be dismutated into water (H2O) and O2 (Fig 1.6). However, in the 
presence of transition metals – such as copper and iron- or O2−, H2O2 generates highly 
reactive hydroxyl radicals, which cause cell damage through the peroxidation of lipids 
(Feletou & Vanhoutte, 2006). In addition, ROS promote the contraction of VSMCs by 
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facilitating the mobilization of calcium and increasing the sensibility of the contractile 
proteins to calcium ions  (Feletou & Vanhoutte, 2006). Together, all these contributors 
further exacerbate the overload of ROS in ED. 
Inflammation is another common underlying mechanism of ED, and there seems to be a 
causal relationship between oxidative stress and inflammation  (Karbach, Wenzel, 
Waisman, Munzel, & Daiber, 2014). Under physiological conditions, appropriate levels of 
NO, released by the healthy endotheloium, control vascular inflammation. However, during 
ED, excess ROS aggravates vascular inflammation  (K. Park & Park, 2015). Oxidative 
stress may amplify the vascular pro-inflammatory signaling pathways, leading to even 
higher levels of ROS, since inflammatory cells release O2·− (Karbach et al., 2014). ROS 
has been shown to upregulate adhesion and chemotactic molecules  (Griendling & 
FitzGerald, 2003), while inflammatory markers such as C-reactive protein (CRP) have 
been shown to decrease eNOS activity  (Venugopal, Devaraj, Yuhanna, Shaul, & Jialal, 
2002). Other than oxidative stress and chronic inflammation, infection, anti-oxidant 
deficiency and abnormal shear stress are all mechanism implicated in ED  (K. Park & 
Park, 2015). 
1.3.3 Consequences of ED 
The presence of ED can be regarded as a clinical syndrome that is associated with, and 
predicts an increased rate of adverse cardiovascular events  (Bonetti et al., 2003). A study 
by Lerman & Zeiher (2005) showed an analysis of close to 2500 patients, which 
demonstrated that ED is strongly and independently associated with cardiovascular events  
(Lerman & Zeiher, 2005). 
Most evidence points towards ED as one of the major pathologic changes between 
exposure to the cardiovascular risk factors, and the development of atherosclerotic CVD 
(Fig 1.9)  (K. Park & Park, 2015). 
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Figure 1.9 shows that reduced NO bioavailability as a consequence of ED results in pro-
atherosclerotic changes to the endothelial mileu  (Heitzer et al., 2001). By upregulating 
platelet aggregation, leukocyte adhesion, and thrombosis, amongst other factors, the 
dysfunctional endothelium is not only an initiator, but also an important factor in the 
progression of atherosclerosis and CVD  (Barton & Haudenschild, 2001). Thus, ED is not 
only a consequent feature of risk factors, but also a possible pathogenic mechanism for 
their onset  (Versari et al., 2009). 
 
ED is associated with most CVDs and risk factors for CVD. Amongst others, examples 
include hypertension, coronary artery disease, chronic heart failure, stroke, peripheral 
vascular disease, insulin resistance, diabetes and chronic kidney failure  (Rajendran et al., 
2013). 
 
The oxidative stress associated with ED also has negative effects, independent of the ED 
as a whole. These include increased VSMC proliferation (resulting in thickening of the 
vascular wall), endothelial cell apoptosis, and increased expression and activity of matrix 
metalloproteinases, which are involved in the establishment of an atherosclerotic plaque  
(Mudau et al., 2012). 
Figure 1.9: Progression from risk factors to atherosclerosis and CVD 
mediated by oxidative stress and ED  (K. Park & Park, 2015). 
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1.3.4 Prevention and Treatment of ED 
The reversal of ED may be a critical point of in the prevention of atherosclerosis and CVD 
since ED has been implicated as the initial, reversible step in these conditions (Mudau et 
al., 2012). Treatment of ED involves the alteration of specific pathogenic pathways, with 
the goal of preserving or restoring endothelial function  (K. Park & Park, 2015).  
 
There are two classes of endothelial therapy (Fig 1.10): primary endothelial therapy 
involves the preservation and improvement of endothelial function in subjects without 
CVD, whereby lifestyle changes are made in order to reduce and prevent exposure to 
cardiovascular risk factors  (Barton & Haudenschild, 2001).  Secondary endothelial therapy 
involves the improvement of the dysfunctional endothelium through the treatment of 
underlying cardiovascular risk factors and established CVDs  (Goff et al., 2014), and is 
applicable to both modifiable (hypertension, obesity, diabetes, dyslipidemia) and non-
modifiable conditions (aging, menopause, coronary or peripheral artery disease, heart 
failure, end-stage renal disease)  (K. Park & Park, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Therapeutic approaches to ED  (K. Park & Park, 2015). CV (cardiovascular); 
PAOD (peripheral arterial occlusive disease). 
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Considering that oxidative stress is regarded by many as the main pathophysiologic 
mechanism leading to impaired NO bioavailability and ED  (Versari et al., 2009), 
antioxidant substances could potentially play a substantial role in the treatment of ED. 
Acute studies have shown high-dose antioxidant vitamins are extremely effective in 
restoring normal endothelial function, however, interventional studies using oral 
administration of antioxidant substances including vitamin C and E have failed to provide 
consistent data  (Virdis et al., 2004). The reason for the lack of benefit of long-term 
antioxidant supplementation in the setting of primary and secondary prevention, however, 
is not clear  (Bonetti et al., 2003). Recent evidence  suggests that certain antioxidants, 
including vitamin E, may be inappropriate to reduce oxidative stress in vivo or may even 
be pro-oxidant under certain conditions  (Landmesser & Harrison, 2001). These mixed 
findings may point to the importance of testing new antioxidants or combining different 
antioxidant compounds in order to observe an adequate reduction of oxidative stress  
(Bonetti et al., 2003), a specific endpoint which will be addressed in this study (see section 
1.8). 
1.4 HIV/AIDS & ART 
HIV is a retrovirus that was first isolated in 1983  (De Cock, 2011) and was subsequently 
proven to be the cause of acquired immunodeficiency syndrome (AIDS) a year later  
(Ruelas & Greene, 2013). Since then, the HIV/AIDS epidemic has evolved to become the 
greatest challenge in global health  (De Cock, Jaffe, & Curran, 2012), and one of the most 
devastating viral pandemics in history  (Freed, 2015). There are two strains of HIV, with 
HIV-1 being the main cause of AIDS, while HIV-2 is associated with isolated infections in 
central and western Africa  (Sharp & Hahn, 2011). With the prolonged period between HIV 
infection and symptomatic AIDS – on average 11 years in adults – there was widespread 
transmission of HIV before recognition of the epidemic and any prevention attempts  (De 
Cock, 2011). In the 1990s, almost 15 years after HIV/AIDS was discovered, ART was 
developed to combat HIV-1 infection  (Laskey & Siliciano, 2014). ART has dramatically 
improved survival of patients with HIV/AIDS (Thienemann et al., 2013), and patients who 
are diagnosed and treated with ART early can experience acceptable immune recovery 
and expect a near‐ normal lifespan  (Laskey & Siliciano, 2014; Thienemann et al., 2013). 
Although effective at suppressing viral replication, current drugs do not eradicate the virus, 
making treatment with ART a life-long necessity  (Freed, 2015). 
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Figure 1.11: Summary of the global HIV epidemic (2016)  (WHO, 2016). 
1.4.1 Epidemiology 
As of 2016, it is estimated that there are 36.7 million people worldwide living with HIV (Fig 
1.11), while around 35 million people have died from AIDS-related illnesses since the start 
of the epidemic  (UNAIDS, 2017; WHO, 2016). Southern Africa carries the highest burden, 
where as few as nine countries - which account for less than 2% of the world’s population - 
represent about one third of global HIV infections  (De Cock et al., 2012). 
 
With the rollout of ART and various prevention programmes in middle-and-low-income 
countries, the most affected populations are now receiving adequate treatment  (Delpech, 
2013). For this reason, the global prevalence of HIV has begun to plateau, and every year, 
there is a promising decline in newly infected individuals. 
1.4.2 Virus Structure, Targets and Life-cycle 
HIV-1 is a retrovirus that belongs to the lentivirus family. Infections with lentiviruses 
typically show a chronic course of disease, a long period of clinical latency and persistent 
viral replication  (Rubbert, Behrens, & Ostrowski, 2007). The HIV virion has a spherical 
shape and a diameter of  roughly 100–130 nm. The viral envelope is composed of a lipid 
membrane, which is derived from the host cell and contains cellular proteins, as well as 
about 7–12 trimeric complexes of viral envelope protein  (Kirchhoff, 2013). The core 
antigen contains two single strands of viral RNA (Fig 1.12) with a length of close to 10,000 
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nucleotides. The virion contains  the enzymatic equipment that is necessary for replication, 
namely a reverse transcriptase (RT), an integrase and a protease  (Rubbert et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Structure of an HIV virion particle  (Rubbert et al., 2007). Gp (glycoprotein); 
gag (group-specific antigen). 
 
The main targets of HIV are CD4+ helper T cells, which are key regulators of the humoral 
and cellular immune responses  (Kirchhoff, 2013). The destruction and depletion of these 
cells renders the body unable to defend itself against opportunistic pathogens, eventually 
resulting in AIDS  (Laskey & Siliciano, 2014). When HIV infects an activated CD4+ T cell, it 
hijacks and manipulates its transcriptional and translational machinery to reproduce itself  
(Kirchhoff, 2013). HIV also has the ability to infect other immune cells, such as 
macrophages and immature dendritic cells, which may play a role in harboring the virus in 
a silent integrated proviral form and thus contribute to the establishment and maintenance 
of viral reservoirs that prevent the eradication of HIV from the human body, even during 
ART  (Kirchhoff, 2013).  
 
The HIV-1 life cycle is complex and can roughly be divided in an early and a late phase of 
replication. The early phase begins with the attachment or fusion of the virion at the cell 
surface, includes reverse transcription of the viral RNA to DNA amongst other steps, and 
ends with the integration of the proviral DNA into the host genome  (Freed, 2015; 
Kirchhoff, 2013). The late phase of replication starts with the initiation of proviral 
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transcription and ends with the release of fully infectious progeny virions, which contain 
activated viral proteases  (Kirchhoff, 2013; Laskey & Siliciano, 2014). This process is 
summarized below in Figure 1.13. The viral life cycle illuminates some of the challenges 
associated with HIV infection. For example, the HIV life cycle lasts just one to two days 
and the viral RT has an extremely high mutation rate of roughly 1 error per 10 000 
nucleotides  (Kirchhoff, 2013). Together, a short generation time, a massive virus 
production rate of up to 2 109 virions per day, and a large error rate  (Sharp & Hahn, 
2011), allow HIV to rapidly adapt to its host environment and to develop resistance against 
ART or immune responses  (Kirchhoff, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.13: A brief summary of the HIV life-cycle  (Kirchhoff, 2013). Env (envelope); 
gp (glycoprotein); p (protein); tat (trans-activator of transcription); Rev (trans-activator 
involved in protein expression); gag (group-activated antigen). 
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1.4.4 Antiretroviral therapy (ART) 
Although there is no cure for HIV, more than 30 different anti-HIV drugs have now been 
approved for clinical use targeting different steps in the viral life cycle  (Ruelas & Greene, 
2013). ART suppresses the viral load by interfering with viral replication (Laskey & 
Siliciano, 2014). The different classes of antiretroviral (ARV) drugs are broadly classified 
by the phase of the retrovirus life cycle that the drug inhibits (Fig 1.14). 
 
 
Figure 1.14: Stages of the HIV life cycle that are targeted by ARV drugs  (Laskey & Siliciano, 
2014). CCR5 (C-C chemochine receptor type 5); CXCR4 (C-X-C chemochine receptor type 4); 
NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors); NNRTIs (non-nucleoside reverse 
transcriptase inhibitors); InSTIs (integrase strand transfer inhibitors); ALLINIs (allosteric integrase 
inhibitors);  Env (envelope); CD4 (cluster of differentiation 4). 
 
There are six main classes of ARVs  (AIDSinfo, 2013; Arts & Hazuda, 2012): The first and 
second ARV classes are co-receptor agonists and entry inhibitors/fusion inhibitors 
respectively. These classes of ARVs compete with specific receptors involved in HIV 
attachment and therefore block the attachment and subsequent entry of the virus into the 
host cell. The third and fourth type, are nucleoside or nucleotide reverse transcriptase 
inhibitors (NRTIs/NtRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
These two classes of ARVs stop the virus from converting its RNA into DNA. The fifth 
class of ARVs, are integrase inhibitors, which inhibit the viral enzyme integrase. Integrase 
is responsible for integration of viral DNA into the DNA of the infected cell. The last type of 
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ARVs, are Protease Inhibitors (PIs). PIs block the viral protease enzyme, which is 
necessary to produce mature and infectious virions. 
 
Initially, ARV drugs were given as monotherapy, but the standard of care has since 
evolved to include the administration of a cocktail or combination of ARV dugs  (Arts & 
Hazuda, 2012), in order to prevent drug resistance (Laskey & Siliciano, 2014). 
Combination therapy, also known as highly active antiretroviral therapy (HAART), consists 
of a combination of at least three ARV drugs - drawn from four of the six main ARV 
classes - where two or more NRTIs typically form the backbone of most regimens  (Carr, 
2003). In modern day treatment, co-formulations of these individual ARVs have reduced 
the “pill burden” and improved patient adherence  (Thompson et al., 2012). There are now 
19 licensed drugs in these four classes (Table 1.3), which can be combined into more than 
3,000 potential HAART regimens  (Carr, 2003). The firm establishment and 
implementation of HAART has led to major declines in opportunistic complications, making 
HIV infection more of a chronic disease than an acute one, and so more drugs are being 
used in more patients for longer periods  (Carr, 2003; Ruelas & Greene, 2013).  
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Table 1.3: Presently available ARV drugs. Drugs in each class are listed in approximate order of 
approval/availability  (Carr, 2003). 
 
1.4.5 HIV & ART in a South African Context 
SA has the largest HIV-infected population globally, with an estimated 7 million people 
living with HIV in 2015 (Statistics South Africa, 2015). The reason for this large South 
African population of HIV-infected people is unclear, but various biological and social 
factors may play a role  (De Cock, 2011). The long-term AIDS-denialism – the view that 
HIV is not the cause of AIDS- in SA may have also played a pivotal role, since it led to the 
delayed implementation of ART by the government and resulted in thousands of deaths. 
 
SA has the largest ART programme in the world (South African National AIDS Council, 
2015). In April 2014, more than 3 million people were receiving ART, which equates to 
47% of people living with HIV in the country  (South African National AIDS Council, 2015). 
This is a monumental increase compared to statistics from 12 years earlier, where only 2% 
of the HIV positive population in SA was receiving ART  (Joint United Nations Programme 
Drug Class Specific Drug 
Nucleoside reverse transcriptase inhibitors 
(NRTIs) 
 
Zidovudine (AZT), didanosine (ddl)*, 
zalcitabine (ddC), lamivudine (3TC)*, 
stavudine (d4T), abacavir (ABC)*, 
emtricitabine (FTC) 
Nucleotide reverse transcriptase inhibitors 
(NRTIs) 
Tenofovir disoproxil fumarate (TDF)*  
Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) 
Nevirapine (NVP), delavordine (DLV), 
efavirenz (EFV)* 
Protease inhibitors (PIs) Saquinavir (SQV), indinavir (IDV), 
ritonavir (RTV), nelfinavir (NFV), 
amprenavir (APV), lopinavir/ritonavir 
(rLPV), atazanavir (AZV)* 
Fusion inhibitors Efuvirtide (ENV; T-20) 
*Administered once daily.  
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on HIV/AIDS, 2010). The extent of the HIV/AIDS epidemic and the need for increased 
access to ART has had a profound effect on already stretched health care systems in SA  
(Levitt et al., 2011). In 2013, SA changed the CD4+ cut-off value at which patients could 
start ART, from 200 to 350 cells/µl, making more people eligible for treatment. By the end 
of 2014, SA increased the level again to 500, expanding eligibility even further  (South 
African National AIDS Council, 2015; UNAIDS, 2016). In 2015, the WHO released 
guidelines recommending people living with HIV be offered ART immediately following 
diagnosis, regardless of CD4+ count (Dutta et al., 2015). As of 2016, SA began 
implementing this recommendation  (South African National AIDS Council, 2016). Despite 
all of these implementations, HIV prevalence still remains as high as 19.2% among the 
general South African population, although, this varies considerably between regions  
(UNAIDS, 2014). 
1.4.5.1 SA First Line Fixed Dose Combination Therapy 
In 2013, a new fixed dose combination (FDC) therapy was implemented in SA, under 
various trade names, including Odimune®. A single Odimune® tablet consists of two 
NRTIs - Emtricitabine (FTC): 200 mg / day, and Tenofovir disoproxil fumarate (TDF): 300 
mg / day – as well as a NNRTI - Efavirenz (EFV): 600 mg / day (Table 1.4) (Davies, 2013). 
This combination constitutes the preferred first-line regimen for previously untreated 
patients  (Meintjes et al., 2014). A once daily FDC tablet has substantially simplified the 
prescription, dispensing and stock management of ART drugs  (Davies, 2013), as well as 
improved treatment adherence and the burden on patients subjected to multiple drug 
regimens  (Meintjes et al., 2014). Table 1.4 summarizes various aspects of the different 
ARV drugs used in South African first line ART. 
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Table 1.4: Summary of ARVs used for first line FDC therapy in SA  (Arts & Hazuda, 2012; Davies, 2013; Does, Thiel, & Johnson, 2003; Meintjes 
et al., 2014; Palmisano & Vella, 2011; Sierra-Aragon & Walter, 2012). 
Name Class 
Recommended 
Dose (mg/day) 
Mr 
(g/mol) 
Mechanism of action Common or severe ADR† 
Alternative 
drugs 
Emtricitabine 
(FTC) 
NRTI 200 247.2 Cellular enzymes phosphorylate 
FTC to FTC-5’- triphosphate 
which in turn competes with the 
natural substrate, deoxycytidine 
5’- triphosphate and is 
subsequently incorporated into 
the nascent viral DNA and leads 
to chain termination. 
Palmar hyperpigmentation, 
hyperlactataemia/ 
steatohepatitis (very low 
potential). 
Lamivudine 
(3TC). 
Tenofovir 
disoproxil 
fumarate 
(TDF) 
NtRTI 300 287.2 TDF diphosphate inhibits HIV RT 
through competition with the 
natural substance 
deoxyadenosine 5’- triphosphate 
and leads to DNA chain 
termination after incorporation 
into the viral-DNA.  
Renal failure, tubular 
wasting syndrome, reduced 
bone mineral density, 
hyperlactataemia/ 
steatohepatitis (very low 
potential). 
Abacavir (ABC). 
Efavirenz 
(EFV) 
NNRTI 600 (at night) – 
400 if < 40kg 
315.7 Diffuses into the host cell and 
binds next to the active site of RT 
which leads to a conformation 
change and inhibits the enzyme’s 
function. It is also a non-
competitive inhibitor of HIV RT 
with respect to template, primer 
or nucleoside triphosphates. 
Central nervous system 
symptoms (vivid dreams, 
problems with concentration, 
dizziness, confusion, mood 
disturbance, psychosis), 
rash, hepatitis, 
gynaecomastia. 
Rilpivirine (RPV), 
nevirapine (NVP) 
– If EFV; RPV 
and NVP are 
contraindicated,  
raltegravir (RAL) 
or a PI can be 
substituted. 
†Life-threatening reactions are included in bold. Mr (molecular weight); ADR (adverse drug reaction); mg (milligram); g (gram); mol (mole); RT (reverse 
transcriptase); kg (kilogram). 
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1.5 HIV, ART and ED/CVD 
It has been established that the prevalence of CVD is augmented in HIV positive patients 
compared with the general population  (Masiá et al., 2007), with recent studies showing 
the relative risk of developing CVD as high as 61% higher in HIV positive populations 
compared to uninfected people  (Islam, Wu, Jansson, & Wilson, 2012). Factors associated 
with HIV infection and ART have been implicated in the premature development of 
atherosclerosis and coronary heart disease (CHD)  (Masiá et al., 2007). CVD is the 
leading comorbidity and cause of death in this population  (DAD Study Group, 2007; 
Thienemann et al., 2013), where ED is thought to be the main link between HIV infection, 
ART and CVD and atherosclerosis  (Francisci et al., 2009), amongst other factors (Table 
1.5)  (de Larrañaga, Petroni, Deluchi, Alonso, & Benetucci, 2003; Wolf et al., 2002). It has 
been reported that enhanced oxidative stress in HIV infected patients may contribute to 
ED, while it has also been shown that ART and therapeutic control of HIV replication 
induces a pro-oxidative state  (Day & Lewis, 2004; Hulgan et al., 2003).  
Table 1.5: Mechanisms by which HIV and ART may adversely affect the vasculature  (Dube et al., 
2008). 
 
HIV infection ART 
Endothelial dysfunction Endothelial dysfunction 
Lipid disorders associated with HIV infection Increased endothelial permeability 
Viral protein-related EC activation Increased oxidative stress 
Systemic inflammatory cytokine-chemokine 
dysregulation 
Increased mononuclear cell adhesion 
Direct HIV infection of endothelium and 
VSMCs 
Insulin resistance 
Enhanced atheroma formation by activated 
macrophages 
Accelerated lipid accumulation in vessel 
wall 
Prothrombotic state Persistent inflammation and immune 
activation 
 Impaired response to vascular injury 
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However, it is still debated whether cardiovascular complications are a consequence of the 
HIV infection itself or due to the long-term use of ART  (Francisci et al., 2009). Certain 
studies have shown that it may be the ART that is responsible for the increased risk for 
CVD  (Obel et al., 2007), with one study in particular showing that the risk of CVD for 
people living with HIV receiving ART was found to be two times greater than the risk for 
HIV positive patients who were treatment-naïve  (Islam et al., 2012). Other studies contest 
this evidence, suggesting HIV infection itself and not ART is the pathological initiator  
(Baker et al., 2011; Francisci et al., 2009). The Strategies for Management of Anti-
Retroviral Therapy (SMART) study, showed that persons undergoing episodic ART had an 
increased risk of cardiovascular events identical to that of patients undergoing continuous 
therapy  (Strategies for Management of Antiretroviral Therapy (SMART) Study Group, 
2006). Some studies have even shown that ART actually has a protective role in terms of 
risk for ED and CVD  (Arildsen, Sørensen, Ingerslev, Østergaard, & Laursen, 2013; 
Francisci et al., 2009; Grubb et al., 2006; Solages et al., 2006; Torriani et al., 2008; Wolf et 
al., 2002), suggesting rather that viral load, CD4+ cell count and cardiovascular risk factors 
are responsible for the endothelial function impairment observed in other studies  (van 
Wijk et al., 2006; Wolf et al., 2002). It is important to note however, that most studies 
showing a cardioprotective role for  ART, were performed in treatment-naive patients, 
initiating short term ART treatment (up to 24 weeks)  (Torriani et al., 2008). Therefore it is 
uncertain if the improvements were due to ART, suppression of viremia, or changes in 
immune activation  (Torriani et al., 2008). Unfortunately, it is still unclear how to distinguish 
the effects of a chronic HIV infection from those of ART  (Skowyra, Zdziechowicz, Mikuła, 
& Wiercińska-Drapało, 2012), making a consensus more difficult to obtain. 
1.5.1 ART induced ED/CVD 
Although ART has dramatically reduced HIV-associated morbidity and mortality  (Jiang et 
al., 2007), life-long treatment may expose patients to an increased risk for developing CVD 
(DAD Study Group, 2007; SMART study group, 2006). With recent consensus guidelines 
recommending the initiation of ART as early as possible in the course of HIV infection, the 
average duration of exposure to ART is increasing, and therefore complications associated 
with treatment are also expected to become more common  (Choi et al., 2011). Despite all 
the confounding reports, the vast majority of trials indicate that ART can lead to ED  
(Skowyra et al., 2012). Cardiovascular complications are considered a new challenge for 
HIV patients receiving ART with numerous studies investigating the effects of ART on the 
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vasculature indicating that ART may impair the function of the vascular endothelium  
(Blanco et al., 2006; Shankar, Dubé, Gorski, Klaunig, & Steinberg, 2005; Stein et al., 
2001). The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study group 
reported that ART was associated with a 26% increase in the rate of myocardial infarction 
(MI) per year of exposure to ARV drugs  (DAD Study Group, 2007). This finding lead to the 
theory that duration of exposure to ART may be one of the main factors associated with 
risk of developing CVD, which has been confirmed in other studies  (Islam et al., 2012). 
 
The major underlying mechanism is thought to be ART-induced NO serum level reduction, 
as well as increased ROS and cholesterol  (Skowyra et al., 2012). ART-induced ROS 
production is thought to be of mitochondrial origin, likely resulting from mitochondrial 
dysfunction and leakage of electrons from a dysfunctional mitochondrial electron transport 
chain  (Jiang et al., 2007). There is controversy however; surrounding which ART class 
has the highest degree of associated risk of developing CVD.  
1.5.1.1 Protease Inhibitors 
The majority of studies investigating ART have demonstrated that PI’s are associated with 
increased cardiovascular risk. PIs are thought to directly induce ED by damaging 
mitochondrial DNA of ECs  (Skowyra et al., 2012). An early study documented severe ED 
in patients who received long-term, PI–based ART (mean duration of ART was 70 months, 
including 31 months of therapy with a PI) but not in those receiving ART without a PI  
(Stein et al., 2001). In contrast, another early observational study of hospitalisation rates in 
Northern California, Klein et al. (2002) found that PIs did not tend to increase the rates of 
hospitalisations for CHD among persons living with HIV. Increased risk of MI in HIV 
patients receiving PI-based ART has been reported by multiple cohorts  (DAD Study 
Group, 2007; Holmberg et al., 2002; Lang et al., 2010). Yeboah et al. (2007) demonstrated 
that the administration of a PI impaired endothelial function in healthy men, while several 
other studies have identified cellular or molecular mechanisms of ED associated with the 
use of PIs  (Grubb et al., 2006; Wang, Chai, Yao, & Chen, 2007; Zhong et al., 2002). 
Clinical and experimental models have shown that PI-induced ED appears to be mediated 
by reduced NO production  (Shankar et al., 2005), due to reduced expression of eNOS  
(Fu, Chai, Yao, & Chen, 2005) and increased ROS  (Dube et al., 2008).  
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1.5.1.3 Nucleoside Reverse Transcriptase Inhibitors 
More recent studies have also implicated NRTI-based ART in playing a damaging role  
(Carr, 2003; Choi et al., 2011; Gallant, Parish, Keruly, & Moore, 2005; Jiang et al., 2007; 
Sutliff et al., 2002; Young et al., 2007), with far less literature being available regarding the 
specific effects of NNRTI-based ART  (Hulgan et al., 2003; Stein et al., 2001). This is of 
particular relevance for South African first line ART, which is composed of two Marti’s and 
one NNRTI. NRTI-based ART use is also associated with an increased risk of CVD, but 
not to the same extent as PI-based ART (Islam et al., 2012). Mitochondrial toxicity is 
recognised as the most common side effect of NRTIs  (Sutliff et al., 2002), and is 
associated with the development of a number of tissue-specific complications  (Lewis & 
Dalakas, 1995). Mitochondrial dysfunction is thought to be the result of two interrelated 
pathophysiological mechanisms that result from defective oxidative phosphorylation, 
namely increased production of mitochondrial ROS and reduced energy production  
(Lewis, Copeland, & Day, 2001). Furthermore, the production of free radicals has been 
implicated in mitochondrial DNA damage and dysfunction in ECs  (Ballinger et al., 2000). A 
study by Sutliff et al. (2002) demonstrated that NRTIs profoundly impaired endothelium-
dependent relaxation in murine aortas, with increased O2− levels being implicated as the 
mediator of these adverse effects. This finding has been supported by numerous other 
studies that have found a link between NRTI toxicity and increased free radical levels  (de 
la Asuncion et al., 1998; Jiang et al., 2007; Jiang, Hebert, Zavecz, & Dugas, 2006). 
Together, these mechanisms are thought to be responsible for the association of NRTI’s 
with accelerated vascular disease such as platelet activation, hyperlipidemia, T-
lymphocyte activation, abnormal endothelial function and vascular inflammation  (Choi et 
al., 2011). In contrast, a recent meta-analysis of clinical trial studies found that NRTIs were 
not associated with a greater risk of MI or major CVD events, despite reports from other 
cohort studies  (Cruciani et al., 2011). 
 
It is important to note that majority of the studies reported in the literature are conducted 
using one or two specific PIs or NRTIs. Therefore one should be wary when making 
conclusions, since adverse effects discovered in a particular drug should not generally be 
considered representative of the entire drug class  (Dube et al., 2008). It is thus very 
important to expand the literature and report findings on all ARV drugs currently in use, 
and in all the different classes of ART. 
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1.6 Melatonin 
Melatonin is a hormone found in all vertebrates, and almost ubiquitously present in 
bacteria, protozoa, plants, fungi and invertebrates  (Hardeland & Poeggeler, 2003). It is 
rhythmically secreted by the pineal gland, and involved in regulation of circadian and, 
sometimes, seasonal rhythms  (Reiter, 1993). Melatonin is an indoleamine, which 
contributes to its amphiphilicity, which means it has the ability to enter any cell, 
compartment or body fluid  (Hardeland, Pandi-Perumal, & Cardinali, 2006). During 
melatonin synthesis, its precursor tryptophan, is taken up from the blood and converted, 
via 5-hydroxytryptophan, to serotonin. Serotonin is then acetylated to form N-
acetylserotonin by arylakylamine N-acetyltransferase (AA-NAT), which, in most cases, 
represents the rate-limiting enzyme. N-acetylserotonin is then converted into melatonin by 
hydroxyindole O-methyltransferase (Fig 1.15) (Pandi-Perumal et al., 2006; Sprenger, 
Hardeland, Fuhrberg, & Han, 1999).  
 
  
Figure 1.15: Pathways of indolic catabolism involved in the formation 
of melatonin (Pandi-Perumal et al., 2006). 
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Pineal melatonin production exhibits a circadian rhythm, with a low level during daytime 
and high levels during night  (Pandi-Perumal et al., 2006). Melatonin is able to retrain the 
circadian rhythm through its short biological half-life, whereby serum levels of 
approximately 0.4 nM peak at night  (Brzezinski, 1997). This circadian rhythm persists in 
most vertebrates, irrespective of whether the organisms are active during the day or during 
the night  (Borjigin, Li, & Snyder, 1999; Claustrat, Brun, & Chazot, 2005). Other than 
regulation of circadian rhythms, melatonin also appears to play a role in 
immunomodulation, reproduction, tumor growth, and aging  (Brzezinski, 1997). Most 
importantly, melatonin has also been shown to exhibit strong antioxidative properties  
(Hardeland et al., 2006). 
1.6.1 Antioxidant Actions 
Melatonin has been reported to have both direct and indirect antioxidant properties (Fig 
1.16)  (Bonnefont-Rousselot & Collin, 2010; Hardeland, 2005; Tan et al., 2002). Direct 
antioxidant properties of melatonin include the scavenging of ROS  (Poeggeler et al., 
2002), while indirectly, melatonin upregulates antioxidant enzymes  (Hardeland, 2005). 
The antioxidant activity of melatonin has been reported at both physiological and 
pharmacological concentrations  (Galano, Tan, & Reiter, 2011; Reiter, Tan, & Maldonado, 
2005), although pharmacological doses of exogenously administered melatonin typically 
provide greater protection from large quantities of free radicals  (Tan, Manchester, Terron, 
Flores, & Reiter, 2007). As a whole, the antioxidant properties of melatonin suggest that it 
could have significant potential in treating chronic diseases associated with oxidative 
stress (Fig 1.16). 
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Figure 1.16: Direct and indirect actions of melatonin in an antioxidative capacity  (Bonnefont-Rousselot & Collin, 2010). Directly, 
melatonin acts as an antioxidant, where it has the ability to directly neutralise reactive species. Indirectly, melatonin up-regulates other 
antioxidant enzymes that in turn, are capable of removing various reactive species. GSH-Px (glutathione peroxidase); ROS (reactive 
oxygen species); SOD (superoxide dismutase). 
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1.6.1.1 Free radical Scavenging 
There is a vast amount of literature documenting melatonin’s ability to directly scavenge 
both ROS and RNS  (Allegra et al., 2003; Poeggeler et al., 2002; Reiter, Tan, Manchester, 
& Qi, 2001; Tan et al., 2002). Specific species removed by melatonin include OH-, H2O2, 
singlet oxygen, O2-, NO and ONOO-. 
Melatonin is able to neutralise OH- by trapping OH- in one of its indole rings  (Tan et al., 
2002). H2O2 and singlet oxygen - an energy-rich form of O2 - are thought to be removed 
through their reaction with melatonin is the presence of the substrate N1-acetyl-N2-formyl-
5-methoxykynuramine (AFMK)  (Tan et al., 2000), although this has only been 
demonstrated in a pure chemical system and whether intracellular melatonin neutralizes 
H2O2 in this manner is unknown  (Reiter et al., 2003). Surrounded by more uncertainty, is 
the  efficacy of melatonin in neutralizing the O2-, which is poorly defined, and still 
particularly unclear in vivo. Far more is known regarding melatonin’s interaction with NO. 
Blanchard et al. (2000) initially showed that melatonin is only capable of interacting with 
NO in the of presence of O2, suggesting that melatonin may rather react with a molecule 
derived from NO, possibly ONOO-  (Reiter et al., 2003). See Table 1.6 for a summary. 
1.6.1.2 Antioxidant Upregulation 
Antioxidant enzymes represent a first line of defence against toxic oxidant reactants by 
metabolizing them to innocuous by-products  (Rodriguez et al., 2004). The main 
antioxidant enzymes upregulated by melatonin are  superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx), glutathione reductase (GRd) and tripeptide 
glutathione (GSH)  (Bonnefont-Rousselot & Collin, 2010; Hardeland, 2005; Hung et al., 
2013; Tengattini et al., 2008). 
As previously mentioned on page 13, SOD converts O2- to H2O2, thereby decreasing the 
formation of ONOO- (Mudau et al., 2012). SOD works in conjunction with other antioxidant 
enzymes such as CAT and GPx, which are also capable of removing H2O2.   (Tengattini et 
al., 2008). CAT promotes the  conversion of H2O2 to H2O and O2, while GPx converts 
peroxides to H2O using GSH as a substrate  (Valko, Rhodes, Moncol, Izakovic, & Mazur, 
2006). Melatonin further facilitates this reaction by maintaining high intracellular levels of 
GSH. Besides upregulating antioxidants, melatonin can also downregulate pro-oxidative 
enzymes like NOS, which in turn decreases NO production, and decreases the amount of 
NO available to react with O2-, ultimately decreasing ONOO- levels  (Aydogan, Yerer, & 
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Goktas, 2006; Karbownik & Reiter, 2000). All these effects of melatonin are summarised in 
Table 1.6 and Figure 1.17 below.  
This regulation of antioxidants and oxidants by melatonin is controlled through messenger-
ribonucleic acid (mRNA)  (Hung et al., 2013). When melatonin binds to its receptor, it 
stimulates the phospholipase C pathway. The consequent increase in calcium 
concentration leads to the phosphorylation of protein-kinase C (PKC). PKC activates 
protein/activation transcription factor cAMP responsive element binding protein and 
activating transcription factor (CREB-ATF)  (Tengattini et al., 2008). This pathway 
modulates immediate early gene transcription and consequently gene transcription 
regulation and antioxidant enzyme levels. 
 
The effects of melatonin on the mitochondria  has become another recent research focus. 
It is well established that the opening of the mitochondrial permeability transition pore 
(mtPTP) causes mitochondrial swelling and rupture of the outer mitochondrial membrane, 
leading to the release of pro-apoptotic factors such as cytochrome c (Petrosillo et al., 
2009). Melatonin appears to have the ability to safeguard the respiratory electron flux, 
reduce oxidant formation by lowering electron leakage, and inhibit the opening of the 
mtPTP  (Hardeland, 2005). A study by Petrosillo et al. (2009) showed that melatonin 
treatment had the ability to completely inhibit mitrochondrial cytochrome c release in the 
hearts of male Wistar rats during ischemia-reperfusion. The same study also found that 
melatonin treated hearts were also less sensitive to mtPTP opening, demonstarting overall 
the protective effect of melatonin through inhibiting the opening of the mtPTP.  
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Table 1.6: Effects of melatonin on ROS/RNS and oxidant enzymes  (Tengattini et al., 2008). ROS 
(reactive oxygen species); RNS (reactive nitrogen species);  (decrease);  (increase). 
 
Action Target Effect 
Scavenging 
ROS 
Hydrogen peroxide  
Hydroxyl radical  
Singlet oxygen  
RNS 
Nitric oxide  
Peroxynitrite anion  
Up-regulation Antioxidant enzymes 
Superoxide dismutase  
Catalase  
Glutathione peroxidase  
Glutathione reductase  
Tripeptide glutathione  
Down-regulation Pro-oxidative enzymes Nitric oxide synthase  
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Figure 1.17: Oxidative stress and sites of action of melatonin  (Kücükakin, Gögenur, Reiter, & 
Rosenberg, 2009; Nduhirabandi, 2010). NADP (nicotinamide adenine dinucleotide phosphate); 
NADPH (the reduced form of NADP); GSH (reduced glutathione); GSSG (glutathione disulfide). 
 
1.6.2 Melatonin in ART induced ED 
As discussed earlier, it has been established that the main cause of ART induced ED is 
oxidative stress due to excessive generation of ROS and RNS, and an imbalance in anti- 
and pro-oxidative substances. For these reasons, it has been suggested that the treatment 
or prevention of ART induced ED might be achieved through the use of antioxidants  
(Dube et al., 2008). A study by De la Asuncion et al. (1998) showed that treatment with 
antioxidant vitamins significantly reduced the development of NRTI-mediated cardiac 
myopathies, while on the other hand, other studies have shown antioxidant vitamins to 
have no effect  (Sutliff et al., 2002), while the clinical use of antioxidants to ameliorate ED 
in patients receiving ART is not well documented  (Dube et al., 2008). Therefore, more 
research is needed in order to determine whether antioxidants other than vitamins can be 
effective in combating ART induced ED. 
Melatonin is the optimal antioxidant since it has both the capacity to scavenge radicals as 
well as upregulate other antioxidants and down-regulate pro-oxidative enzymes 
(Bonnefont-Rousselot & Collin, 2010; Hardeland, 2005; Tan et al., 2002). Melatonin is a 
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particularly favourable putative therapeutic agent for the treatment of ART induced ED 
since it has the ability to cross physiological barriers and enter cells, unlike other 
antioxidants whose actions are limited because of their solubility that limits their 
partitioning between intra- and extra-cellular compartments  (Bonnefont-Rousselot, Collin, 
Jore, & Gardès-Albert, 2011). Melatonin also offers protection against radical-induced 
mitochondrial damage, which is an important attribute considering mitochondria have been 
implicated as one of the main sources of ART-induced ROS generation  (Jiang et al., 
2007; Lewis et al., 2001). Melatonin has the ability to inhibit the mitochondrial production 
of superoxide anion and hydrogen peroxide that directly activates the mtPTP - a critical 
event in mitochondrial-mediated cell death  (Bonnefont-Rousselot et al., 2011). The 
inhibition of the mitochondrial production of O2- and H2O2 by melatonin has been shown to 
maintain the efficiency of oxidative phosphorylation and ATP synthesis while increasing 
the activity of the respiratory complexes  (López et al., 2009). Therefore, in theory, 
melatonin has promising potential as a therapeutic agent, which can be co-administered 
with ART, however, further research is needed. 
1.7 Conclusion 
The wide spread use of ART has dramatically reduced HIV/AIDS related morbidity and 
mortality. With the early commencement of ART, patients are spending longer periods of 
their lives on these drugs, and due to ART-associated increased life expectancy of these 
patients, there is a large population of people currently living with HIV, receiving ART. It 
has been established that long-term or life-long exposure to ART has been associated 
with increased risk of developing ED. ED is a critical factor in the initiation and of 
progression CVD, but with early detection and treatment, ED can be reversed. The 
underlying mechanisms of ART induced ED are still unclear, but the main cause seems to 
be increased levels of ROS/RNS resulting in oxidative stress and damage. It has been 
proposed that antioxidant treatment could be a potential solution; with melatonin 
possessing all the desired properties needed to reduce and potentially reverse ART 
induced ED. However, literature documenting the specific relationship between melatonin 
and ART treatment is scarce, and therefore further research is required. 
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1.8 Problem Identification and Study Aims 
1.8.1 Problem Identification 
There is a substantial amount of literature documenting the relationship between HIV, ART 
and ED (Day & Lewis, 2004; Francisci et al., 2009; Masiá et al. 2007). These studies are 
limited by the inherent difficulty in differentiating between direct drug-based effects and 
potential HIV effects, secondary host immunological responses, or metabolism-mediated 
effects on the endothelium  (Grubb et al., 2006). There is a lack of studies that investigate 
the effects of ART alone, with less than a hand-full of studies to date looking at the effects 
of South African first line FDC ART (EFV + FTC + TDF) on endothelial health (Charania, 
2017; Imperial, 2017; Mashele et al., 2016). With the South African health authorities 
increasing the output and accessibility of ART, and the documented unfavorable effects of 
NRTI’s in particular on the endothelium and cardiovascular system (Choi et al., 2011; 
Jiamg et al., 2007; sutliff et al., 2002), it is important to assess this relationship. Since ART 
is a life-long therapy, it is important to find a potential co-treatment that will not interact with 
the effects of the ARV drugs themselves, as well as a therapy which can be used long 
term without any negative side effects. Melatonin meets these criteria, since it has the 
ability to target all the suggested mechanisms of ROS and RNS production caused by 
ART. Furthermore, melatonin is a naturally occurring hormone that has shown no toxicity, 
even at supra-pharmacological levels (Guardiola-Lemaitre, 1997; Tan et al., 2007). All 
these advantages of melatonin supplementation make the antioxidant hormone a 
preferential choice over other antioxidative supplements. Therefore, we propose that 
melatonin may have the potential to ameliorate potential endothelial damage caused by 
the first line FDC ART drug currently used in SA. 
1.8.2 Main Study Aim 
To investigate the effects of melatonin supplementation during first line FDC ART: an in 
vitro, ex vivo and in vivo approach. 
1.8.2.1 Specific in vitro Study Objectives 
 Determine the individual optimum concentrations of both melatonin and first line 
FDC ART treated aortic endothelial cells (AECs) at which the greatest differences 
are seen when compared to untreated AECs, with respect to: 
o NO production 
o RNS production 
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o Cell viability 
 Use the optimum concentrations obtained in the dose-response experiments above, 
to treat AECs with melatonin and ART in combination, in order to analyse any 
potential synergistic/antagonistic interactions between the two drugs with respect to:  
o NO production 
o RNS production 
o Cell viability 
 Examine various protein activation and/or expression levels of important vascular 
signalling molecules in Melatonin- and/or ART-treated AECs. 
 Examine antioxidant capacity exhibited by Melatonin- and/or ART-treated AECs. 
 
1.8.2.2 Specific ex vivo and in vivo Study Objectives 
 Determine the acute effects of melatonin and ART administration on the vascular 
reactivity of untreated, control male Wistar rat aortas. 
 Determine the chronic effects of melatonin and ART administration on the vascular 
reactivity of male Wistar rats that have been treated for 8 weeks with melatonin 
and/or ART. 
 Examine various protein activation and/or expression levels of important vascular 
signalling molecules in the aortic tissue of male Wistar rats that were treated  for 8 
weeks with melatonin and/or ART. 
 Examine antioxidant capacity exhibited in the aortic tissue of the  rats subjected to 
the same treatment as above. 
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2 - Materials and Methods: In vitro studies 
Chapter 2 contains the materials and methods used for the in vitro aortic endothelial cell 
(AEC) culture experiments. The results for these studies can be found in Chapter 4. 
2.1 Aortic Endothelial Cell Culture 
For all cell culture experiments, a sample size of 1 was considered as an experiment 
conducted on a single day with a single batch of cells (biological replicate). The cells of the 
single experiment (n = 1) were divided amoungst differnet plates and randomly subdivided 
into the various treatment groups (2 - 3 plates per treatment group = technical repliactes). 
The mean value of the technical replicates constitutes the value for a single smaple (n = 
1). This process was then repeated on a different day with a new batch of cells in order to 
increase the sample size. A sample size of 3 – 4 biological replicated (n = 3 – 4) was 
considered sufficient, since it is the standard sample size optimised and used by our 
laboratory (Genis, 2014; Mudau; 2012; Strijdom et al., 2008), as well as used in other 
publications using aortic endothelial cells (Fulton et al., 2002; Mondal et al., 2013). 
2.1.1 Materials 
 AECs (adult rat): Purchased from VEC Technologies (University at Albany 
Foundation, 1 University Pl, Rensselaer, NY 12144, USA). 
 Endothelial cell growth medium (EGM-2): Lonza Ltd (Clonetics, Cambrex Bio 
Science, Walkersville, USA) (supplied by Whitehead Scientific locally). 
 Attachment factor and trypsin (500 BAEE units’ trypsin / 180 μg EDTA•4Naper ml in 
Dulbecco’s PBS): Life Technologies (Carlsbad, California, USA). 
 Foetal bovine serum (FBS): Biochom-Biotech. 
 Dimethyl sulfoxide (DMSO): Sigma-Aldrich (St Louis, Mo, USA).  
2.1.2 Passaging 
Pure primary adult rat AECs were received from the USA in culture in 75 cm3 flasks and 
further grown in EGM-2 growth medium in our own laboratory until fully confluent. EGM-2 
growth medium was supplemented with 10% FBS; heparin; long chain human insulin-like 
growth factor (R3-IGF-1); recombinant human epidermal growth factor (rhEGF); antibiotic 
GA 1000 (contains gentamicin and amphotericin); vascular endothelial growth factor 
(VEGF); ascorbic acid; recombinant human fibroblastic growth factor B (rhFGF-B) and 
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hydrocortisone in accordance with the manufacturer’s instructions. The cells were grown in 
a standard tissue culture incubator (Forma Series II, Thermo Electron Corporation, 
Waltham, MA, USA) at 37 oC in a 40 – 60% humidified, 5% CO2 atmosphere, and received 
fresh medium every second day. The primary AECs were grown to various “Parent (P)- 
generations” (see Figure 2.1) and then suspended in a freezing medium (90 % FBS, 5 % 
growth medium and 5 % DMSO) and stored in liquid nitrogen for future use. Cultures 
between the 4th and 7th generation were used for experiments. These parent cells were 
removed from liquid nitrogen, allowed to thaw and given fresh medium. Once the new 
cultures reached confluency, the cells were washed with phosphate-buffered saline (PBS) 
and incubated with pre-warmed (37 oC) trypsin until cells detached from the bottom of 
gelatin-containing attachment factor-coated 35 mm petri dishes (approximately 3 minutes). 
Using a 1 ml pipette, the detached cells were then rapidly transferred to a 15 ml conical 
tube containing fresh growth media, which deactivates the trypsin and prevents the cells 
from lysing. The tube containing the cells was then centrifuged for 3 minutes at 1000 
revolutions per minute (rpm). The supernatant was aspirated and pellet re-suspended in 
fresh growth medium. The media containing the cells was then split between new 35 mm 
petri dishes that had been pre-incubated with attachment factor for at least 1 hour prior to 
the passage. Passaging to the next generation was performed at a 1:2 ratio. A summary of 
the passaging process can be found in Figure 2.1. 
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Figure 2.1: Passaging and cell aliquot storage procedures  (Genis, 2014). 
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2.2 Experimental Groups and Protocols 
All experiments were performed on confluent cells. The close cell-to-cell contact minimises 
possible cell cycle variability when evaluating experimental results. The cells remain 
morphologically and functionally viable, however since they enter cell-cycle arrest, they are 
no longer proliferative. For all cultures, petri dishes were randomly assigned to respective 
control and experimental groups. Cells were serum starved before being treated in order to 
induce cell cycle synchronization, which enhances the cells’ responses to experimental 
treatment  (Gerber et al., 1998; Russell & Hamilton, 2014), in otherwise healthy cells. For 
cells to be serum starved, they were incubated in medium containing 0 % FBS for 24 
hours prior to treatment with the various drugs. 
2.2.1 Melatonin and Vehicle 
For melatonin dose-response experiments, 23.2 mg of melatonin (Sigma Aldrich, St Louis, 
MO, USA) was dissolved in 150 µl methanol (MeOH) vehicle. This solution was further 
dissolved in a total volume of 10 ml by adding 9.850 ml of distilled water (dH2O), thus 
creating a 10 mM melatonin stock. The 10 mM melatonin stock was further diluted in dH2O 
to make various concentrations. Freshly made melatonin stock was used for every 
experiment, just before treatment. Since melatonin is highly light sensitive, the lights were 
always turned off during preparation, dilution and treatment with melatonin. All tubes 
containing melatonin were also covered in tin foil for extra protection from the light. Vehicle 
preparations followed the same protocol as melatonin preparation, with the omission of 
melatonin. 
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Melatonin dose-response experiments consisted of the following groups: 
 Absolute Control (AC) 
o The AC group is a control group that does not receive any fluorescent probe 
and therefore represents the auto-fluorescence of cells. 
 Control (C) 
o The C group in an untreated group where normal media is added to the 
plate, and the plate is kept in the same conditions as the treated plated over 
the treatment period. 
 Positive Control (+C) 
o The +C group is treated with a product that is known to induce the expected 
effect and therefore validates the experimental procedure. 
 1 nM Melatonin (1 nM Mel) 
 1 nM Vehicle (1 nM Veh) 
 1 µM Melatonin (1 µM Mel) 
 1 µM Vehicle (1 µM Veh) 
 10 µM Melatonin (10 µM Mel) 
 10 µM Vehicle (10 µM Veh) 
Refer to Appendix A for detailed melatonin and vehicle concentration calculations. 
2.2.2 ART and Vehicle 
South African first line FDC ART consists of three individual ARV drugs, namely efavirenz 
(EFV), emtricitabine (FTC), and tenofovir (TDF). For experimental purposes, drugs were 
purchased in their individual ARV form from SantaCruz Biotechnology (WhiteHead 
Scientific in SA). The drugs were received in 10 mg powder form and dissolved in various 
solvents/vehicles.  
For ART dose-response experiments, three concentrations were chosen for each 
individual ARV component (EFV: 5 µM; 8 µM; 12 µM, FTC: 5 µM; 7.5 µM; 10 µM, TDF: 80 
nM; 400 nM; 1 µM). The various concentrations were chosen based on literature 
documenting the use of these specific ARV drugs in cells and rats  (Bertrand & Toborek, 
2015; Borroto-Esoda, Vela, Myrick, Ray, & Miller, 2006; Bousquet, Pruvost, Guyot, 
Farinotti, & Mabondzo, 2009; De Pablo et al., 2012; Glover et al., 2014; Jamaluddin, Lin, 
Yao, & Chen, 2010). The average serum concentration found in humans after taking 
the recommended dose of the relevant individual ARV drug was also taken into 
consideration when deciding on the final concentrations  (Kearney, Flaherty, & Shah, 
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2004; Luber et al., 2010; Molina et al., 2004; Villani et al., 1999). The three concentrations 
were either classed as a low, mid or high concentration for the purposes of this study. For 
experimental treatment, the individual ARV drug components (EFV; FTC and TDF) were 
combined to form a drug cocktail similar to the first line FDC ART drug regimen. The three 
drugs were combined in such a way that the low concentration of each individual ARVs 
were combined to form one low concentration FDC ART regimen. The same was applied 
for the mid and high concentrations (Fig 2.2). See below for the specific concentrations 
used in the low, mid and high concentration groups. 
ART dose-response experiments consisted of the following groups: 
 Absolute Control (AC) 
o The AC group is c control group that does not receive any fluorescent probe 
and therefore represents the auto-fluorescence of cells. 
 Control (C) 
o The C group in an untreated group where normal media is added to the 
plate, and the plate is kept in the same conditions as the treated plated over 
the treatment period. 
 Positive Control (+C) 
o The +C group is treated with a product that is known to induce the expected 
effect and therefore validates the experimental procedure. 
 Low concentration ART (Low ART) 
 Low concentration Vehicle (Low Veh) 
 Mid concentration ART (Mid ART) 
 Mid concentration Vehicle (Mid Veh) 
 High concentration ART (High ART) 
 High concentration Vehicle (High Veh) 
Refer to Appendix B for detailed ARV and vehicle concentration calculations. 
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Figure 2.2: Individual ARV drug concentrations that were combined to make-up the three fixed 
dose combination ART treatment groups. 
2.2.2.1 EFV 
The 10 mg EFV powder was dissolved in 1.5 ml of MeOH vehicle to create an EFV stock 
solution (21.119 mM). This stock was then divided into 40 µl aliquots and frozen away at -
20 oC until needed. For experiments, the required amount of aliquot was thawed and 
added in specific quantities to growth medium to yield the desired final concentration of 
ART. Vehicle preparations followed the same protocol, with the omission of the actual 
drug. 
2.2.2.2 FTC 
The 10 mg FTC powder was dissolved in 4 ml of dH2O vehicle to create an FTC stock 
solution (10.111 mM). This stock was then divided into 65 ul aliquots and frozen away at -
20 oC until needed. For experiments, the required amount of aliquot was thawed and 
added in specific quantities to growth medium to yield the desired final concentration of 
ART. Vehicle preparations followed the same protocol, with the omission of the actual 
drug. 
2.2.2.3 TDF 
The 10 mg TDF powder was dissolved in 40 ml of dH2O vehicle to create TDF stock 
solution A (0.3934 mM). TDF stock solution A was then divided into 350 µl aliquots and 
frozen away at -20 oC until needed. For experiments, the required amount of aliquot was 
thawed, after which a stock solution B (50 µM) was made, in order to obtain the lowest 
concentration that TDF was used in. 127.1 µl TDF of stock solution A was added to 872.9 
µl of dH2O to create TDF stock solution B. Both stocks were added in specific quantities, 
where applicable, to growth medium to yield the desired final concentration of ART. 
Vehicle preparations followed the same protocol, with the omission of the actual drug. 
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2.2.3 Combined drugs and Vehicles 
For the combination studies, one concentration of melatonin and one concentration level 
for ART was selected, based on dose-response results (See Chapter 4, sections 4.1.1 and 
4.1.2). We chose to use 1 nM melatonin along with the high concentration ART, based on 
the fact that these concentrations resulted in the greatest change in the investigated 
variable (Fig 4.6; 4.13; 4.14 & 4.15). The same stock and vehicle preparation methods 
were used in the combination studies as was described above, to achieve the desired 
concentrations, whith the combined vehicle containing a mixture of MeOh (for melatonin 
and EFV) and dH2O (for FTC and TDF). 
2.3 Plate Reader Analyses 
2.3.1 Materials 
 4,5-diaminofluorescein-2/diacetate (DAF-2/DA): Calbiochem (San Diego, CA, USA). 
Dihydrorhodamine-1, 2, 3 (DHR-123): Sigma-Aldrich (St Louis, Mo, USA). 
 Diethylamine NONOate diethylammonium salt (DEA/NO): Sigma-Aldrich (St Louis, 
Mo, USA).  
 Propidium iodide (PI) solution: Biochom-Biotech (San Diego, CA, USA).    
 Authentic peroxynitrite: Millipore (Billerica, MA, USA)  
 All other chemicals and buffer reagents: Merck (Damstadt, Germany).  
2.3.2 Methods 
At the final passage, AECs were re-seeded onto Vision Plates™ (clear bottom, black-
walled 24-well plates) (4titude, Surrey, UK) and grown to confluency for experimentation. 
Upon the establishment of confluence, the cells were serum starved for 24 hours (see 
section 2.2) and treated with the various drugs. After 1- or 24-hours of drug treatment, the 
cells were rinsed with pre-warmed (37 oC) PBS and treated with the applicable fluorescent 
probe (in the dark). The fluorescence intensity was measured using a FLUOstar Optima 
microplate reader (BMG Labtech, Germany). Figure 2.3 A gives an example of an 
experimental layout of a single sample (n = 1) on a given day, while the general protocol 
followed for each experiment is summarised in Figure 2.3 B. Table 2.1 shows the specific 
excitation and emmission wavelengths used on the microplate reader for the various 
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probes. Data generated by the microplate reader was stored and analysed with MARS 
Omega Data Analysis (software version 1.30; BMG Labtech, Germany). 
Table 2.1: Excitation and emmission wavelengths used for the various probes on the microplate 
reader 
 
 
Settings DAF DHR PI 
Excitation 485 485 544 
Emission 520 520 640 
Cells are passaged to the appropriate 
generation in 35 mm plates 
On the final passage, the cells are passaged 
from  
35 mm plates to a 24-well plate On establishment of conf uence, the individual wells are spilt into 
the various treatment groups and treated. See below for an example 
of the layout used for treatment groups on a 24-well plate: 
TG 1 
(Tech. 
rep. #1) 
TG 2 
(Tech. rep. 
#1) 
TG 3 
(Tech. 
rep. #1) 
VG 1 
(Tech. 
rep. #1) 
VG 2 
(Tech. 
rep. #1 
VG 3 
(Tech. 
rep. #1 
TG 1 
(Tech. 
rep. #2) 
TG 2 
(Tech. rep. 
#2) 
TG 3 
(Tech. 
rep. #2) 
VG 1 
(Tech. 
rep. #2) 
VG 2 
(Tech. 
rep. #2) 
VG 3 
(Tech. 
rep. #2) 
TG 1 
(Tech. 
rep. #3) 
TG 2 
(Tech. rep. 
#3) 
TG 3 
(Tech. 
rep. #3) 
VG 1 
(Tech. 
rep. #3) 
VG 2 
(Tech. 
rep. #3) 
VG 3 
(Tech. 
rep. #3) 
Absolute 
Control 
Normal 
Control 
Normal 
Control 
Normal 
Control 
Positive 
Control 
Positive 
Control 
 
TG = Treatment Group 
VG = Vehicle Group 
Tech. rep. = Technical replicate 
 
*This entire plate represents an individual biological replicate 
(n=1) 
Plate is treated with appropriate fluorescent probe 
Plate is taken to the Plate reader for analysis 
A 
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Figure 2.3:  A: (Depicted above on pg 50) Eample of an experimental layout used in plate reader studies. 
B: Summary of steps followed for each plate reader experiment.  
B 
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2.3.2.1 NO Measurements – DAF 
DAF-2/DA is a NO-specific fluorescent probe  (Strijdom, Muller, & Lochner, 2004), which 
measures intracellular NO-production. Upon reacting with NO, DAF- 2/DA is oxidized and 
emits a green fluorescence, which can be measured by the microplate reader. For cell 
treatment, DAF-2/DA was diluted with PBS to a final concentration of 10 µM, and then 
applied to the cells in the 24-well plate for 2 hours at 37 oC (Fig 2.4). After 2 hours, the 
DAF-2/DA-PBS supernatant was aspirated and the cells were washed once with PBS, and 
then covered in 500 µl PBS for microplate reader analysis. 
 
Positive Control: DEA/NO 
DEA/NO is a NO donor, and has previously been shown in our laboratory to be a 
consistent and reliable positive control for intracellular NO measured by DAF-2/DA. 
Designated positive control (+C) wells were first incubated with DAF-2/DA for 1.5 hours, 
before 100 µM DEA/NO was added for an additional period of 30 minutes. In other words, 
DEA/NO was added to the +C wells for the final 30 minutes of the 2-hour DAF-2/DA 
protocol (Fig 2.4 and 2.5). 
 
Figure 2.4: A schematic representation of the protocol used for treatment with DAF-2/DA and 
positive NO control, DEA/NO. 
 
Prepare 
cells for 
plate reader 
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Figure 2.5: DEA/NO (100 µM; 30 minutes) significantly increased mean DAF-2/DA 
fluorescence intensity compared to the normal control in non-serum starved 
samples and serum starved (SS) samples. DEA/NO was included as a positive NO 
control in all experiments (n = 6/ group). All values calculated as mean+SEM. 
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2.3.2.2 RNS Measurements – DHR 
DHR-123 is an uncharged and non-fluorescent indicator of RNS (used as a marker of 
peroxynitrite in this study)  (Tiede, Cook, Morsey, & Fox, 2012) that passively diffuse 
across the membrane, and is oxidized to form cationic rhodamine-123. Rhodamine-123 
eventually localizes in the mitochondria and emits a green fluorescence that is detected by 
the microplate reader. For cell treatment, 2 µM DHR-123 was applied to the cells in the 24-
well plate for 3 hours at 37 oC (Fig 2.6). The fluorescent probe was then washed out and 
further prepared as described in section 2.3.2.1.  
 
Positive Control: Authentic peroxynitrite 
Designated +C wells were first incubated with DHR-123 for 1 hour, before 100 µM 
peroxynitrite was added for an additional period of 2 hours. In other words, peroxynitrite 
was added to the +C wells for the final 2 hours of the 3-hour DHR-123 protocol (Fig 2.6 
and 2.7). 
 
Figure 2.6: A schematic representation of the protocol used for treatment with DHR-123 and 
positive control, authentic peroxynitrite. 
 
 
 
 
 
 
 
Prepare 
cells for 
plate reader 
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2.3.2.3 Cell Viability Measurements – PI 
Cell viability was assessed through the measurement of necrosis. During necrosis, there is 
a loss in cell membrane integrity. PI is able to enter the nucleus following the cell’s loss in 
membrane integrity and bind to the cell’s DNA  (Riccardi & Nicoletti, 2006), allowing for the 
measurement of necrosis  (Wilkins, Kutzner, Truong, Sanchez-Dardon, & McLean, 2002). 
For cell treatment, PI was diluted with PBS to a final concentration of 5 µM, and then 
applied to the cells in the 24-well plate for 15 minutes at 37 oC. After the 15-minute 
incubation period, PI was left on the plate and the cells were taken to the microplate 
reader for analysis. 
 
  
Figure 2.7: Peroxynitrite (100 µM; 2 hours) significantly increased mean DHR-123 fluorescence 
intensity compared to the normal control in non-serum starved samples and serum starved (SS) 
samples. Authentic peroxynitrite was included as a positive control in all experiments (n = 7/ 
group). All values calculated as mean+SEM. 
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Positive Control: dH2O 
When dH2O is added to cells, it diffuses across a semi-permeable membrane from an area 
with low osmolarity (high H2O concentration) to an area of high osmolarity (low H2O 
concentration). Therefore the net result of treating cells with dH2O is the movement of H2O 
molecules over the cell membrane and into the cell. This subjects the cell to osmotic 
stress, which causes the cell to swell and eventually burst. Rupturing of the cell membrane 
due to necrosis allows the PI fluorescent probe to enter and stain the nucleus by 
intercalating with the DNA (Fig 2.8). Designated +C wells were treated with PI that was 
diluted in dH2O, while all the other experimental group wells were treated with PI that was 
diluted in PBS. 
 
  
Figure 2.8: dH2O significantly increased PI staining compared to the normal control in 
non-serum starved samples and serum starved samples. dH2O was included as a 
positive control in all experiments (n = 7/ group). All values calculated as mean+SEM. 
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2.4 Signalling Investigations – Western Blot Analyses 
AEC western blot experiments consisted of the following groups: 
 Control (Contains Combined Vehicle Only) 
 1 nM Melatonin + Combined Vehicle 
 High concentration ART + Combined Vehicle 
 ART + Melatonin + Combined Vehicle 
Unlike the microplate reader experimental groups, western blot experimental groups all 
contained a combined vehicle. This allowed for all groups to be directly compared without 
considering a vehicle effect. The reason for this alteration was due to the space 
restrictions associated with western blot sample loading. Limited loading space meant we 
had to reduce the number of experimental groups in order to cater for an adequate sample 
size (n = 5 / group). The consequence of this alteration was that all melatonin and ART 
concentrations had to be re-calculated. Refer to Appendix C for detailed melatonin, ARV 
and vehicle concentration calculations. A protein concentration of approximately 4.62 – 
7.11 µg/µl was obtained from each petri dish. 
2.4.1 Materials 
 Cell Signaling Technologies (Beverly, MA, USA):  
o eNOS 
o phospho-eNOS (Ser 1177)  
o Cleaved caspase-3  
o Anti-rabbit immunoglobulin G, HRP- conjugated secondary antibody  
 Santa Cruz Biotechnologies (Santa Cruz, CA, USA)  
o Nitrotyrosine 
o p22 PHOX 
o iNOS 
 Clarity™ enhanced chemiluminescence (ECL) detection reagent: Bio-Rad 
(Hercules, CA, USA) 
 Primary and secondary SingalBoost™ Immunoreaction Enhancer: Millipore 
(Billerica, MA, USA). 
 PageRuler™ Prestained Protein Ladder: Thermo Scientific (Lithuania, EU) 
 All other chemicals and buffer reagents: Sigma-Aldrich (St Louis, Mo, USA) and 
Merck (Darmstadt, Germany). 
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2.4.2 Methods 
The Western blotting procedure requires a high yield of protein. On the third passage, cells 
were re-seeded from small 35 mm petri dishes to large 100 mm petri dishes. A single large 
100 mm petri dish was found to yield a sufficient protein concentration for one lysate. 
2.4.2.1 Cell Lysates 
After treatment, AECs were covered in 10 ml PBS and a rubber cell-scraper was used to 
gently lift the cells from the plate. The cell-PBS suspension was then transferred to the 
relevant tube and centrifuged for 3 minutes at 1000 rpm, after which the cell pellets were 
transferred to an eppendorff tube. Zirconium oxide beads (0.15 mm) were added to the 
pellet, along with 650 ul lysis buffer (Table 2.2) followed by homogenization with a Bullet 
Blender™ (Next Advance, Inc., NY, USA). 3 cycles of 1 minute were performed on setting 
5 of the Bullet Blender. In between cycles, samples were allowed to rest for 5 minutes. 
Samples were placed on ice for 30 minutes after which they were centrifuged for 20 
minutes at 15 000 rpm at 4 oC. Protein content of the supernatant was determined using 
the Bradford assay  (Bradford, 1976). Based on the Bradford assay findings, samples were 
prepared containing 2X Laemmli buffer (Table 2.3), lysis buffer and protein lysate, where a 
final protein content of 40 μg/15 μl of sample was achieved. 
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Table 2.2: Lysis buffer contents and preparation.  
 
Table 2.3: Contents of 2X Laemmli buffer  (Laemmli, 1970). 
 
   
Reagent 
Final 
concentration in 
buffer 
Amount of 10X 
stock for 30 ml 
Tris-HCl (pH 7.5) 
EGTA 
20 mM 
1 mM 
3.0 ml 
EDTA  1.0 mM 300 µl 
NaCl 150 mM 4.5 ml 
β-glycerophosphate 1.0 mM 0.006 g 
Tetra-sodium pyrophosphate 2.5 mM 0.03 g 
NaF 50 nM 0.0639 g 
Na3VO4 1.0 mM 3.0 ml 
Triton-X100 (1ml T in 10ml dH2O) 1.0 % 3.0 ml 
Leupeptin 10 µg / ml 30 µl 
Aprotonin 10 µg / ml 30 µl 
Sodium dodecyl sylphate (SDS) 0.1 % 30 µl 
PMSF 50 µg / ml 90 µl 
Distilled water  Fill up to 30 ml 
Reagent Concentration 
SDS 4 % 
Glycerol 20 % 
2-Mercaptoethanol 10% 
Bromophenol blue 0.004 % 
Tris HCl 0.125 M 
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2.4.2.2 Protein Loading and Transfer 
Prepared lysates were boiled for 5 minutes before loading. A PageRuler™ ladder was 
loaded into the first well of every gel (7 µl) followed by 15 µl of lysate for each sample. 26-
well (4–15% gradient) Criterion™ TGX Stain-Free™ Protein Gels (Bio-Rad, CA, 
USA)  were used for all western blot experiments. Gels were run at 140 V for 10 minutes, 
followed by a second 40-minute run at 200 V. After running, the gels were activated for 1 
minute using the Chemidoc™ MP Imager System with   Image Lab™- 5 software (Bio-
Rad, CA, USA), where the gels could be checked for equal protein loading. Following gel 
activation, proteins on the gel were transferred to a Trans-Blot® Turbo™ Midi PVDF 
membrane (Bio-Rad, CA, USA), using the Trans-Blot® Turbo™ Transfer System (Bio-
Rad, CA, USA). The “Standard SD” protocol was used for all transfers and involved a 30 
minute transfer at a constant voltage of 25 V and a varying current of up to 1 A. After the 
transfer the membrane was imaged on the Chemidoc™ again to ensure all proteins 
transferred correctly and evenly. 
2.4.2.3 Immunodetection 
Membranes were blocked for non-specific binding for 1.5 hours in 5 % fat-free milk in Tris-
buffered saline, 0.1 % tween-20 (TBS-Tween). After blocking, membranes were washed 
for 30 minutes (3 x 10 minute cycles) with TBS-tween and then incubated overnight at 4 oC 
with a specific primary antibody (Table 2.4). The next morning, the membranes were 
washed again for 30 minutes in TBS-tween and the incubated with an anti-rabbit 
immunoglobulin G, horseradish peroxidase (HRP) - conjugated secondary antibody for 1 
hour at room temperature. The specific primary and secondary antibody conditions of each 
antibody are shown in Table 2.4. After the 1-hour incubation, membranes were rinsed 
again for 30 minutes, after which protein visualization took place. To visualize the proteins, 
membranes were incubated in Clarity™ for 5 minutes, after which the stain-free 
membranes were exposed on the Chemidoc™. Exposure time and the number of images 
captured were set beforehand and could be visualized throughout the procedure.  
Image Lab™- 5 software standardises the visualised protein bands against the total 
amount of protein per lane transferred to the membrane (the image that was taken 
following transfer of protein to the membrane). The raw values generated by the software 
are then used to normalise all values to the control group, where the control is represented 
by the value 1. See Appendix D for the method used to normalise the data. 
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Some membranes were stripped of their original probe and re-probed for a different 
antibody. To strip membranes of primary and secondary antibodies, membranes were 
washed for 14 minutes (2 x 7 minute cycles) with dH2O, then for 7 minutes with 0.2 M 
NaOH, followed by 14 minutes with dH2O again. Membranes were then blocked in 5 % 
milk for 2 hours and could then be re-probed at a different molecular weight on the 
membrane than the initial antibody; therefore some proteins shared normalization 
membrane images. 
 
Table 2.4: Specifications for each antibody after optimisation for Western blotting.  
Antibody Primary Antibody Dilution Secondary Antibody Dilution 
Phospho-eNOS 
140 kDa 
1:1000 TBS 
(5µl in 5ml) 
1:4000 5% Milk 
(1.25µl in 5ml) 
Total-eNOS 
140 kDA 
1:1000 TBS 
(5µl in 5ml) 
1:4000 5% Milk 
(1.25µl in 5ml) 
iNOS 
131 kDA 
1:200 2.5% Milk 
(25µl in 5ml) 
1:4000 5% Milk 
(1.25µl in 5ml) 
Nitrotyrosine 
90 kDA 
1:5000 TBS 
(1µl in 5ml) 
1:4000 TBS 
(1.25µl in 5ml) 
p22 PHOX 
22 kDa 
1:500 1% Milk 
(10µl in 5ml) 
1:4000 5% Milk 
(1.25µl in 5ml) 
Cleaved 
Caspase-3 
17/19 kDa 
1:500 1o SignalBoost™ 
(10µl in 5ml) 
1:4000 2o SignalBoost™ 
(1.25µl in 5ml) 
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2.5 ORAC Assay 
The oxygen radical absorbance capacity (ORAC) assay is a method to assess the 
antioxidant capacity of biological samples  (Huang, Ou, Hampsch-Woodill, Flanagan, & 
Prior, 2002; Prior et al., 2003). ORAC assays were kindly conducted by Dr D Blackhurst 
(Division of Chemical Pathology, University of Cape Town, SA).  
AECs were passaged and maintained with the same method previously described in the 
section 2.4.2, and treated as previously described under the heading of section 2.4 (See 
Appendix C). After treatment, cells were washed with PBS and then covered with just 
over 1 ml of PBS. The cells were removed from the petri dish surface using a rubber cell 
scraper after which exactly 1 ml cell-PBS suspension was transferred to the relevant 
eppendorff tube. Sample tubes were then frozen and transported to the University of Cape 
Town (UCT) on dry-ice, for analysis. 
For analysis, the cell samples were subjected to sonication using a Virtis VirSonic 100 
(United Scientific (Pty) Ltd, CPT, SA) with 20 x 1 second bursts at 3 watts. At this stage 25 
µl were removed for protein estimation by the Markwell modification of the Lowry method  
(Markwell, Haas, Bieber, & Tolbert, 1978), using bovine serum albumin as the standard. 
Cell samples were then centrifuged at 1000 x g at 4 °C for 15 minutes and the supernatant 
was used for ORAC measurement, using the method previously described by Maarman et 
al. (2015). 
2.6 Statistical Analyses 
All microplate reader data was calculated as mean ± standard error of the mean (SEM), 
with values expressed as a % of the control (control adjusted to 100%). For Western blot 
data, controls were adjusted to the value of 1. Total protein expression was calculated as 
a ratio of the loading control. For the ORAC assays, the antioxidant capacity is expressed 
in trolox equivalents. Trolox is a vitamin-E analogue that is used as the standard measure 
of antioxidant capacity.  
One-way ANOVA with a Bonferroni post-hoc multiple comparison test were used to 
determine significance. Differences with a p-value < 0.05 were considered statistically 
significant. All data was analysed using GraphPad Prism 6 software (GraphPad Software, 
San Diego, CA, USA).  
Sample sizes are indicated below each graph in Chapter 4.  
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3 - Materials and Methods: Ex vivo and In 
vivo studies 
This chapter contains a description of the materials and methods used for the ex vivo and 
in vivo studies. The ex vivo studies consisted of investigations into the organ bath-based 
vascular contraction-relaxation function of aortas obtained from healthy male Wistar rats. 
In these studies, melatonin and/or ART were administered directly to the aortic rings 
mounted in the organ bath, and acute vascular and endothelium-dependent responses 
were measured. The in vivo studies comprised of an 8-week period of oral treatment with 
melatonin and/or ART, followed by organ bath-based investigations into the endothelium-
dependent and endothelium-independent vascular contraction-relaxation function of the 
aortas obtained from the treated animals. The results for these studies can be found in 
Chapter 5. 
3.1 Materials 
 Anaesthetic (Sodium pentobarbitone;   C11H17N2NaO3): Bayer (Isando, Gauteng, 
SA). 
 Sigma-Aldrich (St Louis, Mo, USA): 
o Acetylcholine 
o Phenylephrine 
o Nω-Nitro-L-arginine methyl ester (L-NAME) hydrochloride 
o Sodium Nitroprusside (SNP) 
 All other chemicals and buffer reagents: Sigma-Aldrich (St Louis, Mo, USA) and 
Merck (Darmstadt, Germany). 
3.2 Ethics Clearance and Animal Care 
All experiments were conducted in accordance with the accepted standards for the use of 
animals in research as set out by the South African National Standards document (SANS 
10386: 2008) of the South African Bureau of Standards (SABS). Ethics approval was 
received from The Research Ethics Committee: Animal Care and Use of the University of 
Stellenbosch (US; Faculty of Medicine and Health Sciences; Protocol Number: SU-
ACUD14-00021).  
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Age matched male Wistar rats with an initial weight range between 180 – 200 g were 
provided, housed, and cared for by the Animal Housing Unit of the Faculty of Medicine and 
Health Sciences of US. The animals were housed (2 – 3 rats per cage) in a temperature 
(22 °C) and humidity (40 %) controlled environment where they were subjected to a 
normal12 hour artificial day / night cycle. Animals had free access to a standard rat chow 
diet as well as drinking water. 
3.3 Experimental Protocols and Study Design 
For aortic ring experiments, animals were transferred from the Animal Housing Unit to the 
animal care facility of the Division of Medical Physiology, 1 day prior to sacrifice (usually 
between 2 – 4 animals). This was to ensure animals had a day to recover from the stress 
of being transported as well as time to adapt to their new environment.  
The animals were anesthetised through intraperitoneal (IP) injection of 160 mg / kg sodium 
pentobarbitone in the lower right abdomen. Deep anesthesia was confirmed by the 
disappearance of the pedal pain withdrawal reflex and absence of eye reflexes. 
Euthanasia was achieved by means of a clamshell thoracotomy and eventually 
exsanguination.  
3.3.1 Excision and Mounting of Aortic Rings 
Following the establishment of deep anesthesia, an incision was made through the skin 
and muscle layers across the ventral side of the rat, just below the thoracic region. The 
diaphragm and ribcage were cut in a cranial direction as to expose the thoracic cavity. The 
heart, lungs, trachea and oesophagus were removed. The thoracic aorta (above the 
diaphragm to distal end of the aortic arch) was excised and immediately placed in ice-cold 
Krebs Henseleit buffer (KHB) (Table 3.1). Using a magnifying glass, the perivascular fat 
and connective tissue was removed (Fig 3.1) and the aorta was cut into a 3 - 4 mm ring 
segment that was subsequently mounted onto two stainless steel hooks (Fig 3.2) in a 25 
ml organ bath (AD Instruments, Bella Vista, NSW, Australia) containing oxygenated (95% 
O2 and 5% CO2) KHB. Aortic ring tension was recorded with an isometric force transducer 
(TRI202PAD, Panlab, lCornellà, BCN, Spain) and data was analysed with LabChart 7 
sofware (Dunedin, New Zealand)  (Westcott, 2015).  
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Table 3.1: Composition of Krebs Henseleit buffer. 
 
 
 
  
Ingredients Concentration (mM) 
NaCl 119 
NaHCO3 25 
KCL 4.75 
KH2PO4 1.2 
MgSO4.7H2O 0.6 
Na2SO4 0.6 
CaCl2.H2O 1.25 
Glucose 10 
Figure 3.1: A thoracic aorta excised and cleaned of connective tissue and perivascular fat  
(Loubser, 2014).  
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Figure 3.2: Organ bath with a 4 mm segment of aorta suspended between two 2 steel hooks  
(Loubser, 2014). 
 
3.3.2 Ex Vivo Studies 
For all ex vivo aortic ring experiments, phenylephrine (Phe) was used to induce 
contraction, and acetylcholine (Ach) was used to induce relaxation. Phe is an α-adrenergic 
receptor agonist which acts directly on the VSMCs eventually leading to contraction. Ach 
binds to endothelial surface receptors (Fig 1.3) resulting in an increase in intracellular 
calcium and consequently eNOS activation. eNOS activation leads to the release of NO 
which diffuses to the VSMC layer resulting in  VSMC relaxation. 
The isometric tension measurement protocol used was a modified version of a technique 
previously described by Privet et al. (2004). The mounted aortic rings were stabilised for 
30 minutes at a resting tension of 1.5 g, over which period, the KHB was changed every 
10 minutes with fresh, pre-warmed (37 oC) KHB. After the 30-minute stabilisation, an initial 
functionality test was conducted, whereby 100 nM Phe was added to the organ bath. Once 
the ring was no longer contracting (a plateau was reached), 10 µM Ach was added. Rings 
that showed at least a 70 % relaxation of maximum phenylephrine-induced contraction 
during the initial functionality test were included for further investigations. Following the 
functionality test, the organ bath was rinsed 3 times with fresh, warm KHB and the rings 
were once again stabilised for 30 minutes at a tension of 1.5 g, where the buffer was 
changed every 10 minutes. After the second 30-minute stabilisation period, the relevant 
treatment was added to the organ bath, which was followed by a 30-minute incubation 
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period. Following drug administration and the 30-minutes incubation, aortic ring contraction 
was induced with the cumulative administration of Phe (100 nM – 1 µM). Once a plateau 
was reached, aortic rings were subsequently exposed to cumulative concentrations of Ach 
(30 nM – 10 µM). Experiments were terminated once the aortic rings experienced 
maximum relaxation. Figure 3.3 is a representative LabChart recording showing the aortic 
ring responses to the experimental protocol followed for the ex vivo studies. 
 
Ex vivo aortic ring experiments consisted of the following groups: 
 Control (Contains Combined Vehicle Only) 
 10 µM Melatonin (Sigma Aldrich, St Louis, MO, USA) + Combined Vehicle 
 High concentration ART (SantaCruz Biotechnology, CA, USA) + Combined Vehicle 
 ART + Melatonin + Combined Vehicle 
Ex vivo treatment groups all contained a combined vehicle. This allowed for all groups to 
be directly compared without considering a vehicle effect. A very limited number of rats 
were allocated to the ex vivo portion of this study due to the adjusted protocol’s novel and 
experimental nature. A limited number of rats meant we had to reduce the number of 
experimental groups in order to cater for an adequate sample size (n = 5 - 6). For ex vivo 
studies, a melatonin concentration of 10 µM was used, unlike the 1 nM melatonin 
concentration, which was used for the in vitro studies. The reason for this discrepancy is 
that the ex vivo studies were conducted before the in vitro melatonin dose-response 
experiments were completed, and at that stage, the assumption was made that the higher 
dose of melatonin would be more effective. It only became evident that the lower dose of 
melatonin was in fact the more effective concentration to use, once melatonin dose-
response experiments were completed. Refer to Appendix E for detailed ex vivo 
melatonin, ARV and vehicle concentration calculations. 
  
Stellenbosch University  https://scholar.sun.ac.za
 68 
 
 
 
 
 
3.3.3 In Vivo Studies 
For the in vivo studies, 80 male Wistar rats were divided into the following 4 experimental 
groups (Fig 3.4): 
 Control (Untreated) 
 Melatonin (Sigma Aldrich, St Louis, MO, USA) 
 ART/ Odimune® (Cipla MedPro, Bellville, WC, SA) 
 ART + Melatonin 
One week prior to the start of treatment, rats weighing 180 – 200g were randomly 
separated into the 4 treatment groups. Between 2 and 3 rats were housed per cage 
according to the conditions mentioned in section 3.2. During this week, the water-intake of 
the rats was measured and recorded, but the rats received no other treatment. 
 
 
 
 
Stab 
(30 Min) 
Phe 
(100 nM) 
Ach 
(10 µM) 
Stab 
(30 Min) 
Treatment 
(30 Min) 
Phe 
(100 nM – 1 µM) 
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(30 nM – 10 µM) 
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100nM 
Ach 
10µM 
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Figure 3.3: LabChart recording showing the aortic ring responses to the experimental protocol followed 
for the ex vivo studies. This graph is from the control experimental group where only vehicles were added 
at the treatment period. 
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3.3.3.1 Drug Administration 
Following the initial 1-week water-intake monitoring, an 8-week treatment period was 
initiated. Throughout the 8-week treatment period, rats were weighed once per week 
(Monday morning) and all fluid intake was monitored and measured on a daily basis. Rats 
were caged together in groups of 2 or 3, and therefore the amount of fluid drank per cage 
was measured, and then divided based on the number of rats per cage. 
 
10 mg/kg melatonin was found to be effective in reducing oxidative damage  (Cardinali, 
Cano, Jimenez-Ortega, & Esquifino, 2011; Favero et al., 2017), and is the current 
concentration of melatonin used in other studies within our laboratory. This dose of 
melatonin was administered through the drinking water, where each cage containing a 
given number of rats was given 200 ml a day, and the melatonin-water was measured the 
next day at the same time, to assess the amount of water consumed by each cage daily. 
This amount was then divided by the amount of rats in the given cage in order to calculate 
the mean water consumed by each rat within a single cage. This information, along with 
the average weight of the rats in a specific cage allowed for the calculation of the amount 
of melatonin each cage received for a specific week. This was necessary to ensure the 
rats were always receiving the prescribed dose of melatonin. For example, in cages that 
consumed very high quantities of melatonin-water, a lower stock concentration of 
melatonin was prepared, while cages that drank very little water, needed higher 
concentrations of melatonin in their drinking water to compensate for their reduced water 
consumption. Melatonin powder was dissolved in methanol and made up in stocks every 
Male Wistar Rats 
(n = 80) 
ART + Melatonin 
(n = 19*) 
ART 
EFV: 51.6 mg/kg 
FTC: 17.4 mg/kg 
TDF: 25.8 mg/kg 
(n = 20) 
Melatonin 
10 mg/kg/day 
(n = 20) 
Control 
(n = 20) 
Figure 3.4: Flow chart indicating in vivo treatment groups. *1 rat died the week before treatment was 
initiated. 
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two days, while the drinking water containing melatonin was replaced every day. The 
amount of methanol used to dissolve the melatonin powder was dependent on the amount 
of melatonin stock that was made up, where 0.2% of the amount of stock being made was 
used to determine the quanity of methanol used. For example, if a 500 ml melatonin stock 
was prepared, 1 ml of methanol (0.2% x 500 ml) was used. All drinking bottles containing 
melatonin were covered with two layers of aluminium foil and a metal casing to ensure the 
melatonin was not inactivated by light. For detailed melatonin calculations, stock 
preparation and administration see Appendix F. 
 
For ART treatment, an ART-water drug suspension was administered daily by oral 
gavaging by a qualified staff member (Mr. Noël Markgraaff; Manager: Care and Use of 
Laboratory Animals, SU). Groups that did not receive ART were also gavaged, but with 
water instead of the ART-suspension. The procedure of gavaging involved the insertion of 
a feeding tube along the roof of the animal’s oral cavity towards the animal’s left side and 
down the animal’s esophagus and into the stomach of the animal. The ART-suspension or 
water was therefore injected directly in the stomach of the animal. The rats received 1 ml 
ART-suspension or water per day. The ART-suspension was made up weekly, according 
to the average weekly weight of the cage. To make up the ART-suspension, Odimune® 
tablets were ground into a fine powder using a pestle and mortar. The appropriate amount 
of Odimune® powder was then weighed and added to dH2O, after which the mixture was 
thoroughly mixed and stored in the refrigerator. 
Each Odimune® tablet contains the human recommended daily dose of active ingredients 
(EFV: 600 mg; FTC: 200 mg; TDF: 300 mg) for an average person (70 kg). These values, 
as well as the weekly rat weights, were used to calculate how much tablet powder needed 
to be combined with dH2O in order for the rats to receive the applicable concentrations of 
the three individual ARVs (EFV: 51.6 mg/kg; FTC: 17.4 mg/kg; TDF: 25.8 mg/kg). See 
Appendix G for the method used to calculate the weekly drug dose.  
 
3.3.3.2 Aortic Ring Investigations 
The thoracic aorta was excised, cleaned of connective tissue and suspended in the organ 
bath as described under section 3.3.1. For in vivo experiments, two types of aortic ring 
investigations were conducted. For the first set of experiments we conducted endothelium-
dependent relaxation studies, were Phe was used to induce contraction and Ach was used 
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to induce relaxation (as previously described in section 3.3.2). As a control for these 
endothelium-dependent relaxation studies, some of the rings in this section were pre-
treated with the NOS inhibitor, L-NAME (100 μM) 15 minutes prior to the administration of 
cumulative amounts of Phe and Ach. For these experiments, a single aorta was cut into 
two rings, which were mounted immediately in separate organ baths (Fig 3.5). The normal 
Phe-Ach experiments were always conducted in Organ Bath 1, which L-NAME studies 
were always conducted in Organ Bath 2. 
 
For the second set of experiments we conducted endothelium-independent relaxation 
studies, where Phe was once again used to induce contraction, however, for these studies 
sodium nitroprusside (SNP) - an exogenous NO donor - was used to induce relaxation. 
Since SNP is a NO donor,  relaxation observed is independent of the endothelium, as the 
NO released from SNP diffuses directly into the VSCMs. For SNP investigations, a single 
aorta was once again cut into two rings (Fig 3.5), and all SNP studies were conducted in 
Organ Bath 2. 
Figure 3.5 shows how aortas were separated and cut for the two different studies. 
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Figure 3.5: Scheme indicating procedures performed on cleaned aortic tissue to obtain aortic rings for isometric tension studies.  
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Following the initial stabilisation period, functionality test (done with Phe and Ach for all 
experiments), and the second stabilisation period (as described in section 3.3.2), each 
group was subjected to the following three isometric tension protocols:  
 
1) Cumulative Phe-induced contraction followed by cumulative Ach-induced 
relaxation: Cumulative administration of Phe results in a step-wise increase in the 
total Phe concentration as follows: 100 nM; 300 nM; 500 nM; 800 nM; 1 μM. This 
administration results in cumulative aortic ring contractions. Each dose of Phe was 
administered directly to the organ bath as soon as maximum contraction was 
reached with the previous administration. Once the final dose of Phe was 
administered to produce a final Phe concentration of 1 µM, maximum contraction 
was reached and therefore Ach was administered in order to induce endothelium-
dependent relaxation. Ach was also administered in a cumulative manner resulting 
in step- wise increases in Ach concentrations: 30 nM; 100 nM; 300 nM; 1 μM; 10 
μM. The experimental protocol was terminated once the final Ach administration 
(final concentration: 10 μM) resulted in maximum % relaxation of contraction (Fig 
3.6).  
 
Stab    
(30 min) 
Phe               
(100 nM – 1 µM) 
Phe    
(100 nM) 
Ach     
(10 µM) 
Stab    
(30 min) 
Ach                
(30 nM – 10 µM) 
T
e
n
s
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n
 (
g
) 
Time (mins) 
Phe 
100nM 
Ach 
10µM 
Phe              
100 nM – 1µM 
Ach                
30 nM – 10µM 
Figure 3.6: A representative LabChart recording showing the aortic ring responses to the 
experimental protocol followed for Phe administration followed by Ach. This graph was from an 
aortic ring in the control  group. 
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2) L-NAME pre-treatment, followed by cumulative Phe-induced contraction and 
cumulative Ach-induced relaxation: In this protocol, the role of NOS-derived NO 
was manipulated by pre-administration of the NOS-inhibitor, L-NAME (100 μM) 15 
minutes prior to the cumulative Phe - Ach protocol (Fig 3.7).  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Stab    
(30 min) 
Phe               
(100 nM – 1 µM) 
Phe    
(100 nM) 
Ach     
(10 µM) 
Stab    
(30 min) 
Ach                
(30 nM – 10 µM) 
L-NAME            
(100 µM; 15 min) 
Phe 
100nM 
Ach 
10µM 
Phe              
100 nM – 1µM 
Ach                
30 nM – 10µM 
L-NAME 
100 µM 
Figure 3.7: A representative LabChart recording showing the aortic ring responses to the experimental 
protocol followed for L-NAME pre-treatment followed by Phe and Ach administration. This graph is from an 
aortic ring in the control  group. 
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3) Cumulative Phe-induced contraction followed by cumulative SNP-induced 
relaxation: Phe was administered in a cumulative fashion as mentioned in the first 
protocol. Upon reaching maximum contraction, SNP was administered to induce 
endothelium-independent relaxation. SNP was also administered in a cumulative 
manner resulting in step- wise increases in SNP concentrations: 1.2 nM; 20 nM; 70 
nM; 100 nM; 750 nM. The experimental protocol was terminated once the final 
SNP administration (final concentration: 750 nM) resulted in maximum % relaxation 
of contraction (Fig 3.8). SNP concentrations used were based on various sources 
in the literature  (Ajay & Mustafa, 2006; Ameer, Boyd, Butlin, Avolio, & Phillips, 
2015; Banda, Lefer, & Granger, 1997; Bonaventura, Lunardi, Rodrigues, Neto, & 
Bendhack, 2008; Sutliff et al., 2002). See Appendix H for detailed SNP 
concentration calculations and administration. 
 
 
  
Stab    
(30 min) 
Phe               
(100 nM – 1 µM) 
Phe    
(100 nM) 
Ach     
(10 µM) 
Stab    
(30 min) 
SNP                  
(1.2 nM – 750 µM) 
T
e
n
s
io
n
 (
g
) 
Time (mins) 
Phe 
100nM 
Ach 
10µM 
Phe              
100 nM – 1µM 
SNP                  
1.2 nM – 750 nM 
Figure 3.8: A representative LabChart recording showing the aortic ring responses to the 
experimental protocol followed for Phe administration followed by SNP. This graph is from an aortic 
ring in the control  group. 
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3.4 Signalling Investigations – Western Blot Analyses 
3.4.1 Materials 
The same materials were used as described in Chapter 2, section 2.4.1  
3.4.2 Methods 
Due to the fact that for most samples, only a very small piece of aorta was frozen away, 
two samples from the same experimental group were combined to make one lysate. 
3.4.2.1 Aortic Tissue Lysates 
Aortic tissue that had been previously frozen at -80 oC was stored in liquid nitrogen, along 
with pulverizing equipment and any tools used to scrape or transfer the frozen aortic 
tissue. All these items were kept cold in liquid nitrogen so that when the tissue was 
pulverized it formed a fine powder. Following aortic tissue pulverization, 60 – 106 mg of 
the aortic tissue-powder was placed in an eppendorff tube along with the equivalent mass 
of 1.6 mm stainless steel beads and 600 µl complete lysis buffer (Table 2.2). Samples 
were then homogenised in a Bullet Blender™ (Next Advance, Inc., NY, USA) with the 
following protocol: 
 3 minutes at speed 8 
 5 minutes rest 
 2 minutes at speed 10 
Samples were placed on ice for 30 minutes after which they were centrifuged for 20 
minutes at 15 000 rpm at 4 oC. Protein content was determined by the Bradford assay  
(Bradford, 1976) as mentioned in Chapter 2, section 2.4.2.1. A final protein content of 60 
μg/15 μl of sample was achieved. 
3.4.2.2 Protein Loading, Transfer and Measurement 
Loading of samples onto the Criterion™ TGX Stain-Free™ Protein Gels, subsequent 
transfer to membrane as well as antibody conditions and protein band visualization was 
conducted as described in Chapter 2, sections 2.4.2.2 and 2.4.2.3. 
3.5 ORAC Assay 
ORAC assays were kindly conducted by Dr D Blackhurst (Division of Chemical Pathology, 
University of Cape Town, SA).  
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Aortic tissue for the ORAC assay was prepared through pulverisation in the same manner 
described above in section 3.4.2.1. Aortic tissue-power was placed in an empty eppendorff 
tube where the amount of tissue in mg within each sample tube was recorded. After 
pulverisation, samples were immediately frozen in liquid nitrogen and then transported to 
UCT on dry-ice, for analysis. 
For analysis, aortic samples were homogenised (using an in-house ‘glass-ball’) and 
subjected to the same sonication, protein estimation and ORAC measurement protocols 
described in chapter 2, section 2.5.  
3.6 Statistical Analyses 
Data were analysed using GraphPad Prism 6 software (GraphPad Software, San Diego, 
CA, USA). Aortic ring contraction (Phe) studies are expressed as an increase in gram 
tension from a resting tension of 1.5 g, while relaxation (Ach/SNP) studies are expressed 
as % relaxation of the maximum contraction. Data were statistically analysed by means of 
a two-way ANOVA with a Bonferroni post-hoc multiple comparison test. Additionally, Emax 
values were compared using a one-way ANOVA with a Bonferroni post-hoc multiple 
comparison test. Differences with a p-value < 0.05 were considered statistically significant.  
For Western blot data, controls were adjusted to the value of 1. Total protein expression 
was calculated as a ratio of the loading control.  
For the ORAC assays, the antioxidant capacity is expressed in trolox equivalents. 
For western blot and ORAC data, one-way ANOVA with a Bonferroni post-hoc multiple 
comparison test were used to determine statistical significance. Differences with a p-value 
< 0.05 were considered statistically significant.  
Sample sizes are indicated below each graph in Chapter 5.  
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4 – Results: In vitro studies 
Chapter 4 describes and reports data collected from the in vitro study, the materials and 
methods for which can be found in Chapter 2. 
4.1 Plate Reader Analyses 
The initial aim of the in vitro study set out to determine the individual optimum 
concentrations of both melatonin and first line FDC ART treated aortic endothelial cells 
(AECs) at which the greatest differences were seen when compared to untreated AECs, 
with respect to NO production, RNS production and cell viability. This was investigated 
through dose-response studies whereby AECs were treated with various melatonin and 
ART concentrations for a fixed period.  
For the second aim of the in vitro study, the optimum concentrations obtained in the dose-
response experiments above were used to treat AECs with both melatonin and ART in 
combination, in order to analyse any potential synergistic/antagonistic interactions 
between the two with respect to, NO production, RNS production and cell viability. For 
these studies, a single melatonin and FDC ART concentration was chosen for cell 
treatment over a period of 24 hours. 
Following drug treatment, cells were treated with the applicable fluorescent probes, and 
the consequent cell fluorescence was measured using a plate reader. All treatment groups 
were compared to an untreated control group. Individual treatment groups were also 
compared to their respective vehicles. If no significant difference was seen between a 
group and its respective vehicle, then any significant changes between that particular 
treatment group and the control group were considered a vehicle effect. The n value 
represents the number of individual experiments (biological replicates) that were 
conducted for each endpoint, where each treatment group within an experiment consisted 
of 2 to 3 samples (technical replicates) for which the mean value was calculated. All values 
expressed as a % of the control (control adjusted to 100%). A p-value of < 0.05 was 
considered statistically significant. 
4.1.1 Melatonin Dose-Response Studies 
Dose-response experiments comprised of a 24-hour serum starvation (SS) period, 
followed by a 24-hour melatonin treatment period, followed by probe treatment and plate 
reader analyses. As previously mentioned in section 2.2, serum starvation (SS) was 
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introduced to induce cell cycle synchronization, which enhances the cells’ responses to 
experimental treatment  (Gerber et al., 1998; Russell & Hamilton, 2014), in otherwise 
healthy cells. Three treatment groups for melatonin were included: 1 nM; 1 µM and 10 µM 
melatonin.  Results from these experiments (24-hour SS followed by 24-hour melatonin 
treatment) showed few to no changes between treatments groups, we therefore decided to 
introduce a 1-hour melatonin treatment period following 24-hour SS, to assess the early 
effects of melatonin on the cells. 
4.1.1.1 24h SS + 24h Melatonin Treatment 
DAF-2/DA: NO Production 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (103.0 ± 2.302%), 1 µM 
(103.3 ± 3.432%) and 10 µM (101.8 ± 3.544%) melatonin for 24 hours, showed no 
differences in mean DAF-2/DA fluorescence (NO production) compared to the untreated 
control group (100.0 ± 1.662%) (Fig 4.1). No changes were observed in any vehicle 
groups. 
 
Figure 4.1: The effects of 24h SS followed by 24h melatonin treatment on NO production 
measured by DAF-2/DA fluorescence. NO production expressed as % DAF-2/DA stained cells 
(calculated as a percentage of the untreated control group; Control fluorescence adjusted to 100 
%), n = 3/ group. 
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DHR-123: RNS Production 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (109.3 ± 3.287%), 1 µM 
(104.6 ± 3.266%) and 10 µM (105.8 ± 2.737%) melatonin for 24 hours, showed no 
differences in mean DHR-123 fluorescence (RNS production) compared to the untreated 
control group (100.0 ± 1.080%) (Fig 4.2). No changes were observed in any vehicle 
groups. 
 
 
Figure 4.2: The effects of 24h SS followed by 24h melatonin treatment on RNS production 
measured by DHR-123 fluorescence. RNS production expressed as % DHR-123 stained cells 
(calculated as a percentage of the untreated control group; Control fluorescence adjusted to 
100%), n = 3/ group. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
 81 
PI: Cell Viability (Necrosis) 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (92.56 ± 3.114%) 
melatonin for 24 hours, showed a significant decrease in mean PI fluorescence (necrosis), 
when compared to the untreated control group (100.0 ± 1.041%), and its own vehicle 
(105.3 ± 0.9718%) (Fig 4.3). 1 µM (100.9 ± 1.703%) and 10 µM (102.3 ± 2.075%) 
melatonin treated groups showed no differences in mean PI fluorescence compared to the 
control group (100.0 ± 1.041%). No changes were observed in 1 µM and 10 µM vehicle 
groups. 
 
 
  
 
 
 
 
Figure 4.3: The effects of 24h SS followed by 24h melatonin treatment on necrosis measured by 
PI fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of the 
untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
  
*: p=0.0004 vs control 
#: p=0.0004 vs 1nM vehicle 
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4.1.1.2 24h SS + 1h Melatonin Treatment 
DAF-2/DA: NO Production 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (104.0 ± 1.238%), 1 µM 
(100.5 ± 0.7188%) and 10 µM (101.5 ± 0.8466%) melatonin for 1 hour, showed no 
differences in mean DAF-2/DA fluorescence (NO production) compared to the untreated 
control group (100.0 ±0.9661%) (Fig 4.4). No changes were observed in any vehicle 
groups. 
 
 
Figure 4.4: The effects of 24h SS followed by 1h melatonin treatment on NO production measured 
by DAF-2/DA fluorescence. NO production expressed as % DAF-2/DA stained cells (calculated as 
a percentage of the untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
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DHR-123: RNS Production 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (101.2 ± 1.517%), 1 µM 
(98.5 ± 1.111%) and 10 µM (98.92 ± 1.196%) melatonin for 1 hour, showed no differences 
in mean DHR-123 fluorescence (RNS production) compared to the untreated control group 
(100.0 ± 0.9129%) (Fig 4.5). No changes were observed in any vehicle groups. 
 
 
Figure 4.5: The effects of 24h SS followed by 1h melatonin treatment on RNS production 
measured by DHR-123 fluorescence. RNS production expressed as % DHR-123 stained cells 
(calculated as a percentage of the untreated control group; Control fluorescence adjusted to 100 
%), n = 4/ group. 
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PI: Cell Viability (Necrosis) 
AECs exposed to 24 hours of SS followed by treatment with 1 nM (81.89 ± 3.572%), 1 µM 
(86.89 ± 2.927%) and 10 µM (91.22 ± 2.133%) melatonin for 1 hour, showed a significant 
decrease in mean PI fluorescence (necrosis) respectively, when compared to the 
untreated control group (100.0 ± 0.7993%). All melatonin treatment groups also 
significantly decreased compared to their respective vehicles (1nM Veh: 96.11 ±1.844%; 
1µM Veh: 94.89 ± 1.409%; 10µM Veh: 98.44 ± 1.042%). The 1 nM melatonin treatment 
group also showed a significant decrease in PI fluorescence compared to the 10 µM 
melatonin treatment group (Fig 4.6). 
 
 
 
 
 
 
Figure 4.6: The effects of 24h SS followed by 1h melatonin treatment on necrosis measured by PI 
fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of the 
untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
*: p<0.0001 vs control 
**: p<0.0001 vs control 
***: p<0.0001 vs control 
#: p<0.0001 vs 1 nM vehicle 
$: p<0.0001 vs 1 µM vehicle 
@: p<0.0001 vs 10 µM vehicle 
%: p<0.0001 vs 10 µM melatonin 
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4.1.2 ART Dose-Response Studies 
Dose-response experiments comprised of a 24-hour serum startvation (SS) period, 
followed by a 24-hour ART treatment period, followed by probe treatment and plate reader 
analyses. Three treatment groups for ART were included: Low concentration ART (EFV: 
5µM; FTC: 5µM; TDF: 80nM); Mid concentration ART (EFV: 8µM; FTC: 7.5µM; TDF: 
400nM) and High concentration ART (EFV: 12µM; FTC: 10µM; TDF: 1µM). In contrast to 
the melatonin dose-response studies, a 1-hour treatment period was not included for the 
ART dose-response studies. The shorter 1-hour treatment period was excluded for the 
ART studies since it would have little clinical relevance. 
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4.1.2.1 24h SS + 24h ART Treatment 
DAF-2/DA: NO Production 
AECs exposed to 24 hours of SS followed by treatment with low (100 ± 2.703% vs Veh: 
108.6 ± 1.494%), mid (100.8 ± 3.116% vs Veh: 109.9 ± 2.394%) and high (112.9 ± 2.171% 
vs Veh: 105.4 ± 1.587%) concentration ART for 24 hours, all showed significant 
differences compared to their relative vehicles. However, only high concentration ART 
showed a significant increase in mean DAF-2/DA fluorescence (NO production) compared 
to the untreated control group (100.1 ± 2.224%). High concentration ART also increased 
NO production significantly compared to both low and mid concentration ART (Fig 4.7). 
 
 
 
 
 
Figure 4.7: The effects of 24h SS followed by 24h ART treatment on NO production measured by 
DAF-2/DA fluorescence. NO production expressed as % DAF-2/DA stained cells (calculated as a 
percentage of the untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
 
#: p=0.0015 vs control 
$: p=0.0015 vs [low] vehicle 
@: p=0.0015 vs [mid] vehicle 
%: p=0.0015 vs [high] vehicle 
&: p=0.0015 vs [high] ART 
&&: p=0.0015 vs [high] ART 
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DHR-123: RNS Production 
AECs exposed to 24 hours of SS followed by treatment with low (108.6 ± 2.667%), mid 
(108.8 ± 2.783%) and high (108.8 ± 2.197%) concentration ART for 24 hours, all showed a 
significant increase in mean DHR-123 fluorescence (RNS production) compared to the 
untreated control group (100.0 ± 0.7896%). Only high concentration ART increased 
significantly compared to its vehicle (101.1 ± 2.539%) (Fig 4.8), meaning the increase in 
DHR-123 fluorescence seen in the low and mid concentration ART groups compared to 
the control were vehicle effects. 
 
 
 
 
 
 
Figure 4.8: The effects of 24h SS followed by 24h ART treatment on RNS production measured by 
DHR-123 fluorescence. RNS production expressed as % DHR-123 stained cells (calculated as a 
percentage of the untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
#: p=0.0152 vs control 
##: p=0.0015 vs control 
###: p=0.0015 vs control 
$: p=0.0015 vs [high] vehicle 
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PI: Cell Viability (Necrosis) 
AECs exposed to 24 hours of SS followed by treatment with high (107.3 ± 1.344%) 
concentration ART for 24 hours, showed a significant increase in mean PI fluorescence 
(necrosis) compared to the untreated control group (100.0 ± 0.8571%). Low (101.3 ± 
1.537%) and mid (101.7 ± 1.269%) concentration ART showed no differences in mean PI 
fluorescence when compared to the control. Only high concentration ART increased PI 
fluorescence significantly compared to its vehicle (101.3 ± 1.796%). High concentration 
ART also increased necrosis significantly compared to both the low and mid concentration 
ART groups (Fig 4.9). 
 
 
 
 
Figure 4.9: The effects of 24h SS followed by 24h ART treatment on necrosis measured by PI 
fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of the 
untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
 
#: p=0.0251 vs control 
$: p=0.0251 vs [high] vehicle 
 
&: p=0.0251 vs [high] ART 
&&: p=0.0251 vs [high] ART 
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4.1.3 Combination Studies 
As previously mentioned in section 2.2.3, only a single concentration was used for both 
melatonin and ART in the combination studies. The individual melatonin and ART 
concentrations were selected based on the results observed in the dose-response 
experiments. Based on the above data, 1 nM melatonin and high concentration ART (EFV: 
12µM; FTC: 10µM; TDF: 1µM) were used in the combination studies. A 24-hour SS period 
was once again used, followed by a 24-hour treatment period. 
 
DAF-2/DA: NO Production 
AECs were exposed to 24 hours of SS followed by treatment with 1 nM melatonin (99.83 ± 
1.515%), high concentration ART (98.00 ± 1.571%), as well as a combination of 1 nM 
melatonin + high concentration ART (99.33 ± 2.060%) for 24 hours. Results showed no 
differences in mean DAF-2/DA fluorescence (NO production) between the treatment 
groups and the untreated control group (100.0 ± 1.124%) (Fig 4.10). No changes were 
observed in any vehicle groups. 
 
Figure 4.10: The effects of 24h SS followed by 24h melatonin and ART combination treatment on 
NO production measured by DAF-2/DA fluorescence. NO production expressed as % DAF-2/DA 
stained cells (calculated as a percentage of the untreated control group; Control fluorescence 
adjusted to 100 %), n = 3/ group. 
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DHR-123: RNS Production 
AECs were exposed to 24 hours of SS followed by treatment with 1 nM melatonin (101.3 ± 
0.9574%), high concentration ART (98.33 ± 0.8819%), as well as a combination of 1 nM 
melatonin + high concentration ART (98.89 ± 1.124%) for 24 hours. Results showed no 
differences in mean DHR-123 fluorescence (RNS production) between the treatment 
groups and the untreated control group (100.0 ± 1.124%) (Fig 4.11). No changes were 
observed in any vehicle groups. 
 
 
Figure 4.11: The effects of 24h SS followed by 24h melatonin and ART combination treatment on 
DHR-123 fluorescence. RNS production expressed as % DHR-123 stained cells (calculated as a 
percentage of the untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
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PI: Cell Viability (Necrosis) 
AECs were exposed to 24 hours of SS followed by treatment with 1 nM melatonin (92.43 ± 
3.753%), high concentration ART (121.3 ± 9.114%), as well as a combination of 1 nM 
melatonin + high concentration ART (94.17 ± 5.082%) for 24 hours. When compared to 
the untreated control group (100.0 ± 1.067%), 1 nM melatonin was seen to significantly 
decrease mean PI fluorescence (necrosis). In contrast, the high concentration ART 
treatment group significantly increased mean PI fluorescence compared to the control, as 
well as compared to the 1 nM melatonin treatment group. When combined, the melatonin 
+ ART treatment group significantly decreased mean PI fluorescence compared to the 
group treated with only ART. All treatment groups showed significant differences when 
compared to their relative vehicles (1nM Mel Veh: 111.2 ± 4.277%; High ART Veh: 97.83 ± 
3.381%; Mel + ART Veh: 109.5 ± 3.413%) (Fig 4.12). 
 
 
 
 
 
 
Figure 4.12: The effects of 24h SS followed by 24h melatonin and ART combination treatment on 
PI fluorescence. Necrosis expressed as % PI stained cells (calculated as a percentage of the 
untreated control group; Control fluorescence adjusted to 100 %), n = 3/ group. 
*: p<0.0001 vs control 
**: p<0.0001 vs control 
 
#: p<0.0001 vs 1 nM vehicle 
$: p<0.0001 vs [high] vehicle 
 @: p<0.0001 vs 1 nM melatonin 
%: p<0.0001 vs melatonin + ART vehicle 
&: p<0.0001 vs [high] ART 
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4.2 Western Blot Analyses 
For in vitro cell signaling protein investigations, AECs were serum starved for 24 hours and 
then treated with a combination of 1 nM melatonin and high concentration ART (EFV: 
12µM; FTC: 10µM; TDF: 1µM) for a further 24 hours. The cells were used to make protein 
lysates as described in section 2.4. All western blot experimental groups contained a 
combined vehicle, which allowed for all groups to be directly compared without considering 
a vehicle effect. 
For Western blot data, controls were adjusted to the value of 1. Total protein expression 
was calculated as a ratio of the loading control. A p-value of < 0.05 was considered 
statistically significant. 
4.2.1 NO & RNS Signalling 
For NO and reactive nitrogen species (RNS) signalling, total- and phosphorylated eNOS; 
total iNOS and total nitrotyrosine were examined. eNOS and iNOS are important signaling 
molecules in the production of NO, while nitrotyrosine is a marker of nitrosative stress. 
4.2.1.1 eNOS 
eNOS phosphorylation was significantly lower is the melatonin (0.6354 ± 0.04195), ART 
(0.4348 ± 0.05156) and melatonin + ART (0.2535 ± 0.03983) treatment groups compared 
to the control (1.000 ± 0.1068). The melatonin + ART treatment group also showed 
significantly less levels of eNOS phosphorylation compared to the melatonin treatment 
group (Fig 4.13 A). 
No significant differences were seen in total eNOS expression between any of the 
treatment groups (Mel: 0.9188 ± 0.1187; ART: 0.7479 ± 0.09084; Mel + ART: 0.8895 ± 
0.04375) when compared to the control (1.000 ± 0.1330) (Fig 4.13 B). 
When eNOS phospho/total (P/T) ratios were calculated, the same pattern of significance 
emerged as was seen for the eNOS phosphorylation levels. All treatment groups showed 
significantly lower P/T eNOS levels (Mel: 0.5630 ± 0.01973; ART: 0.4298 ± 0.02480; Mel + 
ART: 0.2614 ± 0.05717) compared to the control (1.000 ± 0.1207), while the melatonin + 
ART treatment group had lower P/T eNOS levels when compared to the melatonin 
treatment group (Fig 4.13 C). 
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Figure 4.13: Changes in the eNOS phosphorylation and expression (Ser 1177) of AECs treated 
with melatonin and/or ART, for 24 hours. A) Analysed results and western blot for phospho-eNOS 
(Ser 1177); B) Analysed results and western blot for total-eNOS; C) Phosphorylated over total 
(P/T) ratio of eNOS (Ser 1177) (n=5/ group). 
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4.2.1.2 iNOS 
No band was detected for iNOS and therefore no statistical analyses could be conducted 
(Fig 4.14). 
  
 
 
 
 
 
4.2.1.3 Nitrotyrosine 
Nitrotyrosine levels in the ART treatment group (2.309 ± 0.3443) was significantly higher 
compared to the control group (1.000 ± 0.1707). When melatonin and ART were combined 
(1.266 ± 0.2876), nitrotyrosine levels decreased significantly compared to the group that 
was treated with ART alone (Fig 4.15). There were no significant differences seen in the 
melatonin group (2.825 ± 1.564). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: No iNOS band was detected in AECs treated with melatonin and/or ART, for 24 
hours. Shown is the western blot for iNOS (n=5/ group). 
Figure 4.15: Changes in nitrotyrosine levels of AECs treated with melatonin and/or ART, 
for 24 hours. Shown are the analysed results and western blot for nitrotyrosine (n=5/ 
group). 
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4.2.2 ROS Signalling 
For reactive oxygen species (ROS) signalling, total- p22 PHOX was examined. p22 PHOX 
is a marker for NADPH-oxidase derived superoxide  (Fukui et al., 1997), a reactive oxygen 
anion. 
4.2.2.1 p22 PHOX 
All treatment groups showed decreased p22 PHOX expression compared to the control 
(1.000 ± 0.1518). Both the ART (0.2039 ± 0.04277) and melatonin + ART (0.2587 ± 
0.008877) combination treatment groups also showed significantly decreased p22 PHOX 
expression compared to the melatonin (0.5217 ± 0.08199) treatment group (Fig 4.16). 
 
 
 
 
 
 
    
 
 
 
 
4.2.3 Cell Viability Signalling 
For cell viability signalling, cleaved caspase-3 was examined. Cleaved caspase-3 is a 
marker of apoptosis  (Kuribayashi, Mayes, & El-Deiry, 2006), which is a programmed form 
of cell death. 
4.2.3.1 Cleaved Caspase-3 
The ART (0.2519 ± 0.03783) and melatonin + ART (0.3878 ± 0.07965) combination 
treatment groups showed significantly decreased cleaved Caspase-3 expression 
compared to the control (1.000 ± 0.1775), as well as compared to the melatonin treatment 
group (0.7586 ± 0.08004) (Fig 4.17). 
Figure 4.16: Changes in the p22 PHOX expression of AECs treated with melatonin and/or ART, for 
24 hours. Shown are the analysed results and western blot for p22 PHOX (n=5/ group). 
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4.3 Antioxidant Capacity Analyses 
For in vitro cell antioxidant capacity analyses, AECs were serum starved for 24 hours and 
then treated with a combination of 1 nM melatonin and high concentration ART (EFV: 
12µM; FTC: 10µM; TDF: 1µM) for a further 24 hours.  All experimental groups contained a 
combined vehicle, which allowed for all groups to be directly compared without considering 
a vehicle effect. 
Antioxidant capacity is expressed in trolox equivalents, which is a vitamin-E analogue that 
is used as the standard measure of antioxidant capacity  (Maarman et al., 2015). A p-value 
of < 0.05 was considered statistically significant. 
4.3.1 ORAC Assay 
No significant differences were seen between melatonin (0.3324 ± 0.01852), ART (0.3134 
± 0.01466) and melatonin + ART (0.3366 ± 0.01324) treatment groups when compared to 
the control (0.2710 ± 0.04975) (Fig 4.18). 
Figure 4.17: Changes in cleaved Caspase-3 expression of AECs treated with melatonin and/or 
ART, for 24 hours. Shown are the analysed results and western blot for cleaved Caspase-3 (n=5/ 
group). 
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Figure 4.18: Antioxidant capacity of AECs treated with melatonin and ART, as well as a combined 
vehicle for 24 hours (n = 5/ group). 
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5 – Results: Ex vivo and In vivo studies 
Chapter 5 describes and reports data collected from the ex vivo and in vivo studies, the 
materials and methods for which can be found in Chapter 3. See Appendix I for biometric 
data obtained from the treated rats udring the treatment protocol. 
5.1 Ex Vivo Studies 
The main aim of the ex vivo studies was to determine the acute effects of melatonin and 
ART administration on the vascular reactivity of untreated, control male Wistar rat aortas. 
To achieve this, drugs were administered as a pre-treatment, directly to an ex vivo organ 
bath containing a stabilised rat aortic ring. For ex vivo studies, 10 µM melatonin was used, 
along with high concentration ART (EFV: 12µM; FTC: 10µM; TDF: 1µM). Following the 30-
minute drug pre-treatment, aortic contraction was induced through the cumulative 
administration of Phe (100 nM – 1 µM). Once maximum contraction was reach, aortic 
relaxation was induced through the cumulative administration of Ach (30 nM – 10 µM). Ex 
vivo treatment groups all contained a combined vehicle. Only endothelium-dependent ex 
vivo studies were conducted due to limited availability of rats, and well as due to the novel 
nature of these investigations. No L-NAME control experiments were included for the ex 
vivo studies due to limited equipment availability. For all ex vivo isometric tension studies, 
Phe-contraction results are expressed as an increase in gram tension from a resting 
tension of 1.5 g, while Ach-relxation results are expressed as % relaxation of the maximum 
phenylephrine-pre-contraction. A p-value of < 0.05 was considered statistically significant. 
5.1.1 Phe-contraction / Ach-relaxation 
Cumulative contraction with Phe, showed that the ART treated aortas contracted 
(measured by increase in g tension from a stable point of 1.5 g) significantly less when 
compared to all other treatment groups (Two-way ANOVA Con: p=0.0070; Mel: p=0.0250; 
Mel + ART: p=0.0001 vs ART) (Fig 5.1 A).  
The addition of Ach induced significantly less relaxation (measured by the % decrease in g 
tension from the point of maximal contraction) in the melatonin + ART group compared to 
the control group  (Two-way ANOVA Con: p=0.0148 vs Mel+ART) (Fig 5.1 B).  
No significant differences were seen in Emax values between the different groups (See 
Table 5.1. for Emax values). Emax is the maximal response of the system. 
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Figure 5.1: Graphs indicating the effects of ex vivo melatonin and ART treatment on Phe induced 
contraction and Ach induced relaxation. A) Aortic ring contractions in response to cumulative 
concentrations of Phe; B) Aortic ring relaxation in response to cumulative concentrations of Ach (n 
= 5-6/ group).  
*: p<=0.0070 vs control 
*: p=0.0250 vs melatonin 
*: p=0.0001 vs ART + Mel 
 
*: p<=0.0148 vs control 
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Table 5.1: Ex vivo Emax values for the various treatment groups. Phe was used to induce 
contraction, and Ach was used to induce relaxation. 
  Control Melatonin ART 
Melatonin  
+ ART 
Phe (g) 
Emax  
± SEM 
2.998 ± 
0.1244 
3.043 ± 
0.1519 
2.833 ± 
0.1369 
3.171 ± 
0.1598 
Ach (%) 
Emax 
± SEM 
78.56 ± 
4.682 
67.47 ± 
4.275 
75.50 ± 
4.685 
61.01 ± 
4.572 
 
5.2 In Vivo Studies 
The main aim of the in vivo studies was to determine the chronic effects of melatonin and 
ART administration on the vascular reactivity of male wistar rats that have been treated for 
8 weeks with melatonin and/or ART.  Additional aims included examining various protein 
activation and/or expression levels, as well as the antioxidant capacity exhibited in the 
aortic tissue of these same male Wistar rats. 
For these in vivo studies, 80 male Wistar rats were randomly divided into four treatment 
groups: control, melatonin (10 mg/kg/day), ART (EFV: 51.6 mg/kg; FTC: 17.4 mg/kg; TDF: 
25.8 mg/kg) and melatonin + ART. The rats received the respective treatments for 8 
weeks, after which the animals were sacrificed, the aortas removed and the following data 
were obtained.  
A p-value of < 0.05 was considered statistically significant. 
5.2.1 Endothelium-dependent aortic ring investigations 
As mentioned in section 3.3.3.2, two types of aortic ring investigations were conducted. 
The first set of aortic ring investigations conducted, were endothelium-dependent 
relaxation studies. For these studies, Phe was used to induce contraction and Ach was 
used to induce relaxation (as previously described above in section 5.1). As a negative 
control for the endothelium-dependent relaxation studies, some of the rings were pre-
treated with the NOS inhibitor, L-NAME (100 μM) 15 minutes prior to the administration of 
cumulative amounts of Phe and Ach in order to confirm that the relaxation responses were 
indeed derived from endothelial NOS-NO release. 
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5.2.1.2 Phe-contraction / Ach-relaxation 
Cumulative contraction with Phe, showed that the ART and melatonin + ART treatment 
groups contracted significantly more overall, when compared to the control group (Two-
way ANOVA Con: p<0.0001 vs ART; Mel+ART) (Fig 5.2 A). 
Ach induced relaxations were similar for all treatment groups (Fig 5.2 B). 
No significant differences were seen in Emax values between the different groups (See 
Table 5.2. for Emax values).  
 
 
 
 
 
  
Figure 5.2: Graphs indicating the effects of in vivo melatonin and ART treatment on Phe induced 
contraction and Ach induced relaxation. A) Aortic ring contractions in response to cumulative 
concentrations of Phe; B) Aortic ring relaxation in response to cumulative concentrations of Ach (n = 
12-16/ group). 
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Table 5.2: In vivo Emax values for the various treatment groups. Phe was used to induce 
contraction, and Ach was used to induce relaxation. 
  Control Melatonin ART 
Melatonin  
+ ART 
Phe (g) 
Emax 
± SEM 
2.635 ± 
0.07303 
2.862 ± 
0.07496 
2.852 ± 
0.07322 
2.851 ± 
0.07378 
Ach (%) 
Emax 
± SEM 
79.80 ± 
3.656 
81.49 ± 
3.662 
84.34 ± 
3.568 
77.72 ± 
3.878 
 
5.2.1.3 L-NAME + Phe-contraction / Ach-relaxation 
Phe Contraction Studies 
Pre-treatment with 100 µM L-NAME caused all treatment groups (Two-way ANOVA 
p<0.0001 in all groups) to contract significantly more when compared to their respective L-
NAME treated group (Fig 5.3 A). The L-NAME+control (3.714 ± 0.2148g) and L-
NAME+melatonin (3.890 ± 0.1897g) groups experienced a ± 35% increase in contraction 
at the maximum Phe concentration compared to the control (2.761 ± 0.07774g) and 
melatonin (2.876 ± 0.08195g) groups, respectively (Fig 5.3 A). The L-NAME+ART (4.021 ± 
0.2713g) group experienced a similar increase in maximum contraction of ± 36% when 
compared to the ART (2.953 ± 0.07830g) group. L-NAME+Mel+ART experienced a slightly 
smaller, but still noteworthy increase in maximum contraction of ± 29% when compared to 
the Mel+ART (2.950 ± 0.07860g) group (Fig 5.3 A). 
However, when L-NAME pre-treated groups were compared with each other, there were 
no differences seen in Phe induced contraction (Fig 5.3 B), between any of the treatment 
groups. 
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Figure 5.3: The effects of L-NAME pre-administration on Phe-induced contraction. A) The 
differences in contraction of aortic rings between treatment groups incubated with or 
without L-NAME. B) The differences in contraction of aortic rings between treatment 
groups pre-treated with L-NAME (n = 4-5/ group). 
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Ach Relaxation Studies 
Figure 5.4 A shows that all treatment groups exposed to L-NAME pre-administration 
relaxed significantly less (Two-way ANOVA p<0.0001 in all groups) when compared to the 
applicable treatment groups not exposed to L-NAME pre-treatment. The L-NAME+control 
(0.7550 ± 0.7187%) and L-NAME+ART (1.191 ± 0.6933%) groups experienced a ± 99% 
decrease in relaxation capacity at the maximum Phe concentration compared to the 
control (79.80 ± 3.656%) and ART (84.34 ± 3.568%) groups, respectively (Fig 5.4 A). The 
L-NAME+melatonin (-1.479 ± 0.7575%) and L-NAME+Mel+ART (-1.245 ± 0.7238%) 
groups both continued to contract, even following the addition of the full cumulative dose 
of Ach (Fig 5.4 A). This meant the final tension (g) after the cumulative addition of Ach in 
these two groups, was higher when compared to the final tension seen after the 
accumulative addition of Phe. When the final mean tension values are compared (after the 
accumulative addition of both Phe and Ach), we see that L-NAME+melatonin had a high 
ending mean tension of 2.21g, while the melatonin group had a much lower ending mean 
tension of 0.25g. The same trend was seend in the L-NAME+melatonin+ART group, which 
had a final mean tension of 2.15g, compared to the much lower final mean tension of 
0.31g in the melatonin+ART. 
When Ach induced relaxation in L-NAME pre-treated groups were compared with each 
other, there were once again no differences seen (Fig 5.4 B), between any of the 
treatment groups. Some aortas continued to contract after the addition of Ach following 
pre-treatment with L-NAME, which consequently resulted in negative Emax values. 
No significant differences were seen in Emax values between the different groups (See 
Table 5.3. for Emax values).  
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Figure 5.4: The effects of L-NAME pre-administration on Ach-induced relaxation. A) The 
differences in relaxation of aortic rings between treatment groups incubated with or 
without L-NAME. B) The differences in relaxation of aortic rings between treatment 
groups pre-treated with L-NAME (n = 4-5/ group). 
Stellenbosch University  https://scholar.sun.ac.za
 106 
Table 5.3: In vivo Emax values for L-NAME pre-treated treatment groups. Phe was used to induce 
contraction, and Ach was used to induce relaxation. 
  Control Melatonin ART 
Melatonin  
+ ART 
Phe (g) 
Emax 
± SEM 
3.714 ± 
0.2148 
3.890 ± 
0.1897 
4.021 ± 
0.2713 
3.793 ± 
0.1767 
Ach (%) 
Emax 
± SEM 
0.7550 ± 
0.7187 
-1.479 ± 
0.7575 
1.191 ± 
0.6933 
-1.245 ± 
0.7238 
 
5.2.2 Endothelium-independent aortic ring investigations 
The second set of aortic ring investigations conducted, were endothelium-independent 
relaxation studies. For these studies, Phe was once again used to induce contraction, 
however, SNP - an exogenous NO donor - was used to induce relaxation. 
5.2.2.1 Phe-contraction / SNP-relaxation 
Cumulative contraction with Phe, showed that the ART and melatonin + ART treatment 
groups exhibited significant pro-contractile properties compared to the control group (Two-
way ANOVA Con: p<0.0001 vs ART; Mel+ART) (Fig 5.5 A). 
SNP induced relaxations were similar for all treatment groups (Fig 5.5 B). 
No significant differences were seen in Emax values between the different groups (See 
Table 5.4. for Emax values).   
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Figure 5.5: Graphs indicating the effects of in vivo melatonin and ART treatment on Phe 
induced contraction and SNP induced relaxation. A) Aortic ring contractions in response to 
cumulative concentrations of Phe; B) Aortic ring relaxation in response to cumulative 
concentrations of SNP (n = 5/ group). 
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Table 5.4: In vivo Emax values for the various treatment groups. Phe was used to induce 
contraction, and SNP was used to induce relaxation. 
  Control Melatonin ART 
Melatonin  
+ ART 
Phe (g) 
Emax 
± SEM 
3.714 ± 
0.2148 
3.890 ± 
0.1897 
4.021 ± 
0.2713 
3.793 ± 
0.1767 
Ach (%) 
Emax 
± SEM 
110.3 ± 
4.639 
113.2 ± 
3.860 
108.1 ± 
4.153 
108.0 ± 
4.130 
 
5.2.3 Western Blot Analyses 
Western blot analyses were performed on snap-frozen aortic tissue of control, melatonin, 
ART and melatonin + ART treated animals in order to determine whether the functional 
data of the vascular reactivity investigations could be explained by changes in intracellular 
signal transduction pathways. 
All blots are calculated and expressed as a ratio of the corresponding loading controls. 
Controls are expressed as 1. 
5.2.3.1 NO & RNS Signalling 
eNOS 
eNOS phosphorylation was significantly lower is the melatonin + ART (0.3292 ± 0.04093) 
treatment group compared to the control (1.000 ± 0.2814). No significant differences were 
seen in the phosphorylation levels of the melatonin (0.5541 ±0.06424) or ART (0.5251 ± 
0.1112) treatment groups (Fig 5.6 A) 
No significant differences were seen in total eNOS expression between any of the 
treatment groups (Mel: 0.6192 ± 0.09478; ART: 0.5239 ± 0.07665; Mel + ART: 0.3522 ± 
0.07480) when compared to the control (1.000 ± 0.3073) (Fig 5.6 B). 
When eNOS P/T ratios were calculated, no significant differences were seen in total eNOS 
expression between any of the treatment groups (Con: 1.000 ± 0.04927; Mel: 1.081 ± 
0.06813; ART 1.156 ± 0.07625; Mel+ART: 1.187 ± 0.1149) (Fig 5.6 C). 
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Figure 5.6: Changes in the eNOS phosphorylation and expression (Ser 1177) in aortic tissue 
from rats treated with melatonin and ART, in vivo. A) Analysed results and western blot for 
phospho-eNOS (Ser 1177); B) Analysed results and western blot for total-eNOS; C) 
Phosphorylated over total (P/T) ratio of eNOS (Ser 1177) (n=5/ group). 
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iNOS 
No significant differences were seen in total iNOS expression between any of the 
treatment groups (Fig 5.7) 
  
Figure 5.7: Changes in iNOS expression in aortic tissue from rats treated with melatonin and 
ART, in vivo. Shown are the analysed results and western blot for iNOS (n=5/ group). 
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Nitrotyrosine 
No significant differences were seen in nitrotyrosine levels between any of the treatment 
groups (Fig 5.8) 
  
Figure 5.8: Changes in nitrotyrosine expression in aortic tissue from rats treated with melatonin 
and ART, in vivo. Shown are the analysed results and western blot for nitrotyrosine (n=5/ group). 
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5.2.3.2 ROS Signalling 
p22 PHOX 
No significant differences were seen in total p22 PHOX expression between any of the 
treatment groups (Fig 5.9). 
 
  
Figure 5.9: Changes in the p22 PHOX expression in aortic tissue from rats treated with melatonin 
and ART, in vivo. Shown are the analysed results and western blot for p22 PHOX (n=5/ group). 
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5.2.3.3 Cell Viability Signalling 
Cleaved Caspase-3 
The ART (0.2735 ± 0.08317) and melatonin + ART (0.4757 ± 0.08704) combination 
treatment groups showed significantly decreased cleaved Caspase-3 expression 
compared to the control (1.000 ± 0.1945). The ART treatment group also showed 
significantly decreased cleaved Caspase-3 expression when compared to the melatonin 
treatment group (0.6309 ± 0.09441) (Fig 5.10). 
 
 
 
  
Figure 5.10: Changes in cleaved Caspase-3 expression in aortic tissue from rats treated with 
melatonin and ART, in vivo. Shown are the analysed results and western blot for cleaved 
Caspase-3 (n=5/ group). 
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5.2.4 Antioxidant Capacity Studies 
Antioxidant capacity studies were performed on snap-frozen aortic tissue of control, 
melatonin, ART and melatonin + ART treated animals. 
Antioxidant capacity is expressed in trolox equivalents, which is a vitamin-E analogue that 
is used as the standard measure of antioxidant capacity.  
5.2.4.1 ORAC Assay 
No significant differences were seen between melatonin (0.0564 ± 0.01664), ART (0.0532 
± 0.01131) and melatonin + ART (0.07225 ± 0.006700) treatment groups when compared 
to the control (0.0430 ± 0.005899) (Fig 5.11). 
 
 
Figure 5.11: Antioxidant capacity of aortic tissue from rats treated with melatonin and ART, in vivo 
(n = 5/ group). 
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6 – Discussion: In vitro studies 
Chapter 6 debates the findings of the results obtained from the in vitro study. The data 
discussed in this chapter can be found in Chapter 4, while the materials and methods can 
be found in Chapter 2. 
 
Throughout the in vitro studies, we set out to examine three important variables: NO and 
RNS levels, ROS levels and cell viability. All three of these factors play important roles in 
the maintenance of endothelial health and vascular function (Mudau et al. 2012; K. Park & 
Park, 2015; Versari et al., 2009). 
NO is viewed as an endothelial cell survival factor  (Dimmeler & Zeiher, 1999), and a 
reduction in NO bioavailability is considered as a marker for ED  (Muniyappa & Sowers, 
2013). However, besides its important beneficial activities, in pathophysiological conditions 
excessive NO production may contribute to oxidative stress and an associated 
inflammatory state with eventual tissue damage  (Pacher et al., 2007). Together, 
excessive NO or RNS, as well as ROS, can cause a decrease in cell viability and 
eventually lead to cell death (Circu & Aw, 2010; Fransen et al., 2012; Marín-García, 2016; 
Murphy, 1999).  For cell viability and cell death, we examined both necrosis and apoptosis. 
Necrosis refers to the pathological or accidental mode of cell death involving irreversible 
swelling of the cytoplasm and distortion of organelles including mitochondria followed by 
rupture of the cell membrane and inflammation that damage the cells and its surrounding 
tissues  (Fadeel & Orrenius, 2005). Apoptosis is a sequential process where the dying cell 
undergoes nuclear and cytoplasmic condensation with blebbing of the plasma membrane 
leading to formation of apoptotic bodies, which are recognised and removed, via 
phagocytosis by macrophages without damaging the surrounding tissues  (Fadeel & 
Orrenius, 2005).  
6.1 Melatonin Dose-Response 
The antioxidant activity of melatonin has been reported at both physiological and 
pharmacological concentrations  (Galano et al., 2011; Reiter et al., 2005), although 
pharmacological dosages of exogenously administered melatonin typically provide greater 
protection from large quantities of free radicals  (Tan et al., 2007). In literature, in vitro 
melatonin supplementation studies conducted on various types of ECs have used a wide 
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range of melatonin concentrations. Some studies have used dosages as low as 0.1 nM  
(Tamura, Silva, & Markus, 2006), while others have used concentrations as high as 50 µM  
(Pogan, Bissonnette, Parent, & Sauve, 2002). However, most studies used a 
concentration range between 1 nM and 10 µM  (Silva et al., 2007; Tamura, Cecon, 
Monteiro, Silva, & Markus, 2009; Urata et al., 1999), and therefore in this study, we 
decided to use 1 nM; 1 µM and 10 µM melatonin in the dose-response studies. 
 
None of the three melatonin dosages tested, elicited any changes in NO (Fig 4.1 & 4.4) or 
RNS production (Fig 4.2 & 4.5), regardless of the treatment period (1h or 24h). This is 
contradictory to most in vitro findings in literature, where these concentrations of melatonin 
have been shown to decrease NO and RNS production  (Jumnongprakhon, Govitrapong, 
Tocharus, & Tocharus, 2016; Reiter et al., 2001; Silva et al., 2007; Tamura et al., 2006; 
Tamura et al., 2009). However, the abovementioned studies were conducted using rat 
brain microvascular endothelial cells as well as rat microvascular cremaster muscle 
endothelial cells. Although these are also endothelial cell lines, the function of endothelial 
cells are specialised depending on their location (Gordon et al., 1991), making a direct 
comparison difficult. On the other hand, and in line with this investigation, a study by 
Tamura et al. (2006) found that the treatment of rat microvascular endothelial cells with 0.1 
nM and 1 nM melatonin had no effect on NO production. However, the observed result in 
the aforementioned study is most likely due to the very short melatonin incubation period 
of 1 minute. No studies have been conducted with the specific ECs examined in this study, 
namely AECs. Therefore further studies would be needed to determine whether the lack of 
changes in NO and ROS levels observed in AECs, as shown in these results, is a 
standard response for an AEC, or if these findings are the result of the specific technique 
used. Various techniques are available to measure NO and RNS production, however, the 
low levels of NO and RNS produced by cultured vascular ECs in vitro exposes the 
sensitivity limits of many of these assays (Kleinhenz et al., 2003). In this case, a potential 
more sensitive alternative to fluorometric detection of NO and RNS may be to use a 
chemiluminescence technique, which has shown to detect these molecules at 
concentrations as low as 1 p.m., compared to the 2-5 nM detection capacity of the 
employed fluorometric method (Kleinhenz et al., 2003). 
 
Conversely, the cell viability studies in the present study showed that 1 nM melatonin was 
the only concentration to decrease necrosis after a 24-hour treatment period (Fig 4.3), 
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which was in line with findings from other studies  (Harms et al., 2000; Song et al., 2014). 
It was however expected that all melatonin concentrations would decrease necrosis, since 
the examined melatonin concentration range (1 nM; 1 µM and 10 µM) has been shown to 
increase cell viability over and incubation period of 24h, in multiple other studies (Celik & 
Maziroglu, 2012; Kim et al., 2011; Osseni et al., 2000). The lack of melatonin activity in the 
1 µM and 10 µM treatment groups after 24 hours of treatment was therefore very 
surprising. In contrast, a study conducted on a human liver cell line (HepG2), showed that 
melatonin treatment at concentrations of 1-10,000  µM over a longer treatment period (24–
96 h) decreased cell viability (Osseni et al., 2000). This finding is line with another study 
conducted in our laboratory, which found that cardiac microvascular endothelial cells 
(CMECs) showed decreased cell viability after 6-24 h melatonin treatment (1 nM; 1 µM 
and 10 µM melatonin)  (Nduhirabandi, 2014). In the current study, AECs showed no 
significant loss in cell viability after treatment with higher concentrations of melatonin over 
24h (Fig 4.3), which may indicate that AECs are more robust than other previously 
investigated cell lines. The robustness of this cell line may also be a possible explination 
for the lack of significant changes seen in the NO and RNS investigations. A potential 
solution may be to apply a harmful but not lethal stimulus to the cells before treatment, in 
order to elicit a protective response by melatonin in otherwise healthy cells. 
After the 1-hour treatment period, all concentrations of melatonin showed a significant 
decrease in necrosis compared to the control, with the addition of 1 nM melatonin 
decreasing necrosis significantly more compared to 10 µM melatonin (Fig 4.6). The study 
by Nduhirabandi (2014) mentioned in the paragraph above, also showed that a melatonin 
treatment (1 nM; 1 µM and 10 µM) period of 1 hour, was the only treatment period where 
melatonin increased cell viability. The current study’s finding that melatonin increases cell 
viability most effectively at low concentrations over a short treatment period may be 
explained by a finding that a higher melatonin concentraton (10 µM) induced GSH 
depletion, that was associated with ROS over-production after only 15 minutes of 
incubation (Osseni et al., 2000). 
 
Overall, these melatonin dose-response findings led us to conclude that a concentration of 
1 nM melatonin would yield the best results in the future combination studies, since it was 
the only dose where significant differences were observed for the 24 hour treatment 
period, and the most effective dose over the 1 hour treatment period. 
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6.2 ART Dose-Response 
Despite confounding reports, many trials indicate that ART leads to ED  (Skowyra et al., 
2012). Cardiovascular complications are considered a new challenge for HIV patients 
receiving ART with numerous studies on the effects of ART on the vasculature indicating 
that ART may impair the function of the vascular endothelium  (Blanco et al., 2006; 
Shankar et al., 2005; Stein et al., 2001). ART has been shown to affect NO levels; either 
through the excessive production of NO  (Torre et al., 2015) or through reduced NO 
production  (Shankar et al., 2005), due to reduced expression of eNOS  (Fu et al., 2005). 
Increases in ROS and RNS production  (Skowyra et al., 2012) have also been 
demonstrated in ART, and together, these factors can lead to decreased cell viability. 
In this study, high concentration ART (EFV: 12µM; FTC: 10µM; TDF: 1µM) significantly 
increased NO production compared to both the control and the other two ART 
concentrations (Fig 4.7). These finding of increased NO production during treatment with 
ART were surprising. Although it has been reported in literature that ART has the ability to 
increase excessive production of NO  (Torre et al., 2015), the study conducted by was 
conducted in humans, making it difficult to compare these results with a cell-based study. 
NO is a cell survival factor (Dimmeler & Zeiher, 1999), and its controlled production plays 
many important roles in the immune and vascular system (Cines et al., 1998). In the case 
of cell injury and the release of inflammatory meadiators, iNOS is responsible for 
producing characteristically high concentrations of NO in shorts bursts in order to protect 
the cells (Matthys & Bult, 1997; Michel & Feron, 1997). Under certain circumstances, this 
high concentration of NO produced by iNOS can become detrimental, and excessive NO 
may damage the vascular wall (Matthys & Bult, 1997) or cause cell death through 
oxidative stress (Murphy, 1999). In the current study, the increase in NO observed 
between the control group and the highest ART concentration treatment group was as 
modest as ±13% (Fig 4.7). A study by Speyer et al., (2003) showed that iNOS induced NO 
production was 20-fold above that found in non-stimulated endothelial cells, where iNOS 
was inactive. Therefore, it is more likely that the modest increase in NO levels seen in the 
current study are more likely to be associated with a protective effect on the endothelium, 
rather than a damaging effect. 
Clinical and experimental models have shown that ART-induced ED appears to be 
mediated by reduced NO production  (Shankar et al., 2005). Most these clinical and 
experimental models make use of protease inhibitors, as opposed to NRTIs and NNRTIs, 
which comprise first line FDC ART used in the current study. The fact that this study 
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observed increased NO production after treatment with NRTI and NNRTI based ART may 
imply that NRTI and NNRTI based therapies may be a safer treatment option with regards 
to endothelial health and maintaining NO homeostasis. Alternatively, the result of this 
study may be due to the relatively short incubation time of 24-hours. A longer treatment 
period is more applicable when treating with ART, since ART-associated ED is usually 
only observed after many years of treatment (Choi et al., 2011; Islam et al., 2012). Further 
studies would need to be conducted to determine if NO production would still increase 
after a longer treatment period. 
When RNS production was examined, high concentration ART was the only concentration 
to significantly increase RNS production (Fig 4.8), with the increase being a slight as ±9% 
higher than the control group. It is not surprising that there were no significant differences 
seen in the two lower concentration ART groups, as well as that the high concentration 
ART group only resulted in a minor increase in RNS production, since no major increase in 
NO production was observed either. These two finding are related, since excessive levels 
of NO are associated with increased ONOO- levels (Forstermann & Munzel, 2006), which 
in turn is associated with the generation of nitrotyrosine (Halliwell, 1997). Therefore, in the 
absence of excessive NO production, excessive production of RNS is also unlikely. One 
study examined the effects of ART in a hCMEC/D3 cell line (in vitro model for blood-brain 
barrier endothelial cells) and found ROS to be highly elevated post ART treatment  
(Manda, Banerjee, Banks, & Ercal, 2011). However, as is the case with most in vitro 
studies done on the effects of ART, this study only examined ROS production and not 
RNS production, as well as used a longer treatment period of 72 hours. Multiple studies 
have demonstrated increased ART-induced ROS production  (Apostolova et al., 2010; 
Skowyra et al., 2012; Weiß et al., 2016), but no studies have looked at the effects of ART 
treatment on RNS (specifically peroxynitrite) in vitro. It is therefore important to further 
investigate the role of RNS in ART-induced ED, by testing differnet classes of ARV drugs 
as well as using different techniques to detect specifi types of RNS to verify a potential 
source of RNS. 
For the cell viability studies, high concentration ART (EFV: 12µM; FTC: 10µM; TDF: 1µM) 
increased necrosis in AECs, when compared to the control (Fig 4.9). High concentration 
ART also showed significantly increased necrosis compared to the other two ART 
concentrations (Fig 4.9). This results correspond with the RNS production results (Fig 4.8), 
where we saw that the high concentration ART group has the largest increase in RNS 
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production, which could potentially, in part, be responsible for the decreased cell viability 
onserved, since inceases in RNS are associated with cell death (Murphy, 1999). 
These results are comparable to a study that demonstrated increased necrosis in human 
umbilical vein endothelial cells (HUVECs) following treatment with EFV  (Weiß et al., 
2016), one of the components of first line FDC ART. The above-mentioned study treated 
cells with 30 – 50 µM EFV. The current study has demonstrated a similar increase in 
necrosis with a much lower concentration of 12 µM EFV. Another study by Zhong et al. 
(2002) showed that protease inhibitor ritonavir directly caused endothelial cell death, 
mainly through necrosis pathways in human dermal microvascular endothelial cells 
(HMECs). The only other study conducted on AECs that examined the effect of first line 
FDC ART treatment on cell viability was conducted in our laboratory. The mentioned study 
showed that first line FDC ART has no effect on cell viability, at any tested concentration, 
compared to the untreated control group (Charania, 2017). This finding is inconsistent with 
the findings of this study, but this discrepancy can most likely be attributed to the lower 
ART concentration ranges used in the other study (maximum ART concentrations – EFV: 
11.2 nM; FTC: 2.6 µM; TDF: 1 µM).  
From our findings, we determined that high concentration ART would be the most effective 
dosage for the subsequent experiments, since it led to the greatest changes in NO- and 
RNS production, as well as necrosis. 
6.3 Effects of melatonin and ART treatment on NO production, 
RNS production and cell viability in AECs 
As mentioned above in section 6.1 and 6.2, from the dose-response studies, it was 
determined that 1 nM melatonin along with high concentration ART (EFV: 12µM; FTC: 
10µM; TDF: 1µM) would be used in the combination studies. 
In the NO- and RNS production combination studies, no significant differences were 
observed between any of the treatment groups (Fig 4.10 and 4.11). This finding was not 
very surprising with regards to the melatonin groups, since in the dose response studies, 
melatonin treatment had no effect on NO- and RNS-production. But for the ART treatment 
groups, we did expect the results from the dose-response studies to be mirrored in the 
combination treatment investigations. One explanation for these contrasting results may 
be that new DAF-2/DA and DHR-123 batches had to be purchased and used for the 
combination experiments.  However, it is unlikely that this change should affect the results, 
since the probes were bought from the same supplier. It is therefore difficult to explain the 
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discrepancy, as the experimental conditions (other than the different fluorescent probe 
batches), were identical to the dose-response studies. 
Results from the cell viability studies where more in line with the dose-response findings. 
We found that 1 nM melatonin significantly decreased necrosis compared to the control, 
while high concentration ART significantly increased necrosis compared to both the control 
and the 1 nM melatonin treatment group (Fig 4.12). When the two drugs were combined, 
we saw a significant decrease in necrosis for the combination group compared to the 
group treated with ART alone (Fig 4.12). In this way, we demonstrated that melatonin was 
able to ameliorate the harmful effects of ART. This is a novel finding, since to the best of 
our knowledge, there are no studies that have demonstrated this in AECs using first line 
FDC ART and melatonin.  
These observations  may be due to melatonin’s antioxidant capabilities, which would allow 
the cells to remain viable in situations of stress where toxins like ART may lead to a loss in 
cell membrane viability. However, more specific  investigations into the underlying 
mechanisms are necessary to determine through what means melatonin is able to induce 
these protective changes. 
6.4 Western Blot Analyses 
6.4.1 NO & RNS Signalling 
It is clear that NO and NOS play key roles in endothelial function, not only in the context of 
inducing vasodilatation, but also through a plethora of other important regulatory actions 
(Cines et al., 1998). It is essential for the healthy endothelium that both NOS (as the most 
important source of vascular NO), and NO are present in desirable quantities, since and 
imbalance in NO and NOS levels can have dire consequences for endothelial health.  
6.4.1.1 eNOS 
eNOS is the most abundant isoform of NOS and is responsible for the NO produced in the 
vasculature, and therefore vessel dilation  (Sandoo et al., 2010). 
Since no changes in NO production were observed with the fluorescent probe assays, it 
was expected that eNOS activation (phosphorylation) (Fig 4.13 A) and expression (total 
protein) levels (Fig 4.13 B) would also remain unchanged. When the phosphorylated 
eNOS was expressed as a ratio of total, the ratio of all treatment groups decreased 
compared to the control group, while the melatonin + ART group also decreased 
significantly compared to the melatonin group (Fig 4.13 C). This ratio was seen to be as a 
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result of decreased phosphorylated eNOS levels as opposed to increased total eNOS 
levels. It is well reported that melatonin has the ability to decrease NO levels through its 
antioxidative capacity  (Jumnongprakhon et al., 2016; Reiter et al., 2001; Silva et al., 2007; 
Tamura et al., 2009). These convincing Western blot results suggest that melatonin 
treatment could decrease NO levels through decreased eNOS activation.  It was 
interesting, however, that the groups treated with ART also showed decreased eNOS 
activation, whilst the dose-response studies showed that ART increased NO production. 
This may imply that ART-induced NO production may be independent of the endothelium 
and eNOS, although further studies would need to be done for further elucidation on this 
point.  
6.4.1.2 iNOS 
While eNOS is associated with the maintenance of basal levels of NO, iNOS has 
traditionally been associated with high output NO-release in response to inflammatory 
mediators  (Buchwalow et al., 2001; Michel & Feron, 1997) and in many cases is 
associated with cytotoxic peroxynitrite formation (Strijdom et al., 2009). 
iNOS was not detected in the AECs (Fig 4.14). This may imply that iNOS might not have 
been expressed or that iNOS levels were so low that the antibody was not able to detect 
iNOS in the cells. Both eNOS and iNOS can therefore be excluded as sources of the 
increased NO production observed. Therefore this increase in NO production seen in the 
dose-response studies still has an unknown source that needs investigating. Potential 
sources of NOS-independent NO include S-nitrosothiols, as well as nitrite and nitrate  
(Chen, Pittman, & Popel, 2008). Under certain conditions, nitrite and nitrate act as a 
reservoir, where different enzymes (hemoglobin, myoglobin, xanthine oxidoreductase, 
mitochondrial cytochrome oxidase, aldehyde dehydrogenase 2, cytochrome P450 
reductase and cytochrome P450) can catalyze the reduction of nitrite or nitrate to generate 
NO  (Zhao, Vanhoutte, & Leung, 2015). Various methods exist to measure NOS-
independent NO formation  (Zweier, Samouilov, & Kuppusamy, 1999), which could be 
examined in future studies. 
6.4.1.3 Nitrotyrosine 
Nitrotyrosine is generated when peroxynitrite reacts with a tyrosine or tyrosine containing 
protein and serves as a marker for nitrosative stress and peroxynitrite damage  (Halliwell, 
1997). Peroxynitrite is generated as a result of the chemical reaction between NO and 
superoxide  (Forstermann & Munzel, 2006).  
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Nitrotyrosine levels in the ART treatment group were significantly higher when compared 
to the control group (Fig 4.15). This finding corresponds to the current literature, which 
suggests that ART leads to the excess production of ROS, particularly superoxide  (Sutliff 
et al., 2002). Superoxide, along with increased levels of NO production leads to the 
production of peroxynitrite and eventually nitrotyrosine.  The treatment group containing 
both melatonin and ART showed significantly lower levels of nitrotyrosine compared to the 
ART group (Fig 4.15). These results may be indicative that melatonin has the ability to 
decrease the nitrosative stress caused by ART. This protection by melatonin is most likely 
due to its antioxidative capacities and its ability to scavenge free radicals like superoxide 
and excess NO (Hardeland, 2005; Poeggeler et al., 2002), thereby decreasing the chance 
that peroxynitrite and nitrotyrosine will form (Fig 6.1). These results are similar to those 
seen in the plate reader studies, where ART significantly increased DHR-123 fluorescence 
compared to the control. Together, these results may suggest that ART induces ED 
through excess production of RNS like peroxynitrite. Most the literature covers the effects 
of ART treatment on ROS production. This study establishes that RNS may play and 
equally important role in the multifactor mechanisms by which ART induces ED. The plate 
reader studies did not however show similar results with regards to the alleviative effect of 
melatonin on RNS levels. This may be due to the fact that the nitrotyrosine antibody is a 
more specific and sensitive probe compared to DHR-123. Further protein and antioxidant 
capacity studies would be needed to confirm melatonin’s specific role in ameliorating 
nitrosative stress. 
 
Figure 6.1: Substrates involved in nitrotyrosine production  (Everson, 2016). 
 
6.4.2 ROS Signalling 
ART has been shown to result in increased ROS-production from various sources  
(Apostolova et al., 2010; Skowyra et al., 2012; Weiß et al., 2016). Superoxide is of 
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particular interest since it is essentially a precursor of other harmful radicals and 
molecules, such as hydrogen peroxide, peroxynitrite, the hydroxyl radical and nitrite. 
6.4.2.1 P22 PHOX 
p22 PHOX is one of multiple subunits of NADPH oxidase, which is responsible for 
superoxide production. p22 PHOX is therefore regarded as a  marker of NADPH-oxidase 
dependent superoxide production  (San Jose, Fortuno, Beloqui, Diez, & Zalba, 2008). 
All treatment groups showed lower levels of p22 PHOX expression compared to the 
control group (Fig 4.16). Both the ART and melatonin + ART groups also showed 
significantly lower p22 PHOX expression compared to the melatonin group, potentially 
indicating that ART may be the factor lowering the p22 PHOX expression levels. These 
results contradict the findings of the DHR-123 investigations where ART increased RNS 
(peroxynitrite) production, as well as opposes many previous reports in literature. This 
inconsistent finding may be due to the fact p22 PHOX is specific to NADPH-oxidase 
dependent superoxide, while DHR-123 is reported to be more sensitive to peroxynitrite, 
although some studies have also shown it to be sensitive to mitochondrial ROS  (Chan & 
Miskimins, 2012; Ischiropoulos et al., 1999; Navarro-Antolin et al., 2001). NADPH-oxidase 
has been implicated as the main source of excess ROS production in the vasculature  
(Hamilton et al., 2002), however, the main source of ART induced superoxide production is 
thought to be of mitochondrial origin, likely resulting from leakage of electrons from a 
dysfunctional mitochondrial electron transport chain  (Jiang et al., 2007). The results from 
the DHR-123 study substantiate this, since the probe is more sensitive to mitochondrial 
ROS and RNS (peroxynitrite), and showed a marked increase in ART treated groups, 
while the p22 PHOX did not. A marker with greater specificity for mitochondrial superoxide 
would need to be evaluated. Superoxide dismutase 2 (SOD-2) is involved in the 
scavenging of superoxide that leaks from the mitochondrial electron transport chain  
(Zelko, Mariani, & Folz, 2002), and therefore could be an alternative target for further 
investigation. 
6.4.3 Cell Viability Signalling 
Previous in vitro investigations have examined cell viability through necrosis. However, 
apoptosis is also an important form of cell death which utilises a different protein 
transduction pathway to necrosis, and may also be involved in ART induced cell damage. 
6.4.3.1 Cleaved Caspase-3 
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Cleaved caspase-3 is a down-stream target of caspase-8 and indicative of apoptosis  
(Kuribayashi et al., 2006). 
The ART and melatonin + ART treatment groups both showed decreased cleaved caspse-
3 expression levels compared to both the control and the melatonin treatment groups (Fig 
4.17). In terms of cell viability, these results contradict the findings from the PI-based 
studies where we saw ART increased necrosis, although apoptosis and necrosis do not 
neccesarily occur simultaneously and therefore cannot be directly compared. These 
confounding results correlate with evidence from literature, which demonstrates that ART 
directly induces mitochondrial dysfunction and ROS production that promotes ED without 
culminating in apoptosis  (Jiang et al., 2007). 
Another explanation for decreased cleaved caspase-3 expression in groups containing 
ART may involve ART-induced NO production, which was observed in the dose-response 
studies. NO has previously been shown to inhibit apoptosis by S-nitrosylation of caspase-3  
(Rossig et al., 1999), leading to its inactivation. 
ART has been shown to be anti-apoptotic in specific cell types  (Badley, 2005; Dieye et al., 
2000), although the exact molecular target responsible for this anti-apoptotic effect 
remains to be defined in vitro and in vivo  (Badley, 2005). The same molecular 
mechanisms could be at work here, but further protein investigations are needed. 
6.5 Antioxidant Capacity Analyses 
The oxygen radical absorbance capacity (ORAC) assay was used to assess the 
antioxidant capacity of the AECs treated with melatonin and ART. Unfortunately, no 
significant differences were seen between any treatment groups (Fig 4.18). It has been 
suggested that antioxidant activity should not be concluded based on a single antioxidant 
test model  (Alam, Bristi, & Rafiquzzaman, 2013). Therefore, it might be prudent to rather 
conduct multiple more specialised and specific assays, such as hydrogen peroxide-; nitric 
oxide- and peroxynitrite radical scavenging assays, as well as thiobarbituric acid reactive 
substances (TBARS) assays which indicate lipid peroxidation. 
6.6 Concluding Remarks 
The first main aim for this in vitro study was to determine the optimum concentrations of 
both melatonin and first line FDC ART used to treat AECs at which the greatest 
differences could be seen when compared to untreated AECs, with respect to NO- and 
ROS production, as well as cell viability. It was established that 1 nM melatonin and high 
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concentration ART (EFV: 12µM; FTC: 10µM; TDF: 1µM) showed the greatest differences 
with regards to examined variables. Unfortunately, the melatonin dose could only be 
based on results from cell viability studies since no significant differences were seen in the 
NO- and ROS production studies. 
The second main aim was to analyse any potential synergistic/antagonistic interactions 
between melatonin and ART in AECs treated with the above-determined concentrations, 
with respect to NO- and ROS production, as well as cell viability. For this aim, the NO- and 
ROS production studies did not show the same trends previously established in the dose-
response studies. However, the changes observed in the dose-response studies were very 
modest, and would have perhaps been mirrored in the combination studies after an 
increase in the smaple size. Cell viability studies were nevertheless followed the same 
trends observed in the dose-response studies and showed that melatonin alleviated 
necrotic damages induced by ART. 
Signalling protein investigations established that the observed ART-induced increase in 
NO production might be independent of the endothelium and eNOS, as well as iNOS, 
while melatonin was shown to have the capacity to ameliorate nitrosative damage. p22 
PHOX signalling eliminated NADPH-oxidase as a potential source of ROS in the ART-
induced increase in ROS production and cleaved caspse-3 investigations showed that 
ART may by pro-necrotic, but it is most likely anti-apoptotic. Antioxidant capacity studies 
showed no significant changes between treatment groups. Overall, melatonin was shown 
to be effective in reducing cell necrosis and nitrosative damage, while ART may increase 
NO- and ROS production, and reduce apoptosis, but the mechanisms behind these 
changes still need further investigation. 
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7 - Discussion: Ex vivo and in vivo studies 
Chapter 7 debates the findings of the results obtained from the ex vivo and in vivo studies. 
The data discussed in this chapter can be found in Chapter 5, while the materials and 
methods can be found in Chapter 3. 
7.1 Ex Vivo Studies 
The main aim of the ex vivo studies was to determine the acute effects of melatonin and 
ART administration on the vascular reactivity of untreated, control male Wistar rat aortas. 
For these studies, Phe was used to induce contraction, while Ach was used to induce 
relaxation. The relevant treatment was added directly to an ex vivo organ bath for 30-
minutes before the addition of cumulative concentrations of Ach and Phe. 
Cumulative contraction with Phe, showed that the ART treated aortas contracted 
significantly less, when compared to all other treatment groups (Fig 5.1 A). This finding 
may be the consequence of an unexpected phenomenon that occurred when ART was 
administered to the ex vivo organ bath (Fig 7.1). Roughly 1 minute after the addition of 
ART to the organ bath, the aortic ring started to spontaneously contract. On average it 
took about 5 minutes to reach maximum spontaneous contraction, before the ring began 
to relax again, eventually relaxing all the way back to a resting tension of 1.5 g before the 
end of the 30-minute ex vivo drug incubation period (Fig 7.1). When the vehicle or 
melatonin was added to the organ bath, no spontaneous contraction occurred. 
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It is possible that this pre-contraction caused by ART may have pre-conditioned the aortic 
ring to contraction, thereby causing it to contract less intensely when exposed to 
cumulative concentrations of Phe. Melatonin had the ability to attenuate the pre-
conditioning effect of ART, since the melatonin + ART group contracted significantly more 
than the ART group during the subsequent cumulative Phe protocol, despite also being 
exposed to a spontaneous pre-contraction following ex vivo drug treatment. It is difficult to 
speculate how melatonin achieves this, since the mechanism of the ART-induced 
spontaneous pre-contraction is not known either. The spontaneous pre-contraction may be 
a result of iNOS activation following a bombardment of ROS generated by the ex vivo 
addition of ART. iNOS activation would lead to an excessive release of NO, which in 
combination with ROS, would be rapidly converted to peroxynitrite and ultimately lead to 
vascular contraction. Acute ART treatment might also directly stimulate pro-contractile 
substances such as endothelin-1 (ET-1), thromboxane A (TXA2) and angotensin II  (Cines 
et al., 1998; Mudau et al., 2012). This may however be slightly more difficult to examine, 
although an ELISA assay may be able to detect these substances within the supernatant. 
Alternatively, the spontaneous contraction may just be a direct drug-induced effect due to 
an unknown toxicity of one of the components of the FDC ART. Individual components of 
the ART (EFV; FTC and TDF) could be examined separately to clarify this point. Finally, 
the actuate treatment of ART might stimulate α-adrenergic receptors to release calcium, 
30-minute drug incubation period 
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Figure 7.1: The spontaneous contraction of ex vivo aortic rings after the addition of A) 
ART and B) ART and melatonin. 
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thereby inducing the rapid contraction. This rapid stimulation and excessive release of 
calcium may exhaust calcium supplies, which would explain the decreased contraction 
experience on administration of Phe. 
However, this is all speculative and further investigations are needed to determine the 
source of this interesting and unexpected phenomenon, as well as the means by which 
melatonin attenuated the pre-conditioning effect of ART. 
Further protein investigations should be conducted, as well as studies conducted with Ca2+ 
channel blockers, to further elucidate the mechanisms at play. The sample sizes should 
also be expanded to shed more light on these findings. 
7.2 In Vivo Studies 
The main aim of the in vivo studies was to determine the chronic effects of melatonin and 
ART administration on the vascular reactivity of male Wistar rats that have been treated for 
8 weeks with melatonin and/or ART.  Additional aims included examining various signalling 
protein activation and/or expression levels, as well as the antioxidant capacity exhibited in 
the aortic tissue of these same male Wistar rats. 
For in vivo experiments, two types of aortic ring investigations were conducted. For the 
first set of experiments we conducted endothelium-dependent relaxation studies, were 
Phe was used to induce contraction and Ach was used to induce relaxation, and rings 
were pre-treated with the NOS inhibitor, L-NAME as a control. For the second set of 
experiments we conducted endothelium-independent relaxation studies, where Phe was 
once again used to induce contraction, however, for these studies SNP - an exogenous 
NO donor - was used to induce relaxation.  
7.2.1 Endothelium-dependent Aortic Ring Investigations 
Cumulative contraction with Phe, showed that the ART and melatonin + ART treatment 
groups contracted significantly more when compared to the control group (Fig 5.2 A). 
These results may implicate ART as the factor leading to increased contractility. Two 
studies by Jiang et al. (2006 and 2010) found that ART treatment had no effect on Phe-
induced contraction. Both these studies used NRTI, azidothymidine (AZT) and the 
protease inhibitor, indinavir. Tests were also done on mice aortas rather than rat aortas. 
Since a different animal model was used, as well as different ART, these two studies 
cannot be directly compared with the current study, and therefore the contradictory results 
are not unexpected. However, FTC, one of the components of first line FDC ART, is also a 
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nucleoside reverse transcriptase inhibitor, like AZT. Perhaps a conclusion that can be 
drawn from the above-mentioned two studies is that the NRTI (FTC) component of the 
combination ART is not responsible for the pro-contractile effects seen. 
Studies examining the effects of ART treatment on aortic contractility are scarce and it is 
therefore difficult to determine what might be the cause of ART-induced pro-contractility. 
Further protein examination would be needed to confirm this mechanism. A potential 
mechanism for this pro-contractile effect may be ART-induced reduced eNOS expression, 
and therefore reduced NO release from the endothelium. Since we saw reduced eNOS 
expression in the ART treated groups in vitro, the same might occur in vivo. 
The fact that the ART groups experienced increased contractility in vivo is an expected 
finding, since ART in vitro is thought to lead to impaired function of the vascular 
endothelium  (Blanco et al., 2006; Shankar et al., 2005; Stein et al., 2001). This is however 
a contradictory result when compared to the observations made in the ex vivo studies, 
where we saw ART treated groups showed anti-contractile properties. The only 
explanation fathomable for these opposing results is that the duration of exposure to ART 
plays a significant role in the resultant contractility effect. In other words, the longer the 
endothelium is exposed to ART for, the greater the risk of developing ED. This theory has 
been supported by many studies, with the Data Collection on Adverse Events of Anti-HIV 
Drugs (DAD) study group reporting that ART was associated with a 26% increase in the 
rate of myocardial infarction (MI) per year of exposure to ARV drugs. Islam et al. (2012) 
also confirmed that the duration of exposure to ART might be one of the main factors 
associated with risk of developing CVD. 
These findings also suggest that melatonin supplementation does not alleviate this pro-
contractile effect of ART. This result contradicts results previously obtained in our labs, 
where melatonin was shown to be a significant pro-relaxant  (Smit-van Schalkwyk, 2016). 
However, these inconsistent findings could be due to multiple factors. This study used a 
higher dose of 10 mg/kg/day melatonin, where the previous study used a dose of 4 
mg/kg/day. This study also used a treatment periods that were 2 weeks longer. 
Furthermore, the previous study used melatonin to alleviate damage caused by nicotine 
rather than ART, which may provide an indication that ART does not cause significant 
enough damage in vivo for melatonin to act in a protective, vasodilatory manner. This 
finding also correctlates with the data obtained from the in vitro melatonin dose-response 
studies, were we found that a shorter treatment period, with a lower melatonin 
concentration was more protective. 
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Ach induced relaxations were similar for all treatment groups (Fig 5.2 B), which is 
surprising considering the few vascular reactivity studies that have been conducted, all 
showed significant findings in Ach-induced relaxation studies  (Jiang et al., 2010; Jiang et 
al., 2006). Previous studies found that ART had an anti-relaxation effect, but as mentioned 
above, these studies did not use the same animal model or ART regime. The results found 
in this study may be may shed light on the fact that first line ART is less likely to induce ED 
than other previously studies ART regimes. 
Results from pre-treatment with the NOS inhibitor, show that L-NAME elicited a strong pro-
contractile effect (Fig 5.3 A) and reduced vasodilatory responses in all the groups (Fig 5.4 
A). These experiments not only confirmed that the vascular isometric tension model was 
functional, but also showed the involvement of NOS and NOS-derived NO in anti-
contractile and vasodilatory responses of the vasculature.  
7.2.2 Endothelium-independent Aortic Ring Investigations 
To determine whether differences in Ach-mediated relaxation were attributable to 
differential responses of the vascular smooth muscle to NO, relaxation responses to the 
NO donor SNP were evaluated. 
For these endothelium-independent investigations, the Phe contraction studies expectedly 
followed the same trend as seen for the endothelium-dependent investigations, where 
cumulative contraction with Phe, showed that the both the ART and melatonin + ART 
treatment groups exhibited significant pro-contractile properties compared to the control 
group (Fig 5.5 A). 
When SNP was used to induce relaxation, no significant differences where seen between 
any treatment groups (Fig 5.5 B). This finding indicates that the smooth muscle component 
of the NO-cGMP pathways remains unchanged during ART treatment  (Sutliff et al., 2002). 
Further protein investigations should be conducted to examine whether this result was 
simply due to the fact that ART did not cause any oxidative damage, or whether SNP 
resulted in normal relaxation despite the presence of damaging increased levels of 
superoxide. This is a phenomenon that many studies have previously demonstrated as 
possible  (Eberhardt et al., 2000; Gunnett, Heistad, & Faraci, 2002), and therefore should 
be further examined. Mechanisms for the dissociation between elevated superoxide and 
unaffected relaxation to SNP remain unclear  (Sutliff et al., 2002). 
Since endothelium-dependent and independent relaxation studies both showed no 
significant differences between groups, it is diffcult to draw any conclusions as to whether 
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ART-induced damage is limited to the endothelium and endothelium-dependent factors 
like eNOS. 
 
7.2.3 Western Blot Analyses 
Western blot analyses were performed on snap-frozen aortic tissue of control, melatonin, 
ART and melatonin + ART treated animals from the endothelium-dependent studies, in 
order to determine whether the functional data of the vascular reactivity investigations 
could be explained by changes in intracellular signal transduction pathways. 
 
No statistically significant changes were seen between any treatment groups in iNOS (Fig 
5.7), nitrotyrosine (Fig 5.8) or p22 PHOX (Fig 5.9) expression, respectively. These results 
were unsurprising considering no differences were seen when Ach induced relaxation was 
examined. However, these results indicate that the pro-contractile influence elicited by 
ART is most likely not due to increased NADPH-dependent superoxide production or due 
to peroxynitrite-related damage.  
7.2.3.1 eNOS 
When the phosphorylated eNOS was expressed as a ratio of total, we saw that there were 
no significant differences between any treatment groups (Fig 5.6 C), despite that fact that 
eNOS phosphorylation was significantly lower in the melatonin + ART treatment group 
compared to the control (Fig 5.6 A). The P/T ratio obtained for the treatment groups was 
most likely due to the fact that the trends seen in eNOS phosphorylation and expression 
were relatively similar, notwithstanding that no significance was seen between groups for 
eNOS expression. This result was expected since there were no changes in vasodilatory 
capacity between groups during relaxation studies. This result does however shed more 
light on the mechanisms behind the ART-induced pro-contractile responses observed in 
this study. Previously it was proposed that this effect might be due to decrease NO 
production from decreased eNOS expression. These results however show that it is 
unlikely that decreased eNOS expression is the mechanism at work. This might point 
towards other contractor factors like endothelin-1 (ET-1), thromboxane A (TXA2) and 
angotensin II  (Cines et al., 1998; Mudau et al., 2012) being upregulated. However, further 
investigations would need to confirm this. 
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7.2.3.2 Cleaved Caspase-3 
The ART and melatonin + ART combination treatment groups showed significantly 
decreased cleaved Caspase-3 expression compared to the control, while the ART 
treatment group also showed significantly decreased cleaved Caspase-3 expression when 
compared to the melatonin treatment group (Fig 5.10). These findings are very similar to 
those seen in the cell viability investigations of the in vitro study (Fig 4.17). Once again it 
seems that ART is the factor associated with decreased apoptosis. This finding further 
cements the anti-apoptotic role of ART, although in these in vivo studies, it would appear 
that this is not influenced by increased NO levels, since there was no increase in 
vasodilation seen in the ART treated groups. Other studies that looked at cleaved 
caspase-3 expression during ART have all been in the presences of HIV, and therefore it 
is difficult to differentiate between the effects of HIV and ART  (Cook-Easterwood, 
Middaugh, Griffin, Khan, & Tyor, 2007; Pitrak et al., 2015). 
7.2.4 Antioxidant Capacity Studies 
The ORAC assay showed no significant differences in antioxidant capacity between 
treatment groups (Fig 5.11). As suggested for the in vitro studies in section 6.5, perhaps 
further antioxidant capacity assays should be performed to confirm this result. 
7.3 Concluding Remarks 
Novel ex vivo studies examining the acute effects of melatonin and ART treatment 
indicated that ART elicited a pro-contractile effect when administered to a healthy rat 
aorta. This resulted in the ART treatment group being pre-conditioned and consequently 
contracting less when compared to all other treatment group. It was also established that 
melatonin does not play a protective role in the presence of ART this situation, since the 
melatonin + ART treatment group relaxed significantly less than the control group. These 
findings are very interesting and need further elucidation through protein investigations. 
In vivo studies demonstrated that ART has no effect on endothelium-dependent or 
independent relaxation, as shown by the lack of differences seen between groups in both 
Ach- and SNP-induced relaxation studies. Both these studies did, however, show that ART 
seems to have a pro-contractile effect. Further investigations are needed to establish by 
what mechanism ART elicits a pro-contractile response, yet  does not affect 
vasorelaxation. 
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Protein investigations were relatively in line with these findings, with cleaved caspase-3 
investigations shedding more light on the fact that NO levels are most likely not involved in 
the anti-apoptotic effects of ART. 
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8 – Overall Conclusions 
This study aimed to investigate the effects of melatonin supplementation during first line 
FDC ART, through an in vitro, ex vivo and in vivo approach. 
The in vitro dose-response studies showed that high concentration ART has the ability to 
induce modest increases in NO and RNS production. Combination studies highlighted that 
melatonin has the ability to ameliorate necrotic damage caused by ART in AECs. 
Signalling investigations ruled out endothelium-dependant NOS as a source of the 
increased NO observed in dose-response studies, as well as excluded NADPH oxidase-
dependent super oxide as the likely source of the increase in RNS observed. Finally, ART 
was shown to have an anti-apoptotic effect, which may have been facilitated by the 
increase in NO observed in the dose-respose studies. Taken together, these results show 
that first line FDC ART is very mildly damaging to the endothelium, and can even be 
protective under certain circumstances. Melatonin was shown to be effective in increasing 
cell viability, but showed no promise of being protective in terms of decreasing excessive 
NO and RNS production. However, since excessive levels of NO and RNS were not 
observed or produced in this study, no conclusions can be drawn as to weather melatonin 
has the ability to decrease excessive levels of NO and RNS in vitro form the current 
findings. 
Ex vivo and in vivo studies shed light on the fact that there are still many unknowns with 
regards to the underlying mechanisms involved in the pro-contractile effects of ART. 
Although ART was shown to definitely elicit contractile responses, the lack of findings in 
the relaxations studies makes it difficult to draw conclusions on the effects of ART on 
aortic endothelial health. Since ART was not shown to decrease relaxation capacity in any 
studies, it could be said that first line FDC ART did not enduce endothelial dusfunction, 
since ART treated aortas showed sufficient vasodilatory responses when compared to 
untreated aortas. Signalling investigations further established that ART has an anti-
apoptotic effect. Whether this finding is specific to the specific reigeme of ART used in this 
study, or a general characteristic of ART, would have to be further investigated. In In vitro 
studies, melatonin was also shown to not have a protective effect in contraction and 
relaxation studies, but this could perhaps just be said for the specific concentration and 
duration of treatment of melatonin used in this study.  Ex vivo and in vivo studies overall 
showed that first line FDC ART does not induce reduced relaxation capacity, usually 
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associated with endothelial dysfunction, while 10 mg/kg/day melatonin treatment over an 8 
week period did not provide protective effects. 
Taken together, these in vitro, ex vivo and in vivo investigations allowed for a very board 
overview of the topic and allowed for the examination of vascular endothelial function on a 
cellular and functional scale. Although it is difficult to fully compare the different models, 
each aspect of this study allowed for the development and finding of important 
investigations that still need to be conducted, which could eventually lead to a better 
understanding behind the mechanisms by which ART potentially causes endothelial 
damage. 
Overall, from these studies, it cannot be explicitly said that South African first line FDC 
therapy induces damaging endothelial changes, and that melatonin has the ability to 
alleviate those changes. However, particular findings did indicate that further 
investigations are need to be conducted, specifically with regards to the necrotic effects of 
ART and the acute effects of ART.  
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8.1 Advantages, Limitations and Future Directions  
Currently, very few studies exist that investigate the effects of South African first line FDC 
ART. This study also investigated the effects of ART in isolation from HIV infection, 
allowing for a more accurate perspective of the effects of ART. This study showed that 
ART induced necrosis as measured by propidium iodide, can be decreased by conjunctive 
melatonin treatment. This study also demonstrated that acutely administered ART caused 
short-term spontaneous contraction, which resulted in an anti-contractile response in ART-
treated aortas when exposed to cumulative concentrations of Phe. Both these findings are 
novel and require further study to clarify the mechanisms by which these actions occur.  
Limitations of this study include the use of only three fluorescent probes for the plate 
reader investigations. In particular, a marker for apoptosis and well as a more specific 
marker for mitochondrial ROS should be included. Antibodies specific to mitochondrial 
ROS could also be included to better understand the mechanisms of ART-induced ROS 
production. 
Small sample sizes are a prominent limitation in the in vitro western blot analyses. A new 
method should be developed in order to allow for the combination of multiple parent cell 
lines when making a single set of lysates, where cells could potentially be treated and then 
frozen until enough different parent cell lines have been grown. 
Another potential limitation of this in vitro study might be its potential to translate to clinical 
relevance, since the long-term effects of ART are the main cause of ART-induced ED, 
whereas a treatment period of only 24 hours was examined. 
Time and equipment-constraints meant that L-NAME studies could not be conducted for 
the endothelium-independent SNP relaxation investigations. This would be an interesting 
aspect to add to these studies. Signalling investigations should also be conducted in future 
studies examining the endothelium-independent chronic effects of ART treatment, as wee 
as the ex vivo acute effects of ART treatment. 
8.2 Specific roles in the study 
 All in vitro cell culture experiments were conducted in the Medical Physiology 
Division on the Faculty of Medicine and Health Science at Stellenbosch University, 
by the student, with the exception of the ORAC assay which was conducted by Dr D 
Blackhurst at the University of Cape Town. 
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 All animal drug treatments were prepared and administered by the student, with the 
exception of the ART gavaging procedure, which was performed by Mr N 
Markgraaff and Mr S Smit. 
 Animal housing, care, feeding and treatment occurred in the Animal Housing Unit of 
the Faculty of Medicine and Health Science at Stellenbosch University. 
 All ex vivo and in vivo experiments were conducted in the Medical Physiology 
Division on the Faculty of Medicine and Health Science at Stellenbosch University, 
by student, with the exception of the ORAC assay, which was conducted by Dr D 
Blackhurst at the University of Cape Town. 
8.3 Research outputs associated with the study  
 Rawstorne, J., Strijdom, H., Webster, I., Westcott, C. The effects of melatonin 
supplementation on vascular tissue during first line ART: an in vitro and in vivo 
study. 45th conference of the Physiology Society of Southern Africa, hosted by 
university of Pretoria, 27- 31 August 2017. (Received an honorary mention for one 
of the top presentations presented for the Wyndham Competition) 
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Appendix A: In vitro melatonin and vehicle concentration 
calculations 
Melatonin Preparation (1 nm; 1 µM; 10 µM): 
 Weight off 23.2 mg melatonin and add it to 150 µl methanol (MeOH). 
 Vortex solution well and make up to 10 ml by adding 9.850 ml distilled water (dH2O) 
= 10 mM Melatonin Stock 
 To make up 10 µM melatonin: Add 10 µl of the 10 mM Melatonin Stock to 9.990 ml 
of medium. 
 To make up 1 µM melatonin: Add 2 µl of the 10 mM Melatonin Stock to 19.998 ml 
of medium. 
 To make up 1 nM melatonin:  
o Add 1 ml of the 10 mM Melatonin Stock to 9 ml of dH2O = STOCK A (1 mM 
melatonin). 
o Add 1 ml of STOCK A to 9 ml of dH2O = STOCK B (100 µM melatonin). 
o Add 1 ml of STOCK B to 9 ml of dH2O = STOCK C (10 µM melatonin). 
o Add 2 µl of STOCK C (10 µM melatonin) to 19.998 ml of medium. 
 
MeOH Vehicle Preparation (1 nm; 1 µM; 10 µM): 
 Add 150 µl MeOH to adding 9.850 ml distilled water (dH2O) = 10 mM Vehicle 
Stock 
 To make up 10 µM vehicle: Add 10 µl of the 10 mM Vehicle Stock to 9.990 ml of 
medium. 
 To make up 1 µM vehicle: Add 2 µl of the 10 mM Vehicle Stock to 19.998 ml of 
medium. 
 To make up 1 nM vehicle:  
o Add 1 ml of the 10 mM Vehicle Stock to 9 ml of dH2O = STOCK A (1 mM 
vehicle). 
o Add 1 ml of STOCK A to 9 ml of dH2O = STOCK B (100 µM vehicle). 
o Add 1 ml of STOCK B to 9 ml of dH2O = STOCK C (10 µM vehicle). 
o Add 2 µl of STOCK C (10 µM vehicle) to 19.998 ml of medium. 
*All melatonin preparations are done in the dark 
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Appendix B: In vitro ART and vehicle concentration calculations 
 
Efavirenz (5.0 µM; 8 µM; 12 µM): 
MW:  315.67 g/L 
Dissolve 10mg in 1.5 ml of Methanol. 
C  = m/MV 
 = 0.01g/(315.67 g/l x 0.0015l) 
 = 0.010559551 M 
 = 21119 µM 
 
5.0 µM: 
C1V1 = C2V2 
21119 µM x V1 = 5.0 µM x 1000µl 
V1 = 0.24 µL per 1 ml medium 
 
8 µM: 
C1V1 = C2V2 
21119 µM x V1 = 8 µM x 1000µl 
V1 = 0.38 µl per 1 ml medium 
 
12 µM: 
C1V1 = C2V2 
21119 µM x V1 = 12 µM x 1000µl 
V1 = 0.57 µl per 1 ml medium 
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Emtricitabine (5 µM; 7.5 µM;  10 µM): 
MW:  247.25 g/L 
Dissolve 10mg in 4 ml of Milipore H2O. 
C  = m/MV 
 = 0.01g/(247.25 g/l x 0.004l) 
 = 0.0101112235 M 
 = 10111.2 µM 
 
5 µM: 
C1V1 = C2V2 
10111.2 µM x V1 = 5 µM x 1000µl 
V1 = 0.5 ul per 1 ml medium 
 
7.5 µM: 
C1V1 = C2V2 
10111.2 µM x V1 = 7.5 µM x 1000µl 
V1 = 0.74 ul per 1 ml medium 
 
10 µM: 
C1V1 = C2V2 
10111.2 µM x V1 = 10 µM x 1000µl 
V1 = 1.2 µl per 1 ml medium 
  
Stellenbosch University  https://scholar.sun.ac.za
 142 
Tenofovir (80 nM; 400 nM;  1 µM): 
MW:  635.51 g/L 
Dissolve 10mg in 40 ml of Milipore H2O. 
C  = m/MV 
 = 0.01g/(635.51 g/l x 0.04l) 
 = 0.0003934 M 
 = 393.38 µM (Stock A) 
 
80 nM: 
Dilute stock of 393.38 µM: 
Add 127.1 µl of Stock A to 872.9 µl of Millipore water (Stock B) (Now the concentration of 
Stock B is 50 µM) 
C1V1 = C2V2 
50 µM x V1 = 0.08 µM x 1000µl 
V1 = 1.6 µl per 1 ml medium 
 
400 nM (from stock A): 
C1V1 = C2V2 
393.38 µM x V1 = 0.4 µM x 1000µl 
V1 = 1.02 µl per 1 ml medium 
 
1 µM (from stock A): 
C1V1 = C2V2 
393.38 µM x V1 = 1 µM x 1000µl 
V1 = 2.54 µl per 1 ml medium 
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Appendix C: Western Blot and ORAC 1 nM melatonin, high 
concentration ART and vehicle concentration calculations 
(combined vehicles) 
Control Group (Combined Vehicles): 
 1.14 µl MeOH per 1 ml medium (Melatonin & EFV vehicle) 
 3.74 µl (1.2 µl + 2.54 µl) dH2O per 1 ml medium (FTC and TDF vehicles) 
 1000 µl medium – 4.88 µl (1.14 µl + 3.74 µl) = 995.1 µl medium 
Melatonin Group (+Combined Vehicles): 
 Weigh off 0,002 g melatonin and add to 10 ml MeOH = Melatonin/MeOH STOCK A 
 Add 10 µl of STOCK A to 9.990 ml MeOH = Melatonin/MeOH STOCK B 
 1.14 µl Melatonin/MeOH STOCK B per 1 ml medium (Melatonin & EFV vehicle) 
 3.74 µl (1.2 µl + 2.54 µl) dH2O per 1 ml medium (FTC and TDF vehicles) 
 1000 µl medium – 4.88 µl (1.14 µl + 3.74 µl) = 995.1 µl medium 
ART Group (+Combined Vehicles): 
*The same pre-made ART stocks were used that were mentioned in Appendix B: 
EFV = 21119 µM (0.57 µl per 1 ml medium) 
FTC = 10111.2 µM (1.2 µl per 1 ml medium) 
TDF = 393.38 µM (2.54 µl per 1 ml medium) 
 0.57 µl EFV/MeOH per 1 ml medium (EFV vehicle) 
 1.2 µl FTC/dH2O per 1 ml medium (FTC vehicle) 
 2.54 µl TDF/dH2O per 1 ml medium (TDF vehicle) 
 0.57 µl MeOH per 1 ml medium (melatonin vehicle) 
 1000 µl medium – 4.11 µl (0.57 µl + 3.54 µl) = 995.9 µl medium 
Melatonin + ART Group (+Combined Vehicles): 
 Weigh off 0,004 g melatonin and add to 10 ml MeOH = Melatonin/MeOH STOCK A 
 Add 10 µl of STOCK A to 9.990 ml MeOH = Melatonin/MeOH STOCK B 
 0.57 µl Melatonin/MeOH STOCK B per 1 ml medium (Melatonin vehicle) 
 0.57 µl EFV/MeOH per 1 ml medium (EFV vehicle) 
 1.2 µl FTC/dH2O per 1 ml medium (FTC vehicle) 
 2.54 µl TDF/dH2O per 1 ml medium (TDF vehicle) 
 1000 µl medium – 4.88 µl (1.14 µl + 3.74 µl) = 995.1 µl medium 
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Appendix D: Western Blot Raw Data Normalisiation 
1. “Volume Intensity” values are retrieved from Image Lab™- 5 Software for both the 
loading-control and the specific antibody (eNOS in the example below). 
2. For each sample within a treatment group (which represents a single lane on the 
Western blot gel/membrane), the volume intensity of the specific antibody is divided 
by the volume intensity of the corresponding lane or sample of the loading-control. 
Eg: eNOS “Control group/lane 1” is divided by Loading-control “Control group/lane 
1” 
3. An average is then determined for each treamnet group. 
4. The data is then normalised by dividing the antibody/loading-control value of each 
lane by the average “Control group” antibody/loading-control value (see value 
highlighted in red). 
5. An average value is the determined per treatment group. 
EXAMPLE DATA: 
Loading-control 
    
     
Groups 
Volume 
Intensity Average Normalisation Average 
Controls 
506844 
 
0,7644 
 691977 
 
1,0436 
 517413 
 
0,7803 
 505011 
 
0,7616 
 1094028 663055 1,6500 1,0 
Melatonin 
648843 
 
0,9786 
 
610935 
 
0,9214 
 
732069 
 
1,1041 
 
884052 
 
1,3333 
 
1054911 786162 1,5910 1,2 
ART 
866268 
 
1,3065 
 
1296165 
 
1,9548 
 
893295 
 
1,3472 
 
528723 
 
0,7974 
 
766155 870121 1,1555 1,3 
ART + Melatonin 
581490 
 
0,8770 
 
873522 
 
1,3174 
 
678015 
 
1,0226 
 
677742 
 
1,0222 
 
679848 698123 1,0253 1,1 
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t-eNOS 
     
      
Groups 
Volume 
Intensity 
t-
eNOS/Loading
-control Average Normalisation Average 
Controls 
1412446 2,786747007 
 
1,1035 
 1465338 2,117610845 
 
0,8386 
 1230642 2,37845203 
 
0,9419 
 1848826 3,66096184 
 
1,4497 
 1840748 1,682541946 2,52526 0,6663 1,0 
Melatonin 
1938342 2,987382156 
 
1,1830 
 1819790 2,978696588 
 
1,1796 
 1705102 2,329154765 
 
0,9223 
 1564416 1,769597264 
 
0,7008 
 1621046 1,536666126 2,32030 0,6085 0,9 
ART 
1868986 2,157514764 
 
0,8544 
 1551508 1,196998839 
 
0,4740 
 1598114 1,789010349 
 
0,7084 
 1359554 2,571391825 
 
1,0183 
 1324526 1,728796392 1,88874 0,6846 0,7 
ART + Melatonin 
1276268 2,194823643 
 
0,8691 
 1675758 1,918392439 
 
0,7597 
 1735104 2,559093825 
 
1,0134 
 1633310 2,409928852 
 
0,9543 
 1461328 2,149492239 2,24635 0,8512 0,9 
 
*In the case of eNOS, a P/T ratio also needs to be determined. “P/T ratio” refers to the 
phospho-eNOS volume intensity divided by the total-eNOS volume intensity for each 
sample. Se pg 146 for example data. 
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p-eNOS 
        
         
Groups 
Volume 
Intensity Average Normalisation Average P/T ratio Average P/T ratio normalisation Average 
Controls 
226269 
 
1,218803933 
 
0,160 
 
1,326801227 
 222894 
 
1,200624406 
 
0,152 
 
1,259833713 
 117099 
 
0,63075685 
 
0,095 
 
0,788086909 
 174402 
 
0,93942097 
 
0,094 
 
0,781282472 
 187578 185648 1,010393841 1,0 0,102 0,121 0,84399568 1,0 
Melatonin 
142893 
 
0,769696911 
 
0,074 
 
0,610566832 
 116856 
 
0,629447924 
 
0,064 
 
0,53184172 
 125280 
 
0,674824022 
 
0,073 
 
0,608532869 
 97344 
 
0,524346022 
 
0,062 
 
0,515358685 
 107388 117952 0,578448293 0,6 0,066 0,068 0,548672351 0,6 
ART 
118440 
 
0,637980182 
 
0,063 
 
0,524861854 
 71793 
 
0,386714887 
 
0,046 
 
0,383248746 
 77085 
 
0,415220384 
 
0,048 
 
0,399498157 
 68733 
 
0,370232116 
 
0,051 
 
0,418717872 
 67572 80725 0,363978359 0,4 0,051 0,052 0,422531358 0,4 
ART + Melatonin 
73566 
 
0,396265198 
 
0,058 
 
0,477406055 
 51102 
 
0,27526227 
 
0,030 
 
0,252568541 
 34542 
 
0,186061393 
 
0,020 
 
0,164882525 
 32760 
 
0,176462604 
 
0,020 
 
0,166122299 
 43368 47068 0,233602875 0,3 0,030 0,032 0,245795738 0,3 
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Appendix E: Ex vivo 10 µM melatonin, high concentration ART and 
vehicle concentration calculations (combined vehicles) 
*Calculations made for 20 ml organ bath filled with Krebs Henseleit buffer (KHB)  
Control Group (Combined Vehicles): 
 22.8 µl MeOH in 20 ml organ bath  (Melatonin & EFV vehicle) 
 70.6 µl dH2O in 20 ml organ bath (FTC and TDF vehicles) 
Melatonin Group (+Combined Vehicles): 
10 µM melatonin: 
*For high concentration EFV (12 µM), 11.4 µl MeOH will be used in 20 ml system since EFV has a set stock 
concentration that cannot be altered. Therefore 11.4 µl MeOH needs to be used for final 10µM melatonin 
when in combination with ART (and EFVs MeOH vehicle). For melatonin alone, 22.8 4 µl MeOH needs to be 
used to account for EFV vehicle. 
C1V1 = C2V2 
(C1) x (22.8 µl) = (10 µM) x (20000µl) 
C1 = 0.00877193 M 
MW:  232.278 g/mol 
m  = (0.00877193 M) x (232.278 x 0.003) 
 = 0.006 g melatonin in 3 ml MeOH 
 22.8 µl Melatonin/MeOH in 20 ml organ bath  (Melatonin & EFV vehicle) 
 70.6 µl dH2O in 20 ml organ bath (FTC and TDF vehicles) 
ART Group (+Combined Vehicles): 
*The same pre-made ART stocks were used that were mentioned in Appendix B & C: 
EFV = 21119 µM (11.4 µl per 20 ml medium) 
FTC = 10111.2 µM (19.8 µl per 20 ml medium) 
TDF = 393.38 µM (50.8 µl per 20 ml medium) 
 11.4 µl EFV/MeOH in 20 ml organ bath  
 19.8 µl FTC/dH2O in 20 ml organ bath   
 50.8 µl TDF/dH2O in 20 ml organ bath   
 11.4 µl MeOH per 1 ml medium (melatonin vehicle) 
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Melatonin + ART Group (+Combined Vehicles): 
C1V1 = C2V2 
(C1) x (11.4 µl) = (10 µM) x (20000µl) 
C1 = 0.01754386 M 
MW:  232.278 g/mol 
m  = (0.01754386 M) x (232.278 x 0.003) 
 = 0.012 g melatonin in 3 ml MeOH 
 11.4 µl Melatonin/MeOH in 20 ml organ bath 
 11.4 µl EFV/MeOH in 20 ml organ bath  
 19.8 µl FTC/dH2O in 20 ml organ bath   
 50.8 µl TDF/dH2O in 20 ml organ bath   
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Appendix F: In vitro melatonin stock preparation 
*Calculations for 1 cage 
The rats get 10 mg/kg/day Melatonin which is calculated as follows: 
10mg/kg/day = 10mg/1000g/day = 0.01mg/g/day 
1. Weigh the rats on Monday mornings, and then calculate the average weight per 
cage 
     Example: 
     (293.1g + 283.6g + 312.4g + 295.8g)/4 = 296.2g 
 
2. Multiply the average weight by 0.01mg/g/day 
     Example: 
     296.2g x 0.01 = 3mg melatonin per day [A] 
 
3. The week before treatment started, rats were given 200ml of normal water on 
Monday around 16:30, and the next day at the same time, the left over water was 
measured to calculate how much water that cage drank in 24 hours. These 7 values 
are then averaged per cage, and divided by the amount of rats in the cage (usually 
4) to get the average amount drank per rat in that cage. 
 
     Example (Cage 1): 
                          Water given (ml)   Water left (ml)   Amount drank (ml) 
Monday                     200                         28                        172 
Tuesday                     200                         100                      100 
Wednesday               200                         80                        120 
Thursday                    200                         68                        132 
Friday                          200                         78                        122 
Saturday                     200                         48                        152 
Sunday                        200                         22                        178 
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(172 + 100 + 120 + 132 + 122 + 152 +178)/7 = 140ml average water drank by cage 1 per 
day 
140ml/4 = 35ml average water drank per rat in cage 1 per day [B] 
 
4. Calculate grams meltonin needed to ensure each rat is getting 10mg/kg/day when 
drinking an average of 35ml  day. For the stock, 500ml of melatonin stock is 
prepared on Monday, and give the rats in their bottle (200ml per day). The stock 
lasts two days. The extra 100ml in the bottle is in case of spillage, and gets thrown 
away if not used. On Wednesday a fresh 500ml stock is made and on Friday 1 
x 250ml stock (For friday) and 1 x 500ml stock (for Sat & Sun) is made. 
 
     Example: 
     Melatonin (mg) needed in 500ml "stock" = [A]/([B]/500ml) = [0.03mg]/([35ml]/500ml) 
                                                                                                               = 42.4mg Melatonin 
                                                                                                               = 0,042g Melatonin 
 
5. Melatonin is then weighed off and dissolved in 1ml methanol (Meltonin is very 
insoluble in water, but only 0.2% methanol of the total stock is used - therefore the 
potential effect of the methanol is considered negligible) and added to 500ml 
distilled water. 
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Appendix G: In vitro ART stock preparation 
The daily dose (mg / kg) of each active ingredient for a human was calculated as follows:  
 
AId = 
!" /
!t  
AId = Daily dose of active ingredient (mg / kg).  
AI = Active ingredient (mg).  
mt = Average body mass of a human(kg).   
(8.6 mg / kg / day EFV; 2.9 mg / kg / day FTC; 4.3 mg / kg / day TDF)  
Daily dosage per animal (mg / kg) was calculated according to the USA FDA guidelines 
using a conversion factor of X 6 to convert human to rat ratio:  
AIrat = 6(AId )  AIrat = Daily dose of active ingredient for a rat (mg / kg)  
AId = Daily dose of active ingredient (mg / kg)  
(EFV: 51.6 mg / kg / day; FTC: 17.4 mg / kg / day; TDF: 25.8 mg /kg / day).  
Thus, for treated groups, the daily dose of active ingredients per animal needed was 
calculated weekly based on the average TBM of each group as follows:  
AId/r = AIrat(Mavg)  AId/r = Daily dose of active ingredient per rat (mg / kg).  
AIrat = Active ingredient for a rat (mg).  
Mavg = Average TBMof rats in a group (kg).  
The mass of the 3 active ingredients combined in each tablet was 1100 mg (600 mg EFV 
+ 200 mg FTC + 300 mg TDF). The actual % (m / m) of the active ingredients in each 
tablet was calculated according to the mass of the tablet as follows:  
AI% = !"T !T  
AI% = % Mass active ingredient in the tablet.  
AIT = Total mass of active ingredient, 1100 g.  
mT = Total mass of the crushed tablet (g).  
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The amount (mg) of crushed powder of the tablet needed for a treated group with a certain 
average TBM (350 g per animal for example) was calculated as follow:   
EFV:AIrat =51.6mg/kg/day  
AId/r = AIrat(Mavg)  
= (51.6 mg / kg)(0.35 kg)  
= 33.22 mg  
AId/r = Daily dose of active ingredient per rat (mg / kg).  
AIrat = Active ingredient for a rat (mg).  
Mavg = Average TBM of rats in a group (kg).  
 
If the % (m/m) of active ingredient is 68 % (for example), the amount (mg) of tablet powder 
weighed off was calculated as follow:  
AIw = AId/r(AI%)  
= 33.22 mg (68 %)  
= 22.58  
AIw = Mass of the tablet powder weighed off per rat (mg). 
AId/r = Daily dose of active ingredient per rat (mg / kg).  
AI% = Mass % active ingredient in the tablet.  
 
To prepare enough of the FDC for 4 rats for 8 days:   
MTP = mp(N)(d)   MTP = Total mass of crushed powder per group per week (g).  
mp = Mass of the crushed tablet needed per rat daily (mg).  
N = Number of rats in the group. 
d = Number of days  
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Odimune™ tablets and crushed in a pestle and mortar and weighed according to the 
above formula. ARVs were made weekly by dissolving the required weight in the 
appropriate amount of dH2O is needed. 
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Appendix H: SNP concentration calculations 
 A pestle and mortar was used to crush 1 small SNP crystal.  
 0.001g of SNP powder was weighed off from the crushed crystal and and add to 50ml 
0.9% saline = SNP STOCK (60 µM). The tube was covered in tinfoil.  
SNP Dilutions:  
1.2nM: 
C1V1 = C2V2 
(60 µM) x V1 = 0.0012 µM x 25000 µl 
V1 = 0.5 µl in a 25 ml organ bath 
 
20nM  
C1V1 = C2V2 
(60 µM) x V1 = 0.0188 µM x 25000 µl 
V1 = 7.8 µl in a 25 ml organ bath 
 
70nM 
C1V1 = C2V2 
(60 µM) x V1 = 0.0488 µM x 25000 µl 
V1 = 20.3 µl in a 25 ml organ bath 
 
100nM  
C1V1 = C2V2 
(60 µM) x V1 = 0.03 µM x 25000 µl 
V1 = 12.5 µl in a 25 ml organ bath 
 
750nM  
C1V1 = C2V2 
(60 µM) x V1 = 0.65 µM x 25000 µl 
V1 = 270.8 µl in a 25 ml organ bath 
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Appendix I: Male Wistar Rat Biometric Data 
  
Increase in rat body mass (g) over the 8-week treatment period. Starting weights 
were recorded at week 0, and end weights were recorded before animal sacrifice. 
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Mean fluid intake (ml/rat/day) over the 8-week treatment period. 
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